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SCIENTIFIC OPINION  
Scientific Opinion on Flavouring Group Evaluation 18, Revision 2 
(FGE.18Rev2): 
Aliphatic, alicyclic and aromatic saturated and unsaturated tertiary 
alcohols, aromatic tertiary alcohols and their esters from chemical groups 6 
and 8.1 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)2, 3  
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European 
Food Safety Authority was requested to evaluate 32 flavouring substances in the Flavouring Group 
Evaluation 18, Revision 2, using the Procedure in Commission Regulation (EC) No 1565/2000. None 
of the substances were considered to have genotoxic potential. The substances were evaluated through 
a stepwise approach (the Procedure) that integrates information on structure-activity relationships, 
intake from current uses, toxicological threshold of concern, and available data on metabolism and 
toxicity. The Panel concluded that 28 substances [FL-no: 02.041, 02.052, 02.054, 02.120, 02.123, 
02.129, 02.140, 02.144, 02.147, 02.149, 02.150, 02.168, 02.171, 02.181, 02.184, 02.197, 02.203, 
02.206, 02.219, 02.226, 02.230, 02.253, 09.171, 09.356, 09.614, 09.617, 09.671 and 09.808] do not 
give rise to safety concerns at their levels of dietary intake, estimated on the basis of the MSDI 
approach. For the remaining four substances [FL-no: 02.146, 02.185, 02.191 and 09.669] no 
appropriate NOAEL was available and additional data are required. Besides the safety assessment of 
these flavouring substances, the specifications for the materials of commerce have also been 
considered and for six substances information is lacking.  
© European Food Safety Authority, 2011 
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SUMMARY  
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (the Panel) to provide scientific advice to the Commission on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was requested to evaluate 32 flavouring substances in the 
Flavouring Group Evaluation 18, Revision 2 (FGE.18Rev2), using the Procedure as referred to in the 
Commission Regulation (EC) No 1565/2000. These 32 flavouring substances belong to chemical 
groups 6 and 8, Annex I of the Commission Regulation (EC) No 1565/2000. 
The present Flavouring Group Evaluation deals with 32 saturated and unsaturated aliphatic acyclic and 
alicyclic tertiary alcohols, aromatic tertiary alcohols and their esters. Based on their structures, the 
candidate substances can be subdivided into 8 subgroups. 
Nineteen of the 32 candidate substances possess one or more chiral centres and/or can exist as 
geometrical stereoisomers due to the presence of a double bond: [FL-no: 02.120, 02.129, 02.140, 
02.144, 02.146, 02.147, 02.149, 02.150, 02.168, 02.191, 02.197, 02.206, 02.226, 02.230, 02.253, 
09.171, 09.614, 09.671 and 09.808]. For five of these substances [FL-no: 02.146, 02.147, 02.168, 
02.191 and 02.197] the stereoisomeric composition has not been specified sufficiently. For four of 
these five substances [FL-no: 02.147, 02.168, 02.191 and 02.197] the stereoisomeric composition of 
the mixture has not been specified. 
Twenty of the 32 candidate substances are classified into structural class I, 11 candidate substances are 
classified into structural class II and one is classified into structural class III according to the decision 
tree approach. 
Twenty-four out of the 32 candidate substances have been reported to occur in a wide range of food 
items. 
In its evaluation, the Panel as a default used the Maximised Survey-derived Daily Intake (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe. However, when the 
Panel examined the information provided by the European Flavouring Industry on the use levels in 
various foods, it appeared obvious that the MSDI approach in a number of cases would grossly 
underestimate the intake by regular consumers of products flavoured at the use level reported by the 
Industry, especially in those cases where the annual production values were reported to be small. In 
consequence, the Panel had reservations about the data on use and use levels provided and the intake 
estimates obtained by the MSDI approach.  
In the absence of more precise information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a modified Theoretical Added Maximum Daily Intake 
(mTAMDI) approach based on the normal use levels reported by Industry. In those cases where the 
mTAMDI approach indicated that the intake of a flavouring substance might exceed its corresponding 
threshold of concern, the Panel decided not to carry out a formal safety assessment using the 
Procedure. In these cases the Panel requires more precise data on use and use levels. 
2-Methylpropan-2-ol [FL-no: 02.052] provided an equivocal evidence of genotoxicity in some in vitro 
assays, while it was clearly negative in vivo in cytogenetic tests conducted up to the maximum 
tolerated dose. The overall weight of the experimental evidence and the lack of structural alerts for 
genotoxicity for this substance and its metabolites do not raise concern for in vivo genotoxicity. For 
the other substances in this group the available data considered valid do not give rise to any safety 
concerns with respect to genotoxicity.  
Twenty-eight of the candidate substances are anticipated to be metabolised to innocuous products. For 
the remaining four candidate substances no metabolism data are available and therefore they cannot be 
predicted to be metabolised to innocuous products. No appropriate NOAEL was available for these 
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four candidate substances [FL-no: 02.146, 02.185, 02.191 and 09.669] or for the supporting 
substances. Therefore, additional data are required for these four candidate substances.  
It is considered that, on the basis of the default MSDI approach, 28 of the 32 candidate substances 
[FL-no: 02.041, 02.052, 02.054, 02.120, 02.123, 02.129, 02.140, 02.144, 02.147, 02.149, 02.150, 
02.168, 02.171, 02.181, 02.184, 02.197, 02.203, 02.206, 02.219, 02.226, 02.230, 02.253, 09.171, 
09.356, 09.614, 09.617, 09.671 and 09.808] would not give rise to safety concerns at the estimated 
levels of intake arising from their use as flavouring substances. For the remaining four substances [FL-
no: 02.146, 02.185, 02.191 and 09.669], no appropriate NOAEL was available or for the supporting 
substances. Therefore, additional data are required for these four candidate substances.  
The mTAMDI values for the 20 candidate substances from structural class I range from 3900 to 14000 
microgram/person/day. For 10 of the 11 candidate substances from structural class II, the mTAMDI 
values are 3900 microgram/person/day for each of nine candidate substances, and 1600 
microgram/person/day for one candidate substance. For one candidate substance [FL-no: 02.146] from 
structural class II no data on use and use levels are provided. For the one candidate substance from 
structural class III the mTAMDI is 5700 microgram/person/day. Accordingly, the estimated intakes 
for the 31 candidate substances for which use levels are provided are above the thresholds of concern 
for their structural classes. Therefore, for these 31 substances and the one substance for which no use 
and use levels have been provided more reliable exposure data are required. On the basis of such 
additional data, these flavouring substances should be reconsidered along the steps of the Procedure. 
Following this Procedure additional toxicological data might become necessary.  
In order to determine whether the conclusion for the candidate substances can be applied to the 
materials of commerce, it is necessary to consider the available specifications. Adequate specifications 
including complete purity criteria and identity for the materials of commerce have been provided for 
the 32 candidate substances. However, information on the stereoisomeric composition has not been 
specified sufficiently for five substances [FL-no: 02.146, 02.147, 02.168, 02.191 and 02.197]. In 
addition, the composition of the mixture of  [FL-no: 02.129] is missing and for [FL-no: 02.129 and 
02.146] are other information on specification lacking. Thus, the final evaluation of the materials of 
commerce cannot be performed for six substances [FL-no: 02.129, 02.146, 02.147, 02.168, 02.191 and 
02.197], pending further information. 
In conclusion, for four flavouring substances [FL-no: 02.146, 02.185, 02.191 and 09.669] the Panel 
considered that additional data are needed. For six substances [FL-no: 02.129, 02.146, 02.147, 02.168, 
02.191, and 02.197] information on specifications/stereoisomerism/composition of mixture is missing. 
For 24 flavouring substances [FL-no: 02.041, 02.052, 02.054, 02.120, 02.123, 02.140, 02.144, 02.149, 
02.150, 02.171, 02.181, 02.184, 02.203, 02.206, 02.219, 02.226, 02.230, 02.253, 09.171, 09.356, 
09.614, 09.617, 09.671 and 09.808] evaluated using the Procedure the Panel considered that they 
would present no safety concern at their estimated levels of intake estimated on the basis of the MSDI 
approach.   
 
KEYWORDS 
Flavourings, safety, aliphatic, alicyclic, aromatic, saturated, unsaturated, tertiary alcohols.   
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BACKGROUND 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996a) lays down a 
Procedure for the establishment of a list of flavouring substances the use of which will be authorised 
to the exclusion of all other substances in the EU. In application of that Regulation, a Register of 
flavouring substances used in or on foodstuffs in the Member States was adopted by Commission 
Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 2009/163/EC (EC, 
2009a). Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are 
divided into 34 chemical groups. Substances within a group should have some metabolic and 
biological behaviour in common. 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a), which is broadly based on the 
Opinion of the Scientific Committee on Food (SCF, 1999a). For the submission of data by the 
manufacturer, deadlines have been established by Commission Regulation (EC) No 622/2002 (EC, 
2002b).  
The FGE is revised to include substances for which data were submitted after the deadline as laid 
down in Commission Regulation (EC) No 622/2002 and to take into account additional information 
that has been made available since the previous Opinion on this FGE.  
The Revision also includes newly notified substances belonging to the same chemical groups 
evaluated in this FGE. 
After the completion of the evaluation programme the Union List of flavouring substances for use in 
or on foods in the EU shall be adopted (Article 5 (1) of Regulation (EC) No 2232/96) (EC, 1996a). 
HISTORY OF THE EVALUATION  
FGE Opinion adopted 
by EFSA 
Link No. of 
candidate 
substances 
FGE.18 3 March 2006 http://www.efsa.europa.eu/en/scdocs/scdoc/331.htm 24 
FGE.18Rev1 29 January 2008 http://www.efsa.europa.eu/en/scdocs/scdoc/978.htm 30 
FGE.18Rev2 30 September 2010  32 
The present Revision of FGE.18, FGE.18Rev2, includes the assessment of two additional candidate 
substances [FL-no: 02.129 and 02.146]. Information on toxicity and/or metabolism on the substance 
[FL-no: 02.129] is included. No information on toxicity and/or metabolism is available for [FL-no: 
02.146]. A search in open literature for did not provide any further data on toxicity or metabolism for 
these substances. 
Since the publication of FGE.18Rev1 additional information toxicity on [FL-no: 02.120, 02.140, 
02.144 and 02.197] has become available and is included.  
Since the publication of FGE.18Rev1 additional information on specifications on six 
substances has become available [FL-no: 02.147, 02.168, 02.197, 02.226, 02.230 and 02.253] 
(EFFA, 2010a). 
Based on the additional information made available by Industry, it was also considered appropriate to 
merge the two subgroups 7 and 8 in the previous revision of this FGE to one subgroup 7 in this current 
revision of this FGE. 
Flavouring Group Evaluation 18, Revision 2
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TERMS OF REFERENCE 
The European Food Safety Authority (EFSA) is requested to carry out a risk assessment on flavouring 
substances in the Register prior to their authorisation and inclusion in a Union List according to 
Commission Regulation (EC) No 1565/2000 (EC, 2000a). In addition, the Commission requested 
EFSA to evaluate newly notified flavouring substances, where possible, before finalising the 
evaluation programme. 
ASSESSMENT 
1. Presentation of the Substances in Flavouring Group Evaluation 18, Revision 2 
1.1. Description 
The present Flavouring Group Evaluation 18, Revision 2 (FGE.18Rev2) using the Procedure as 
referred to in the Commission Regulation (EC) No 1565/2000 (EC, 2000a) (The Procedure – shown in 
schematic form in Annex I of this FGE), deals with 32 saturated and unsaturated aliphatic acyclic and 
alicyclic tertiary alcohols, aromatic tertiary alcohols and their esters from chemical groups 6 and 8, 
Annex I of Commission Regulation (EC) No 1565/2000 (EC, 2000a). The 32 flavouring substances 
under consideration (candidate substances), with their chemical Register names, FLAVIS- (FL-), 
Chemical Abstract Service- (CAS-), Council of Europe- (CoE-) and Flavor and Extract Manufactures 
Association- (FEMA-) numbers, structure and specifications, are listed in Table 1. 
The present FGE consists of seven aliphatic saturated tertiary alcohols and one ester of such [FL-no: 
02.041, 02.052, 02.147, 02.181, 02.184, 02.219, 02.253 and 09.356]; five are aliphatic unsaturated 
tertiary alcohols which possess isolated terminal double bonds and two are esters thereof [FL-no: 
02.123, 02.144, 02.150, 02.168, 02.226, 09.614 and 09.671]; three aliphatic unsaturated tertiary 
alcohols with conjugated terminal double bonds and one ester of such [FL-no: 02.146, 02.185, 02.191 
and 09.669]; one aliphatic unsaturated tertiary alcohol which does not possess terminal double bonds 
[FL-no: 02.140]; two monocyclic saturated tertiary alcohols and one ester thereof [FL-no: 02.054, 
02.171 and 09.617]; two monocyclic unsaturated tertiary alcohols [FL-no: 02.129 and 02.230]; two 
mono- and bicyclic unsaturated tertiary alcohols with an isolated terminal double bond [FL-no: 02.149 
and 02.206]; one bicyclic unsaturated ester [FL-no: 09.808], one tricyclic saturated ester [FL-no: 
09.171] and two bi- and tricyclic tertiary alcohols [FL-no: 02.197 and 02.120] and one tertiary alcohol 
with an aromatic substituent [FL-no: 02.203].  
A summary of the safety evaluation is summarised in Table 2a. 
The hydrolysis products of the candidate esters are listed in Table 2b. 
The 32 candidate substances are closely related structurally to 26 flavouring substances (supporting 
substances). Twenty-three of these were evaluated in the group of “Aliphatic acyclic and alicyclic 
terpenoid tertiary alcohols and structurally related substances” and one, menthol, was evaluated in the 
group “Substances structurally related to menthol” at the 51st JECFA meeting (JECFA, 2000a). Two 
supporting substances were evaluated at the 63rd JECFA meeting (JECFA, 2005c), one in the group 
“Aliphatic and alicyclic hydrocarbons” and the other in the group “Aromatic hydrocarbons”. The 
names and structures for the 26 supporting substances are listed in Table 3, together with their 
evaluation status. 
1.2. Stereoisomers 
It is recognised that geometrical and optical isomers of substances may have different properties. Their 
flavour may be different, they may have different chemical properties resulting in possible variability 
in their absorption, distribution, metabolism, elimination and toxicity. Thus, information must be 
provided on the configuration of the flavouring substance, i.e. whether it is one of the 
Flavouring Group Evaluation 18, Revision 2
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geometrical/optical isomers, or a defined mixture of stereoisomers. The available specifications of 
purity will be considered in order to determine whether the safety evaluation carried out for candidate 
substances for which stereoisomers may exist can be applied to the material of commerce. Flavouring 
substances with different configurations should have individual chemical names and codes (CAS 
number, FLAVIS number etc.). 
Nineteen of the 32 candidate substances possess one or more chiral centres and/or can exist as 
geometrical stereoisomers due to the presence of a double bond: [FL-no: 02.120, 02.129, 02.140, 
02.144, 02.146, 02.147, 02.149, 02.150, 02.168, 02.191, 02.197, 02.206, 02.226, 02.230, 02.253, 
09.171, 09.614, 09.671 and 09.808]. For five of these substances [FL-no: 02.146, 02.147, 02.168, 
02.191 and 02.197] the stereoisomeric composition has not been specified sufficiently. For four of 
these flavouring substances [FL-no: 02.147, 02.168, 02.191 and 02.197] Industry has informed that 
they exist as a “mixture of isomers”. However, the Panel does not consider this information sufficient 
and requests data on the actual ratios (see Table 1). 
1.3. Natural Occurrence in Food 
Twenty-four out of 32 candidate substances have been reported to occur widely in fruits, liquorice, 
milk powder, cabbage, mushroom, various herbs, coffee, tea, chicken, wine and rum. Quantitative data 
on the natural occurrence in food have been reported for 13 of these 32 substances (TNO, 2000). 
These reports include among others: 
• 2-Methylbutan-2-ol [FL-no: 02.041]: Up to 0.1 mg/kg in cherimoya, up to 0.1 mg/kg in 
loquat, up to 0.01 mg/kg in passion fruit, 0.00002 mg/kg in sapodilla fruit, 0.0007 mg/kg in 
chicken, 0.2 mg/kg in rum 
• 2-Methylpropan-2-ol [FL-no: 02.052]: 0.25 mg/kg in grape, up to 0.1 mg/kg in mango, 0.0021 
mg/kg in guava fruit 
• p-Menthane-1,8-diol [FL-no: 02.054]: Up to 0.37 mg/kg in cranberry 
• Cedrol [FL-no: 02.120]: 1900 mg/kg in calamus (European), up to 100 mg/kg in cinnamon 
• 2-Methylbut-3-en-2-ol [FL-no: 02.123]: 3.3 mg/kg in mango, up to 2.5 mg/kg in coffee, 1 
mg/kg in tea, 0.6 mg/kg in black currants, 0.1 mg/kg in cranberry, up to 0.1 mg/kg in passion 
fruit, 0.05 mg/kg in bilberry, up to 0.05 mg/kg in cherimoya, 0.002 mg/kg in papaya, trace 
amounts in cabbage, trace amounts in cardamom, 0.003 mg/kg in milk powder 
• Elemol [FL-no: 02.149]: 0.37 mg/kg in grapefruit juice  
• p-Menthan-8-ol [FL-no: 02.171]: 0.01 mg/kg in grapefruit juice 
• 2-Methylpentan-2-ol [FL-no: 02.181]: 0.01 mg/kg in plumcot  
• 3-Methylpentan-3-ol [FL-no: 02.184]: 0.034 mg/kg in plumcot 
• Myrcenol [FL-no: 02.185]: 1.1 mg/kg in liquorice, trace amounts in blueberry, 0.04 mg/kg in 
grapefruit juice, 0.04 mg/kg in grape  
• Ocimenol [FL-no: 02.191]: 0.04 mg/kg in apricot, 0.01 mg/kg in grapefruit juice. 
According to TNO eight of the substances have not been reported to occur naturally in any food items. 
These substances are: 1,2-dihydrolinalool [FL-no: 02.140], 3,6-dimethyloctan-3-ol [FL-no: 02.147], 
geranyl linalool [FL-no: 02.150], 1,2,3,4,4a,5,6,7-octahydro-2,5,5-trimethylnaphthalen-2-ol [FL-no: 
02.197], 2,6-dimethyl-2-heptanol [FL-no: 02.219], 2,4-dimethyl-4-nonanol [FL-no: 02.253], nerolidyl 
acetate [FL-no: 09.671] and guaiyl acetate [FL-no: 09.808] (TNO, 2000). 
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2. Specifications 
Purity criteria for the 32 substances have been provided by the Flavouring Industry (EFFA, 2004a; 
EFFA, 2005e; EFFA, 2006k; EFFA, 2007h; EFFA, 2010a; Flavour Industry, 2009c; Flavour Industry, 
2009f) (Table 1). 
Judged against the requirements in Annex II of Commission Regulation (EC) No 1565/2000 (EC, 
2000), the purity criteria for [FL-no: 02.129 and 02.146] are insufficient as boiling point is missing for 
[FL-no: 02.129] and for [FL-no: 02.146] is a boiling point and an minimum assay value missing. 
Furthermore, the stereoisomeric composition / composition of mixture need to be specified for [FL-no: 
02.129, 02.146, 02.147, 02.168, 02.191 and 02.197]. Otherwise the specifications are adequate for all 
32 candidate substances (see Section 1.2 and Table 1). 
3. Intake Data 
Annual production volumes of the flavouring substances as surveyed by the Industry can be used to 
calculate the “Maximised Survey-derived Daily Intake” (MSDI) by assuming that the production 
figure only represents 60 % of the use in food due to underreporting and that 10 % of the total EU 
population are consumers (SCF, 1999a). 
However, the Panel noted that due to year-to-year variability in production volumes, to uncertainties 
in the underreporting correction factor and to uncertainties in the percentage of consumers, the 
reliability of intake estimates on the basis of the MSDI approach is difficult to assess. 
The Panel also noted that in contrast to the generally low per capita intake figures estimated on the 
basis of this MSDI approach, in some cases the regular consumption of products flavoured at use 
levels reported by the Flavour Industry in the submissions would result in much higher intakes. In 
such cases, the human exposure thresholds below which exposures are not considered to present a 
safety concern might be exceeded. 
Considering that the MSDI model may underestimate the intake of flavouring substances by certain 
groups of consumers, the SCF recommended also taking into account the results of other intake 
assessments (SCF, 1999a). 
One of the alternatives is the “Theoretical Added Maximum Daily Intake” (TAMDI) approach, which 
is calculated on the basis of standard portions and upper use levels (SCF, 1995) for flavourable 
beverages and foods in general, with exceptional levels for particular foods. This method is regarded 
as a conservative estimate of the actual intake by most consumers because it is based on the 
assumption that the consumer regularly eats and drinks several food products containing the same 
flavouring substance at the upper use level. 
One option to modify the TAMDI approach is to base the calculation on normal rather than upper use 
levels of the flavouring substances. This modified approach is less conservative (e.g., it may 
underestimate the intake of consumers being loyal to products flavoured at the maximum use levels 
reported) (EC, 2000a). However, it is considered as a suitable tool to screen and prioritise the 
flavouring substances according to the need for refined intake data (EFSA, 2004a). 
3.1. Estimated Daily per Capita Intake (MSDI Approach) 
The intake estimation is based on the Maximised Survey-derived Daily Intake (MSDI) approach, 
which involves the acquisition of data on the amounts used in food as flavourings (SCF, 1999a). These 
data are derived from surveys on annual production volumes in Europe. These surveys were conducted 
in 1995 by the International Organization of the Flavour Industry, in which flavour manufacturers 
reported the total amount of each flavouring substance incorporated into food sold in the EU during 
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the previous year (IOFI, 1995). The intake approach does not consider the possible natural occurrence 
in food. 
Average per capita intake (MSDI) is estimated on the assumption that the amount added to food is 
consumed by 10 % of the population4 (Eurostat, 1998). This is derived for candidate substances from 
estimates of annual volume of production provided by Industry and incorporates a correction factor of 
0.6 to allow for incomplete reporting (60 %) in the Industry surveys (SCF, 1999a). 
In the present Flavouring Group Evaluation the total annual volume of production of the 32 candidate 
substances from use as flavouring substances in Europe has been reported to be 10800 kg (EFFA, 
2004b; EFFA, 2005e; EFFA, 2006k; EFFA, 2007h; Flavour Industry, 2009c; Flavour Industry, 
2009f). For the supporting substances the total annual volume of production is approximately 58000 
kg (JECFA, 2000a). 
On the basis of the annual volume of production reported for the 32 candidate substances, MSDI 
values for each of these flavourings have been estimated (Table 2a). 
Ninety-four percent of the total annual volume of production for the candidate substances is accounted 
for by terpineol [FL-no: 02.230] with 10200 kg. The estimated MSDI of terpineol from use as a 
flavouring substance is 1200 microgram/capita/day. The daily per capita intakes for each of the 
remaining substances are less than 30 microgram (Table 2a). 
3.2. Intake Estimated on the Basis of the Modified TAMDI (mTAMDI) 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values 
is based on the approach used by SCF up to 1995 (SCF, 1995). 
The assumption is that a person may consume a certain amount of flavourable foods and beverages per 
day. 
For the present evaluation of the 32 candidate substances, information on food categories and normal 
and maximum use levels5,6,7 were submitted for 31 of the 32 candidate substances by the Flavour 
Industry (EFFA, 2004a; EFFA, 2005e; EFFA, 2006k; EFFA, 2007a; EFFA, 2007h; Flavour Industry, 
2009c). The 31 candidate substances are used in flavoured food products divided into the food 
categories, outlined in Annex III of the Commission Regulation (EC) No 1565/2000 (EC, 2000a), as 
shown in Table 3.1. For one of the candidate substances no use levels have been submitted [FL-no: 
02.146]. See corresponding entry in Table 3.1. For the present calculation of mTAMDI, the reported 
normal use levels were used. In the case where different use levels were reported for different food 
categories the highest reported normal use level was used. 
                                                     
 
4 EU figure 375 millions. This figure relates to EU population at the time for which production data are available, and is consistent (comparable) with 
evaluations conducted prior to the enlargement of the EU. No production data are available for the enlarged EU. 
5 ”Normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th percentile of reported usages (EFFA, 2002i). 
6 The normal and maximum use levels in different food categories (EC, 2000) have been extrapolated from figures derived from 12 model flavouring substances 
(EFFA, 2004e). 
7 The use levels from food category 5 “Confectionery” have been inserted as default values for food category 14.2 “Alcoholic beverages” for substances for 
which no data have been given for food category 14.2 (EFFA, 2007a). 
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Table 3.1 Use of Candidate Substances 
Food 
category 
Description Flavourings used 
01.0 Dairy products, excluding products of category 2 31 except [02.197], no 
data for [FL-no: 02.146] 
02.0 Fats and oils, and fat emulsions (type water-in-oil) 31 except [02.197, 
02.226], no data for [FL-
no: 02.146] 
03.0 Edible ices, including sherbet and sorbet 31 except [02.197, 
09.671], no data for [FL-
no: 02.146] 
04.1 Processed fruits 31 except [02.197, 02.226, 
02.230], no data for [FL-
no: 02.146] 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses 
and legumes), and nuts & seeds 
[09.171], no data for [FL-
no: 02.146] 
05.0 Confectionery 31 except [02.197], no 
data for [FL-no: 02.146] 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, 
pulses & legumes, excluding bakery 
31 except [02.197, 
02.230], no data for [FL-
no: 02.146] 
07.0 Bakery wares 31 except [02.197], no 
data for [FL-no: 02.146] 
08.0 Meat and meat products, including poultry and game 31 except [02.129, 02.197, 
02.226], no data for [FL-
no: 02.146] 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  31 except [02.129, 02.197, 
02.226, 02.230, 02.253], 
no data for [FL-no: 
02.146] 
10.0 Eggs and egg products None, no data for [FL-no: 
02.146] 
11.0 Sweeteners, including honey None, no data for [FL-no: 
02.146] 
12.0 Salts, spices, soups, sauces, salads, protein products etc. 31 except [02.197], no 
data for [FL-no: 02.146] 
13.0 Foodstuffs intended for particular nutritional uses 31 except [02.129, 02.197, 
02.226, 02.230], no data 
for [FL-no: 02.146] 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products 31 no data for [FL-no: 
02.146] 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts 31 except [02.197], no 
data for [FL-no: 02.146] 
15.0 Ready-to-eat savouries 31 except [02.129, 
02.197], no data for [FL-
no: 02.146] 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that 
could not be placed in categories 1 – 15 
31 except [02.197, 02.226, 
02.230], no data for [FL-
no: 02.146] 
 
According to the Flavour Industry the normal use levels for the 31 candidate substances for which use 
level data are available, are in the range of 2 - 200 mg/kg food, and the maximum use levels are in the 
range of 5 - 500 mg/kg (EFFA, 2002i; EFFA, 2004a; EFFA, 2005e; EFFA, 2006k; EFFA, 2007a; 
EFFA, 2007h; Flavour Industry, 2009c) (see Table II.1.2, Annex II). 
The mTAMDI values for the 20 candidate substances from structural class I (See Section 5) range 
from 3900 to 14000 microgram/person/day. For the 10 candidate substances from structural class II 
the mTAMDI values are 3900 microgram/person/day for each of nine candidate substances, and 1600 
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microgram/person/day for one candidate substance. For the one substance from structural class III the 
mTAMDI value is 5700 microgram/person/day (see Section 6).  
For detailed information on use levels and intake estimations based on the mTAMDI approach, see 
Section 6 and Annex II. 
4. Absorption, Distribution, Metabolism and Elimination 
Seven of the candidate substances in this group are esters [FL-no: 09.171, 09.356, 09.614, 09.617, 
09.669, 09.671 and 09.808]. Hydrolysis data are not available for any of these esters. However, in 
vitro hydrolysis data for the supporting substance linalyl acetate, indicate that these seven esters can be 
anticipated to be hydrolysed. The carboxylic acids resulting from the hydrolysis of these seven 
candidate substances are acetic acid, propanoic acid and valeric acid, which will all be incorporated in 
normal metabolic processes such as beta-oxidation and the citric acid cycle. The alcohols resulting 
from the hydrolysis of these esters are tertiary alcohols and their metabolisms are considered further 
below, together with the candidate tertiary alcohols in this Flavouring Group Evaluation. 
A consideration of the chemical structures of the candidate substances, their anticipated pathways of 
metabolism and the extent to which data on one substance may support the metabolism of another 
substance has indicated that it is appropriate to divide the candidate substances in FGE.18Rev2 into 
eight subgroups of more closely related structures. This subdivision is shown in Table 4.1. 
Table 4.1. Candidate Substances Divided into Subgroups of Related Chemical Structures 
Subgroup FL-no Candidate substance Chemical group 
1 
02.041 2-Methylbutan-2-ol 
Aliphatic saturated tertiary alcohols 
and one ester thereof 
02.052 2-Methylpropan-2-ol 
02.147 3,6-Dimethyloctan-3-ol 
02.181 2-Methylpentan-2-ol 
02.184 3-Methylpentan-3-ol 
02.219 2,6-Dimethyl-2-heptanol 
02.253 2,4-Dimethyl-4-nonanol 
09.356 1,1-Dimethylethyl propionate 
2 
02.123 2-Methylbut-3-en-2-ol 
Aliphatic unsaturated tertiary 
alcohols with isolated terminal 
double bonds and two esters thereof 
02.144 2,6-Dimethyloct-7-en-2-ol 
02.150 Geranyl linalool 
02.168 Isophytol 
02.226 [S-(cis)]-3,7,11-Trimethyl-1,6,10-dodecatrien-3-ol 
09.614 Linalyl valerate 
09.671 Nerolidyl acetate 
3 
02.146 3,7- Dimethylocta-1,5,7-trien-3-ol 
Aliphatic unsaturated tertiary 
alcohols with conjugated terminal 
double bonds and one ester thereof 
02.185 Myrcenol 
02.191 Ocimenol 
09.669 Myrcenyl acetate 
4 02.140 1,2-Dihydrolinalool Aliphatic unsaturated tertiary alcohol (without terminal double bond) 
5 
02.054 p-Menthane-1,8-diol 
Monocyclic saturated and 
unsaturated tertiary alcohols and one 
ester thereof 
02.129 Bisabola-1,12-dien-8-ol 
02.171 p-Menthan-8-ol 
02.230 Terpineol 
09.617 p-Menthan-8-yl acetate 
6 
02.149 Elemol Monocyclic and bicyclic unsaturated 
tertiary alcohols with isolated 
terminal double bonds 02.206 Sclareol 
7 
02.197 1,2,3,4,4a,5,6,7-Octahydro-2,5,5-trimethylnapthalen-2-ol Bi- and tricyclic tertiary alcohols and 
esters 02.120 Cedrol 
09.171 Cedryl acetate 
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Table 4.1. Candidate Substances Divided into Subgroups of Related Chemical Structures 
Subgroup FL-no Candidate substance Chemical group 
09.808 Guaiyl acetate 
8 02.203 2-Phenylpropan-2-ol Tertiary alcohol with an aromatic substituent 
 
Subgroup 1: Metabolism studies of the three candidate substances 2-methylbutan-2-ol [FL-no: 
02.041], 2-methylpropan-2-ol [FL-no: 02.052] and 2-methylpentan-2-ol [FL-no: 02.181] show that 
these are conjugated with glucuronic acid before excretion in the urine. When rats were given 2-
methylpropan-2-ol by gavage, acetone was excreted in small amounts, and when given 2-methylbutan-
2-ol by gavage, diols were excreted. This indicates that an additional metabolic pathway of the three 
candidate substances is oxidation of methyl groups. From these metabolism studies it is anticipated 
that the candidate substances 2-methylbutan-2-ol [FL-no: 02.041], 2-methylpropan-2-ol [FL-no: 
02.052], 3,6-dimethyloctan-3-ol [FL-no: 02.147], 2-methylpentan-2-ol [FL-no: 02.181], 3-
methylpentan-3-ol [FL-no: 02.184], 2,6-dimethyl-2-heptanol [FL-no: 02.219], 2,4-dimethyl-4-nonanol 
[FL-no: 02.253] and the hydrolysis product 2-methylpropan-2-ol from the candidate substance 1,1-
dimethylethyl propionate [FL-no: 09.356] are conjugated with glucuronic acid and excreted in the 
urine, or that they can undergo oxidation to yield the corresponding diols, which are also expected to 
be excreted as their respective glucuronic acid conjugates. 
Subgroup 2: Linalool is a supporting substance to the candidate substances 2-methylbut-3-en-2-ol, 
linalyl valerate, nerolidyl acetate, isophytol, [S-(cis)]-3,7,11-trimethyl-1,6,10-dodecatrien-3-ol and 
geranyl linalool [FL-no: 02.123, 09.614, 09.671, 02.168, 02.226 and 02.150], which all have an 
isolated terminal double bond in close proximity to the tertiary alcohol group. As these substances or 
their respective alcohol moieties have a free hydroxyl group, they may be directly conjugated. 
Seventy-two hours after intragastrical application of 500 mg/kg bw 14C-labelled linalool to 12 weeks 
old rats 58-60 % of the dose was excreted in the urine, 12-15 % in the faeces and 25-27 % in the 
expired air. In tissues 3-4 % residual activity was found. Beyond unchanged linalool the main 
metabolites in urine and faeces were dihydrolinalool and tetrahydrolinalool, mainly conjugated with 
sulphate or glucuronic acid. The study also indicated that the reduction mainly took place in the gut 
(Rahman, 1974a). In addition, the metabolism of linalool indicates that these candidate substances 
may also be metabolised by omega-oxidation of methyl groups and excreted in the urine as the 
oxidation product as such or after conjugation with glucuronic acid. No oxidation of the terminal 
double bond in linalool was observed, indicating no formation of epoxide intermediates. 
For 2,6-dimethyloct-7-en-2-ol [FL-no: 02.144] the structure differs from the supporting substance 
linalool and the other candidate substances in this group in that the isolated terminal double bond is 
located distant from the tertiary alcohol group. However, any risk from epoxide formation of this 
compound is considered to be low since at low dose such epoxides formed are anticipated to be 
efficiently metabolised by conjugation with glutathione or by epoxide-hydrolase mediated hydrolysis, 
and in line with the discussion in FGE.07Rev2, the candidate substance 2,6-dimethyloct-7-en-2-ol 
[FL-no: 02.144] can be evaluated via the A-side of the Procedure scheme. Moreover, the tertiary 
alcohol group  can be directly conjugated with glucuronic acid. 
Subgroup 3: Myrcene [FL-no: 01.008] is a supporting substance to the four candidate substances 3,7-
dimethylocta-1,5,7-trien-3-ol, myrcenol, ocimenol and myrcenyl acetate [FL-no: 02.146, 02.185, 
02.191 and 09.669]. These substances also have alcohol moieties that can be directly conjugated. In 
addition, further oxidation of methyl groups may occur. As shown for myrcene, oxidation of 
conjugated terminal double bonds in the candidate substances may occur, resulting in epoxide 
intermediates. However the available genotoxicity data for myrcene do not indicate a genotoxic 
potential for this substance even in the presence of metabolic activation. Nevertheless, it cannot be 
anticipated that these candidate substances will be metabolised to innocuous products.  
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Subgroup 4: 1,2-Dihydrolinalool [FL-no: 02.140] has been shown to be directly conjugated with 
glucuronic acid like the supporting substance linalool, and excreted. After incubation of linalool or 
linalyl acetate with gut microflora from rat, mice or sheep dihydrolinalool and tetrahydrolinalool are 
formed as metabolites (Rahman, 1974a). In vivo metabolism studies in rats on 14C-labelled linalool 
demonstrated that linalool can be metabolised to dihydrolinalool and further to tetrahydrolinalool in 
the gut and excreted in urine and faeces as sulphates and glucoronides (Rahman, 1974a). Additionally, 
it might be oxidised at the methyl groups, introducing new hydroxyl groups that also can be 
conjugated and excreted.  
Subgroup 5: From the metabolism studies of alpha-terpineol and menthol it is anticipated that the 
candidate substances terpineol [FL-no: 02.230], p-menthane-1,8-diol [FL-no: 02.054], bisabola-1,12-
dien-8-ol [FL-no: 02.129] and p-menthan-8-ol [FL-no: 02.171] (also an hydrolysis product of 
candidate substance: p-menthan-8-yl acetate [FL-no: 09.617]) may undergo allylic oxidation of the 
exocyclic methyl group. This could be further oxidised to a carboxylic acid group. Alternative or 
subsequent metabolism may occur by conjugation with glucuronic acid, followed by excretion in the 
urine.  
Subgroup 6: A metabolism study on elemol [FL-no: 02.149] indicates that the substance is absorbed 
from the gastrointestinal tract and mainly excreted in conjugation with glucuronic acid or sulphate, 
although one oxidised metabolite, hydroxyelemol, was also found in lower amounts. No oxidation of 
the isolated terminal double bond of elemol was found; accordingly, epoxidation of elemol [FL-no: 
02.149] and sclareol [FL-no: 02.206], which have the same structural features as elemol, would not be 
anticipated. 
Subgroup 7: Two metabolism studies on cedrol indicate that the candidate substances cedrol [FL-no: 
02.120], cedryl acetate [FL-no: 09.171] guaiyl acetate [FL-no: 09.808] and 1,2,3,4,4a,5,6,7-octahydro-
2,5,5-trimethylnaphthalen-2-ol [FL-no: 02.197] will be further hydroxylated and excreted in urine as 
such or as conjugates. 
Subgroup 8: In metabolism studies, the supporting substance 1-isopropyl-4-methylbenzene [FL-no: 
01.002] (synonym: p-cymene) was oxidised at the isopropyl side chain yielding 2-(p-tolyl)-2-
propanol, which is not further oxidised, but excreted unchanged or as a glucuronic acid conjugate. It is 
anticipated that the candidate substance 2-phenylpropan-2-ol [FL-no: 02.203] will follow the same 
pathway and be excreted unchanged or in conjugation with glucuronic acid. 
In summary, 28 of the candidate substances [FL-no: 02.041, 02.052, 02.054, 02.120, 02.123, 02.129, 
02.140, 02.144, 02.147, 02.149, 02.150, 02.168, 02.171, 02.181, 02.184, 02.197, 02.203, 02.206, 
02.219, 02.226, 02.230, 02.253, 09.171, 09.356, 09.614, 09.617, 09.671 and 09.808] are anticipated to 
be metabolised to innocuous products.  
Four of the candidate substances [FL-no: 02.146, 02.185, 02.191 and 09.669] (all in subgroup 3) 
contain conjugated terminal double bonds and data from a supporting substance, myrcene [FL-no: 
01.008] indicate that these may be oxidised, giving rise to epoxide intermediates. Thus, it cannot be 
anticipated that these three substances will be metabolised to innocuous products. Despite evidence for 
the formation of epoxide intermediates, the supporting substance produced negative results in in vitro 
genotoxicity studies and the Procedure can be applied for the safety evaluation of these four candidate 
substances.  
A more detailed discussion of the metabolism of the candidate substances in this evaluation is 
provided in Annex III. 
5. Application of the Procedure for the Safety Evaluation of Flavouring Substances 
The application of the Procedure is based on intakes estimated on the basis of the MSDI approach. 
Where the mTAMDI approach indicates that the intake of a flavouring substance might exceed its 
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corresponding threshold of concern, a formal safety assessment is not carried out using the Procedure. 
In these cases the Panel requires more precise data on use and use levels. For comparison of the intake 
estimations based on the MSDI approach and the mTAMDI approach, see Section 6. 
For the safety evaluation of the 32 candidate substances from chemical groups 6 and 8 the Procedure 
as outlined in Annex I was applied, based on the MSDI approach. The stepwise evaluations of the 32 
substances are summarised in Table 2a. 
Step 1 
Twenty of the 32 candidate substances of EU chemical groups 6 and 8 are classified into structural 
class I, 11 candidate substances are classified into stuctural class II and one candidate substance is 
classified into structural class III according to the decision tree approach presented by Cramer et al. 
(Cramer et al., 1978). 
Step 2 
Twenty-eigth of the candidate substances [FL-no: 02.041, 02.052, 02.054, 02.120, 02.123, 02.129, 
02.140, 02.144, 02.147, 02.149, 02.150, 02.168, 02.171, 02.181, 02.184, 02.197, 02.203, 02.206, 
02.219, 02.226, 02.230, 02.253, 09.171, 09.356, 09.614, 09.617, 09.671 and 09.808] are anticipated to 
be metabolised to innocuous products and proceed via the A-side of the Procedure scheme. 
Four of the candidate substances [FL-no: 02.146, 02.185, 02.191 and 09.669] contain conjugated 
terminal double bonds and data from the supporting substance myrcene [FL-no: 01.008] indicate that 
these may be oxidised, giving rise to epoxide intermediates. Despite evidence for the formation of 
epoxide intermediates, the supporting substance produced negative results in in vitro genotoxicity 
studies and therefore the Procedure was applied to these four candidate substances [FL-no: 02.146, 
02.185, 02.191 and 09.669]. In conclusion, the four substances [FL-no: 02.146, 02.185, 02.191 and 
09.669] proceed via the B-side of the Procedure scheme. 
Step A3 
Seventeen of the candidate substances [FL-no: 02.054, 02.120, 02.140, 02.144, 02.149, 02.168, 
02.171, 02.206, 02.219, 02.226, 02.230, 02.253, 09.171, 09.614, 09.617, 09.671 and 09.808], which 
are anticipated to be metabolised to innocuous products have been assigned to structural class I. These 
substances have estimated European daily per capita intakes (MSDI) ranging from 0.0012 to 1200 
microgram (Table 2a). These intakes are below the threshold of concern of 1800 
microgram/person/day for structural class I. 
Ten of the candidate substances [FL-no: 02.041, 02.052, 02.123, 02.147, 02.150, 02.181, 02.184, 
02.197, 02.203 and 09.356], which are predicted to be metabolised to innocuous products have been 
assigned to structural class II. These substances have European daily per capita intakes (MSDI) of 
0.0012 to 12 microgram. These intakes are below the threshold of concern of 540 
microgram/person/day for structural class II. 
One of the candidate substances [FL-no: 02.129] which is predicted to be metabolised to innocuous 
products has been assigned to structural class III. This substance has European daily per capita intake 
(MSDI) of 27 microgram. This intake is below the threshold of concern of 90 microgram/person/day 
for structural class III. 
Based on results of the safety evaluation sequence these 28 candidate substances [FL-no: 02.041, 
02.052, 02.054, 02.120, 02.123, 02.129, 02.140, 02.144, 02.147, 02.149, 02.150, 02.168, 02.171, 
02.181, 02.184, 02.197, 02.203, 02.206, 02.219, 02.226, 02.230, 02.253, 09.171, 09.356, 09.614, 
09.617, 09.671 and 09.808] proceeding via the A-side of the Procedure scheme do not pose a safety 
concern when used as flavouring substances at estimated levels of intake. 
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Step B3 
The four candidate substances (all in subgroup 3), which could not be predicted to be metabolised to 
innocuous products [FL-no: 02.146, 02.185, 02.191 and 09.669] have been assigned to structural class 
I and II. These substances have estimated European daily per capita intakes (MSDI) ranging from 
0.0012 to 12 microgram (Table 2a). These intakes are below the thresholds of concern of 1800 and 
540 microgram/person/day for structural class I and II, respectively. Accordingly, they proceed to step 
B4 of the Procedure. 
Step B4 
No NOAEL could be derived for any of the four candidate substances proceeding via the B-side or for 
structurally related substances. Accordingly, further data are required for these four candidate 
substances [FL-no: 02.146, 02.185, 02.191 and 09.669].  
6. Comparison of the Intake Estimations Based on the MSDI Approach and the mTAMDI 
Approach 
The estimated intakes for 18 of the 20 candidate substances in structural class I, based on the 
mTAMDI, are 3900 microgram/person/day, and for the two remaining substances 7000 and 14000 
microgram/person/day, respectively. For these 20 candidate substances the mTAMDI is above the 
threshold of concern of 1800 microgram/person/day. For comparison of the intake estimates based on 
the MSDI approach and the mTAMDI approach, see Table 6.1. 
The estimated intakes for nine of the 11 substances assigned to structural class II, based on the 
mTAMDI, are 3900 microgram/person/day, and for the remaining one substance 1600 
microgram/person/day. These are all above the threshold of concern for structural class II substances 
of 540 microgram/person/day. For one candidate substance [FL-no: 02.146] no use and use levels have 
been provided by Industry. For comparison of the MSDI and mTAMDI values, see Table 6.1. 
The estimated intake for the substance assigned to structural class III, based on the mTAMDI is 5700 
microgram/person/day, which is above the threshold of concern for structural class III substances of 
90 microgram/person/day. For comparison of the MSDI- and mTAMDI-values see Table 6.1. 
Thus, for all the candidate substances further information is required. This would include more reliable 
intake data and then, if required, additional toxicological data. 
For comparison of the MSDI and mTAMDI values, see Table 6.1 
 
Table 6.1 Estimated intakes based on the MSDI approach and the mTAMDI approach 
FL-no EU Register name MSDI 
(μg/capita/day) 
mTAMDI 
(μg/person/day) 
Structural 
class 
Threshold of concern 
(µg/person/day) 
02.054 p-Menthane-1,8-diol 11 3900 Class I 1800 
02.120 Cedrol 13 3900 Class I 1800 
02.140 1,2-Dihydrolinalool 0.044 3900 Class I 1800 
02.144 2,6-Dimethyloct-7-en-2-ol 0.0012 3900 Class I 1800 
02.149 Elemol 1.6 3900 Class I 1800 
02.168 Isophytol 0.037 3900 Class I 1800 
02.171 p-Menthan-8-ol 0.012 3900 Class I 1800 
02.206 Sclareol 0.67 3900 Class I 1800 
02.219 2,6-Dimethyl-2-heptanol 0.012 3900 Class I 1800 
02.226 [S-(cis)]-3,7,11-Trimethyl-1,6,10-
dodecatrien-3-ol 
0.049 7000 Class I 1800 
02.230 Terpineol 1200 14000 Class I 1800 
02.253 2,4-Dimethyl-4-Nonanol 0.24 3900 Class I 1800 
09.171 Cedryl acetate 0.99 3900 Class I 1800 
09.614 Linalyl valerate 0.43 3900 Class I 1800 
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09.617 p-Menthan-8-yl acetate 0.012 3900 Class I 1800 
09.671 Nerolidyl acetate 0.061 3900 Class I 1800 
09.808 Guaiyl acetate 0.0012 3900 Class I 1800 
02.185 Myrcenol 0.012 3900 Class I 1800 
02.191 Ocimenol 0.012 3900 Class I 1800 
09.669 Myrcenyl acetate 8.6 3900 Class I 1800 
02.041 2-Methylbutan-2-ol 2.7 3900 Class II 540 
02.052 2-Methylpropan-2-ol 0.012 3900 Class II 540 
02.123 2-Methylbut-3-en-2-ol 0.0012 3900 Class II 540 
02.146 3,7-Dimethylocta-1,5,7-trien-3-ol 12  Class II 540 
02.147 3,6-Dimethyloctan-3-ol 0.0012 3900 Class II 540 
02.150 Geranyl linalool 0.026 3900 Class II 540 
02.181 2-Methylpentan-2-ol 0.12 3900 Class II 540 
02.184 3-Methylpentan-3-ol 0.0012 3900 Class II 540 
02.197 1,2,3,4,4a,5,6,7-Octahydro-2,5,5-
trimethylnaphthalen-2-ol 
0.026 1600 Class II 540 
02.203 2-Phenylpropan-2-ol 0.0012 3900 Class II 540 
09.356 1,1-Dimethylethyl propionate 0.0012 3900 Class II 540 
02.129 Bisabola-1,12-dien-8-ol 27 5700 Class III 90 
7. Considerations of Combined Intakes from Use as Flavouring Substances 
Because of structural similarities of candidate and supporting substances, it can be anticipated that 
many of the flavourings are metabolised through the same metabolic pathways and that the 
metabolites may affect the same target organs. Further, in case of combined exposure to structurally 
related flavourings, the pathways could be overloaded. Therefore, combined intake should be 
considered. As flavourings not included in this FGE may also be metabolised through the same 
pathways, the combined intake estimates presented here are only preliminary. Currently, the combined 
intake estimates are only based on MSDI exposure estimates, although it is recognised that this may 
lead to underestimation of exposure. After completion of all FGEs, this issue should be readdressed. 
The total estimated combined daily per capita intake of structurally related flavourings is estimated by 
summing the MSDI for individual substances. 
The four substances for which additional data are requested (See Section 5) [FL-no: 02.146, 02.185, 
02.191 and 09.669] and belonging to structural class I and II, will not be included in the combined 
intake. The combined intakes have been calculated for the remaining candidate and supporting 
substances. 
On the basis of the reported annual production volumes in Europe (EFFA, 2004b), the estimated 
combined daily per capita intake as flavourings of the 17 candidate substances assigned to structural 
class I is approximately 1200 microgram, which does not exceed the threshold of concern for a 
compound belonging to structural class I of 1800 microgram/person/day.  
On the basis of the reported annual production volumes in Europe the estimated combined daily per 
capita intake as flavouring of the 10 candidate flavouring substances assigned to structural class II is 
approximately 3 microgram, which does not exceed the threshold of concern for a compound 
belonging to structural class II of 540 microgram/person/day.  
The 28 candidate substances are structurally related to 26 supporting substances of which 23 were 
evaluated by JEFCA at its 51st meeting (JECFA, 2000a) and three were evaluated by the JECFA at its 
63rd meeting (JECFA, 2005c). The total combined intake (in Europe) of the candidate and the 
supporting substances all assigned to structural class I is approximately 24000 microgram/capita/day, 
which exceeds the threshold of concern for the corresponding structural class (1800 
microgram/person/day). 
However, the major contribution to the total combined intake of flavouring substances assigned to 
structural class I (94 %) is provided by four supporting substances, namely menthol [FL-no: 02.015] 
(16000 microg/capita/day), linalool [FL-no: 02.013] (2200 microg/capita/day), alpha-terpineol [FL-
no: 02.014] (2600 microg/capita/day) and linalyl acetate [FL-no: 09.013] (1700 microg/capita/day).  
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The estimated intake of menthol [FL-no: 02.015] and of alpha-terpineol [FL-no: 02.014] corresponds 
to 0.310 mg/kg bw/day. This represents 8 % of the acceptable daily intake (ADI) of 4 mg/kg bw/day 
for menthol established at the 51st JECFA meeting (JECFA, 2000a). 
The reported NOAEL of 24 mg/kg bw/day for linalyl acetate (the lowest reported NOAEL) is 340-fold 
higher than the estimated combined intake of 0.07 mg/kg bw/day of linalool [FL-no: 02.013] and 
linalyl acetate [FL-no: 09.013]. 
Excluding the four major contributors (menthol, linalool, alpha-terpineol and linalyl acetate), the total 
estimated combined intake (in Europe) for the candidate and supporting substances belonging to 
structural class I is approximately 552 microgram/capita/day, which does not exceed the threshold of 
concern for the corresponding structural class (1800 microgram/person/day). 
The total estimated combined intake (in Europe) of the candidate and the supporting substances 
assigned to structural class II is 6.5 microgram/capita/day, which does not exceed the threshold of 
concern for the corresponding structural class (540 microgram/person/day). 
The intake of the one candidate substance assigned to structural class III is 27 microgram/capita/day. 
No supporting substances are assigned to structural class III and thus calculation of a combined intake 
for this substance is not applicable. 
8. Toxicity 
8.1. Acute Toxicity 
Data are available for 16 of the 32 candidate substances and for 19 of the 26 supporting substances. 
The oral LD50 values in rats, mice or rabbits ranged from 230 to 50000 mg/kg body weight (bw). 
The magnitudes of the LD50 values indicate that the oral acute toxicity is low for the candidate and 
supporting substances.  
The acute toxicity data are summarised in Annex IV, Table IV.1. 
8.2. Subacute, Subchronic, Chronic and Carcinogenicity Studies 
Data are available for six of the candidate substances, 2-methylpropan-2-ol [FL-no: 02.052], cedrol 
[FL-no: 02.120], 2-methylbut-3-en-2-ol [FL-no: 02.123], bisabola-1,12-dien-8-ol [FL-no: 02.129], 
2,6-Dimethyloct-7-en-2-ol [FL-no: 02.144], and sclareol [FL-no: 02.206] (see Annex IV, Table IV.2).  
A number of studies have been conducted on 2-methyl-propan-2-ol [FL-no: 02.052], as described 
below: 
In a 10-week study in male rats, exposure to drinking water containing 0.5 % 2-methylpropan-2-ol 
[FL-no: 02.052] (equivalent to 500 mg/kg bw/day) resulted in histopathological changes in the liver 
and kidney. No other tissues were examined or analyses performed (Acharya et al., 1997).  
Ninety-day studies were performed in Fisher F344/N rats and B6C3F1 mice, in conjunction with 2 
year chronic toxicity/carcinogenicity studies, which are described below. The main findings after 90 
days were, in rats, hyperplasia and inflammation of the urinary bladder in males receiving 2 % and 
males and females receiving 4 % 2-methylpropan-2-ol in the drinking water (equivalent to 2000 and 
4000 mg/kg bw/day, respectively), increased incidence of nephropathy in females receiving 0.5 %, 1 
% and 4 % (equivalent to 500, 1000 and 4000 mg/kg bw/day) and increased severity of nephropathy in 
males at all treatment doses (intakes of 250 mg/kg bw/day and above). In mice, transitional epithelial 
hyperplasia and inflammation were observed in the urinary bladder in 2 % and 4 % group males 
(equivalent to 5000 and 10,000 mg/kg bw/day, respectively) and 4 % group females (equivalent to 
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10,000 mg/kg bw/day) (Lindamood et al., 1992; NTP, 1995b). These observations were consistent 
with earlier 90-day studies using the same species and strains and the same dose levels, except that 
there was no reference in the short report to renal effects in rats (Brown & Wheeler, 1979). 
In the 2-year study on 2-methylpropan-2-ol [FL-no: 02.052] in F344/N rats, the animals 
(60/sex/group) were dosed via drinking water containing, for males 0, 0.125, 0.25 or 0.5 % (equivalent 
to 0, 90, 200 or 420 mg/kg bw/day) and for females 0, 0.25, 0.5 or 1 % (equivalent to 0, 180, 330 or 
650 mg/kg bw/day), 2-methylpropan-2-ol. Survival was significantly reduced in the 0.5 % male group 
and 1 % female group. Severity of nephropathy and incidence and severity of transitional cell 
nephropathy were reported to be increased in all treated groups. Foci of mineralisation were observed 
in the renal papillas in all treated groups, and the incidence of renal mineralisation was significantly 
increased in the 0.5 % male group. The incidences of focal renal tubular hyperplasia and adenoma 
were observed to be increased in a dose-related manner in all treated male groups but did not reach 
statistical significance. Combined incidences of renal tubular adenomas and carcinomas were 
significantly increased in the 0.25 % male group, although not in the 0.5 % dose group. Renal tubular 
hyperplasia was observed in one female in the 1 % dose group (NTP, 1995b). A review subcommittee 
for the US National Toxicology Program (NTP) concluded that the study showed ‘some evidence of 
carcinogenic activity’ in the males and ‘no evidence of carcinogenic activity’ in the females (NTP, 
1995b). 
Further examination of renal samples from the 90-day study in F344/N male rats revealed a significant 
increase in the quantity of hyaline droplets and number of intracytoplasmic deposits of abnormal shape 
(crystalline rhomboid structures) in treated groups compared to controls, indicating that the 
nephropathy observed in male rats was at least in part due to alpha-2  µ-globulin (Takahashi et al., 
1993). The NTP review subcommittee noted that the increased severity of nephropathy also seen in 
females indicated that the mechanism for renal toxicity is not limited to increased accumulation of 
alpha-2 µ-globulin (NTP, 1995b) ; however, tumours were observed in males only and appear to be 
related to a dose-related increase in renal tubule hyperplasia, which occurred in males only. 
The B6C3F1 mice (60/sex/group) received drinking water containing 0, 0.5, 1 or 2 % 2-methylpropan-
2-ol [FL-no: 02.052] (equivalent to 0, 540, 1040, 2070 mg/kg bw/day in males and 0, 510, 1020 or 
2100 mg/kg bw/day in females) for 2 years. Survival of the 2 % male group was significantly reduced 
compared to controls. Incidence of follicular cell hyperplasia of the thyroid were significantly 
increased in all treated male groups and in the 1 % and 2 % female groups. Incidence of follicular cell 
adenoma was significantly increased in the 2 % female group. The combined incidences of follicular 
cell adenomas and carcinomas was observed to be increased in the 1 % male group, although this did 
not reach statistical significance. However, the incidence of adenoma exceeded the highest incidence 
seen in historic NTP drinking water controls. Chronic inflammation of the urinary bladder was 
significantly increased in the 2 % male and female groups, and transitional cell hyperplasia in the 
urinary bladder was significantly increased in the 2 % female group. No NOAEL could be derived 
from this study for males; the NOAEL in females was 0.5 % in the diet, equivalent to 510 mg/kg 
bw/day (NTP, 1995b). An NTP review subcommittee concluded that the study demonstrated 
‘equivocal evidence of carcinogenic activity’ in male mice and ‘some evidence of carcinogenic 
activity’ in females (NTP, 1995b). The Panel concluded that these tumours appear to be secondary to 
follicular cell hyperplasia, which was observed in all treated male groups and mid- and high-dose 
female groups.  
The Panel concluded, taking into account the clear lack of a genotoxic potential in vivo, that the 
carcinogenic effects observed in male rats and in mice appear likely to be due to threshold-based 
mechanisms. Therefore, the overall results do not preclude evaluating 2-methylpropan-2-ol and 
structurally related candidate substances through the Procedure.  
In a 90-day study, 2,6-dimethyloct-7-en-2-ol [FL-no: 02.144] was administered by gavage to ten male 
and ten female Sprague-Dawley rats at dose levels of 10, 50, 500 and 1000 mg/kg bw/day. A control 
group of ten males and ten females was dosed with vehicle (corn oil) alone (Dunster et al. 2006). In 
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female rats, treatment related effects such as decrease in body weight, platelet counts, thromboplastin 
time, haemoglobin, hematocrit, erythrocyte counts, increase in serum aspartate aminotransferase, 
alanine aminotransferase, urinary creatinine were observed doses of 500 and/or 1000 mg/kg bw/day. 
No such changes were observed in females at the lower doses tested and therefore, 50 mg/kg bw/day 
was considered to constitute a No Observed Adverse Effect Level (NOAEL) for females. In the kidney 
of male rats, a greater incidence and/or severity of groups of basophilic tubules and/or globular 
accumulations of eosinophilic material were observed at all doses tested. Dunster et al., 2007 
considered these findings to be consistent with the presence of hydrocarbon nephropathy, which 
results from the excessive accumulation of alpha2-urinaryglobulin. The latter was indicated by 
positive staining with Mallory' s Heidenhain stain in renal proximal tubular epithelial cells, frequently 
associated with tubular degenerative changes. alpha2-Urinaryglobulin is found only in the proximal 
tubular epithelium of adult male rats. Dunster et al. 2007, concluded that this effect is not indicative of 
a hazard to human health and that 10 mg/kg/day should be regarded as the NOAEL for males (Dunster 
et al., 2007). 
A NOAEL of 150 mg/kg bw/day in rats is available from a 28-day oral toxicity study conducted on 2-
methylbut-3-en-2-ol [FL-no: 02.123] (BASF, 1994a).  
A NOAEL of 850 mg/kg bw/day in rats is available from a 28-day oral toxicity study conducted on 
bisabola-1,12-dien-8-ol [FL-no: 02.129] (Habersang et al., 1979). 
A 32-day oral toxicity study on both sclareol [FL-no: 02.206] and cedrol [FL-no: 02.120] was 
conducted in Charles River Laboratories CD (SD) rats. Two groups of 10 rats received dose levels of 
approximately 8.8 mg/kg bw/day of sclareol and two groups of 10 rats received dose levels of 
approximately 8.4 mg/kg bw/day of cedrol. The animals were dosed seven days per week via gavage. 
No adverse effects were observed (IOFI, 2006a). 
Data are available for six supporting substances [FL-no: 01.008, 02.013, 02.015, 09.013, 09.423 and 
09.830] and two other related substances (linalyl cinnamate and geranyl acetate) administered as a 
mixture together with citronellyl acetate (See Annex IV, Table IV.1).  
Linalool [FL-no: 02.013] was reported to result in no significant adverse effects compared to control 
when administered to rats at 50 mg/kg bw/day as a 50 % mixture with citronellol via the diet for 84 
days. No further details are available. Similarly linalyl acetate [FL-no: 09.013], linalyl isobutyrate 
[FL-no: 09.423] and geranyl acetate [FL-no: 09.011] administered as a mixture at doses of dosed 24, 
27 and 48 mg/kg bw/day respectively resulted in no adverse effects (Oser, 1967). 
No adverse effects were reported in rats (10/sex/group) given diets containing 0, 1000, 2500 or 10,000 
ppm linalyl isobutyrate [FL-no: 09.423] (equivalent to 0, 50, 125 or 500 mg/kg bw/day) (Hagan et al., 
1967) for 18 weeks. Few study details are available. Similarly no adverse effects were reported in a 
similar study on terpinyl acetate [FL-no: 09.830] given diet containing 0, 1000, 2500 or 10,000 ppm 
(equivalent to 0, 50, 125 or 500 mg/kg bw/day) for 20 weeks (Hagan et al., 1967). 
The repeated dose toxicity data are summarised in Annex IV, Table IV.2. 
8.3. Developmental / Reproductive Toxicity Studies 
Data are available for two candidate substances: 2-methylpropan-2-ol [FL-no: 02.052] and 2,6-
dimethyloct-7-en-2-ol [FL-no: 02.144].  
In a study on 2-methylpropan-2-ol [FL-no: 02.052], doses of 0.5, 0.75 or 1 % liquid diet (equivalent to 
approximately 3400, 4900 and 6400 mg/kg bw/day) administered to mice on days 6-20 of gestation 
were associated with reduced performance of offspring in four neurobehavioural tests: righting reflex, 
cliff avoidance and open field (conducted on days 2, 4, 6, 8 and 10 post-parturition) and roto-rod 
(conducted on days 14, 16, 18, 20 and 22). The authors indicated that there was some evidence of 
Flavouring Group Evaluation 18, Revision 2
 
 
20 EFSA Journal 2011; 9(5):1847 
recovery in the first three tests but not the latter during the periods of study (Daniel & Evans, 1982). In 
a second study, administration of 1557 mg/kg bw/day to pregnant CBA/J and C57BL/6J mice by oral 
gavage during days 6-18 of gestation resulted in a significant increase in the incidence of foetal 
resorptions and a significant decrease in the number of live births per litter. No foetal malformations 
were observed (Faulkner et al., 1989). The Panel noted that these experimental studies were conducted 
using very high doses and were not of concern when compared with the low exposure arising from use 
as flavouring substances. 
In a study on 2,6-dimethyloct-7-en-2-ol [FL-no: 02.144], doses of 0, 250, 500 or 1000 mg/kg bw/day 
were administered to Charles River Laboratory CD(SD) rats via corn oil gavage on gestational days 7-
17. Observations for viability, adverse clinical signs, abortion, and premature delivery were conducted 
before and approximately one hour following treatment and once thereafter. Body weight gains in the 
high-dose group were reduced by 5 % when compared to controls; weight losses were observed after 
the first two doses. Although these observations were not significant, they were considered to be 
evidence of a threshold level for maternal toxicity. Both maternal absolute and relative feed 
consumption values were significantly reduced in the 1000 mg/kg bw/day group compared to vehicle 
control. Reduced feed consumption was most prominent on gestational days 7-10, which correlated 
with the weight losses and reduced weight gains that occurred during the initial days of the dosing 
period. Body weights for combined male and female foetuses were reduced approximately 3 % in the 
1000 mg/kg bw per day group compared to vehicle controls (the reduction was statistically significant 
for females). No other litter parameters were affected by dosages of 2,6-dimethyloct-7-en-2-ol as high 
as 1000 mg/kg bw per day. Upon inspection, there were no foetal gross external alterations or foetal 
soft tissue or skeletal malformations observed in the experiment. There were no observable soft tissue 
variations, and skeletal variations were limited to two reversible minor changes. First, there was 
evidence of a threshold (but statistically significant) increase in supernumerary ribs, along with 
associated significant increases and decreases in the respective numbers of thoracic and lumbar 
vertebrae. Second, there was evidence of a small but statistically significant retardation in ossification 
of the metatarsal bones in the hind paws, evident as a reduction in the mean number of ossified 
metatarsal bones. The results indicate that 1000 mg 2,6-dimethyloct-7-en-2-ol/kg bw per day produced 
threshold levels of maternal and developmental toxicity. As such, the maternal and developmental no-
observable-adverse-effect levels (NOAELs) for 2,6-dimethyloct-7-en-2-ol are considered to be 500 
mg/kg/day (Politano et al., 2008). 
Data are available for three supporting substances [FL-no: 02.013, 02.015 and 01.008] (See Annex IV, 
Table IV.3). 
A NOAEL of 365 mg/kg bw/day was reported for linalool [FL-no: 02.013]. A higher dose of 729 
mg/kg bw/day resulted in decreased live litter size and increased pup mortality; maternal toxicity was 
observed at all doses tested (Hoberman & Christian, 1989). NOAELs of 185 to 425 mg/kg bw/day 
(highest doses tested) were reported for menthol [FL-no: 02.015] in teratological studies in rats, mice, 
hamsters and rabbits (Food and Drug Research Laboratories, Inc., 1973). Three studies have been 
performed in rats on myrcene [FL-no: 01.008]; two developmental toxicity studies (one in which 
myrcene was administered to dams on days 6-15 of gestation and one in which dosing was from day 
15 of gestation until weaning) and a single generation study. NOAELs were 500 mg/kg bw/day, 250 
mg/kg bw/day and 300 mg/kg bw/day, respectively (Delgado et al., 1993a; Delgado et al., 1993b; 
Paumgartten et al., 1998). 
The developmental/reproductive toxicity data are summarised in Annex IV, Table IV.3. 
8.4. Genotoxicity Studies 
Data from in vitro tests are available for nine candidate [FL-no: 02.052, 02.041, 02.120, 02.123, 
02.129, 02.140, 02.144, 02.168 and 02.197] and for eight supporting substances [FL-no: 01.002, 
01.008, 02.013, 02.014, 02.015, 02.097, 09.013 and 09.830]. Data from in vivo tests are available for 
Flavouring Group Evaluation 18, Revision 2
 
 
21 EFSA Journal 2011; 9(5):1847 
two candidate [FL-no: 02.052 and 02.123] and for three supporting substances [FL-no: 01.008, 02.013 
and 02.015].  
2-Methylpropan-2-ol [FL-no: 02.052] was negative in reversion tests in Salmonella typhimurium 
TA1535, TA1537, TA98 and TA100, without and with metabolic activation by rat and hamster liver 
S9 (Zeiger et al., 1987). A borderline (less than two-fold) increase in revertants in strain TA1535 was 
observed in two other studies (Haworth et al., 1981a; Haworth et al., 1981b), which were not available 
for evaluation. A marginal increase in sister chromatid exchange (SCE) was reported from two studies 
with Chinese hamster ovary (CHO) cells, which could not be evaluated because the papers were 
submitted incompletely (Putman, 1985; Thilagar et al., 1981). A borderline increase in mutant 
frequency was observed in mouse-lymphoma TK +/- cells in a single test in the absence of metabolic 
activation, whereas negative results were obtained in repeated experiments with S9 (McGregor et al., 
1988b). Again, similar results are quoted in the summary of an unpublished study not available for 
evaluation (Kirby et al., 1981). Finally, a slight increase of petite (mitochondrial) mutations was 
reported in yeast after treatment with 2-methylpropan-2-ol (Jiménez et al., 1988), but this effect is not 
considered relevant for genotoxicity assessment. 
1,2-Dihydrolinalool [FL-no: 02.140] was negative in S. typhimurium TA97, TA100, TA102, TA1535, 
without and with metabolic activation (Gocke, 1999a). In one test, 1,2-dihydrolinalool was negative 
without S9 but increased the number of revertants in TA98 with metabolic activation. This positive 
finding could not be reproduced in subsequent tests with TA98 (Gocke, 1999a).  
The remaining candidate substances, for which genotoxicity data have become available in this 
Revision 2 of FGE.18; Bisabola-1,12-dien-8-ol [FL-no: 02.129], cedrol [FL-no: 02.120], 2,6-
dimethyloct-7-en-2-ol [FL-no: 02.144], 1,2,3,4,4a,5,6,7-octahydro-2,5,5-trimethylnaphthalen-2-ol 
[FL-no: 02.197] were all negative in reversion tests in the following test objects, without and with 
metabolic activation by rat liver S9: [FL-no: 02.129]: S. typhimurium TA97a, TA98, TA100, TA102, 
TA1535, TA1537 up to 5000 µg/plate; [FL-no: 02.120]: S. typhimurium TA97a, TA98, TA102, 
TA1535 up to 5000 µg/plate; [FL-no: 02.144]: S. typhimurium TA98, TA100, TA102, TA1535, 
TA1537 up to 5000 µg/plate; and [FL-no: 02.197]: S. typhimurium TA98, TA100, TA1535, TA1537 
and E. coli WP2 uvrA up to 250 µg/plate without metabolic activation and up to 500 µg/plate with 
metabolic activation. The studies were considered valid. 
A negative result was obtained in a sister chromatid exchange (SCE) study on bisabola-1,12-dien-8-ol 
[FL-no: 02.129] with Chinese hamster ovary (CHO) cells. The data were presented in a review, but 
considered valid.  
In vivo, 2-methylpropan-2-ol gave clearly negative results in a rat bone marrow micronucleus test, 
after intraperitoneal (i.p.) administration of a range of doses (six doses from 39 to 1250 mg/kg bw), 
which reached complete lethality at the highest dose (NTP, 1997c). Negative results were also 
obtained in the mouse peripheral blood micronucleus assay, after 13 weeks of oral exposure to 3000 to 
40000 ppm in drinking water. There was no deviation in the PCE/NCE ratio in treated animals, but 
signs of general toxicity were observed at the two highest doses, indicating significant systemic 
exposure (NTP, 1995b). In another study, 2-methylpropan-2-ol was negative in the mouse bone 
marrow micronucleus assay when given by ip injections at doses up to 1250 mg/kg bw (three daily 
administrations) (NTP, 1996c). The alleged positive result obtained with 2-methylpropan-2-ol in a rat 
bone marrow chromosomal aberration test after oral administration of 1/5 of the LD50 (Barilyak & 
Kozachuk, 1988) is considered inconclusive, because the result is not adequately supported by 
experimental data. 
Terpineol [FL-no: 02.230] (the mixture of alpha-terpineol, beta-terpineol, delta-terpineol and gamma-
terpineol) was tested negative in a rec assay in Bacillus subtilis (Oda et al., 1978).  
Alpha-terpineol [FL-no: 02.014] was reported to give weakly positive results (as a dose-dependent 
increase in mutation frequency both with and without S9 activation with a maximum increase of 2.2-
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fold compared with the control) in an Ames-type mutagenicity assay in one (TA102) of four S. 
typhimurium strains tested (TA97a, TA98, TA100, TA102). alpha-Terpineol was incorporated into 
agar plates up to 2500 microgram/plate, either with or without S9 metabolic activation (Gomes-
Carneiro et al., 1998). 
In other studies, alpha-terpineol gave consistently negative results in Ames assays in S. typhimurium 
strains TA98, TA100, TA1535, TA1537 and TA1538, either with or without S9 metabolic activation 
(Florin et al., 1980; Lorillard, 1983b; Heck et al., 1989). 
In an in vivo/in vitro study designed to investigate the mutagenicity of the metabolites of beta-
terpineol [FL-no: 02.097], Sprague-Dawley rats were administered a single dose of 0.5 ml (452 mg) of 
beta-terpineol by gavage and the urine was collected for 24-hours. The urine (500 microl) was 
hydrolysed with beta-glucuronidase. Hydrolysed and un-hydrolysed urine samples, ether extracts of 
the urine, and aqueous fractions of the urine-ether extracts were then separately incubated with S. 
typhimurium strains TA98 and TA100 without S9 activation. Neither beta-terpineol, nor any of the 
urinary solutions isolated from the urine of rats given 452 mg doses of beta-terpineol, showed any 
evidence of mutagenicity in either TA98 or TAl00 without metabolic activation (Rockwell & Raw, 
1979). 
In gene mutation tests in mouse lymphoma cells, alpha-terpinol was non-mutagenic when applied of 
doses up to 250 nl/ml (with S9) and 300 nl/ml (without S9) (Lorillard, 1982); negative results were 
also obtained in another study in which alpha-terpineol was tested up to 0.5 µl/ml (without S9) and 
0.75 µl/ml (with S9) (Kirby et al., 1984). Based on the negative results obtained in gene mutation tests 
in mammalian cells, and in view of the sensibility of the TK+ /- system to mutagens specifically active 
toward the S. typhimurium strain TA102, the Panel concluded that alpha-terpineol does not raise 
concern for genotoxicity. 
Overall, 2-methylpropan-2-ol provided an equivocal evidence of genotoxicity in some in vitro assays, 
while it was clearly negative in vivo in cytogenetic tests conducted up to the maximum tolerated dose. 
The overall weight of the experimental evidence does not raise concern for in vivo genotoxicity. 
2-Methylbut-3-en-2-ol [FL-no: 02.123] was reported to be negative in two bacterial gene mutation 
tests and in an in vivo micronucleus test; however, the unpublished study reports are not available for 
re-evaluation. 
 
The available data considered valid do not give rise to safety concerns with respect to genotoxicity. 
The genotoxicity data are summaries in Annex IV, Table IV.4 and Table IV.5. 
9. Conclusions 
In the present Flavouring Group Evaluation 18, Revision 2 (FGE.18Rev2) seven of the candidate 
substances are aliphatic saturated tertiary alcohols and one is an ester of such, five are aliphatic 
unsaturated tertiary alcohols which possess isolated terminal double bonds and two are esters of such, 
three are aliphatic unsaturated tertiary alcohols with conjugated terminal double bonds and one is an 
ester of such, one is an aliphatic unsaturated tertiary alcohol which does not possess terminal double 
bonds, two are monocyclic saturated tertiary alcohols and one is an ester of such, two are a 
monocyclic unsaturated tertiary alcohol, two are mono- and bicyclic unsaturated tertiary alcohols with 
an isolated terminal double bond, one is a bicyclic unsaturated ester, three are bi- and tricyclic tertiary 
alcohols and one is a tertiary alcohol with an aromatic substituent. 
Nineteen of the 32 candidate substances possess one or more chiral centres and/or can exist as 
geometrical stereoisomers due to the presence of a double bond: [FL-no: 02.120, 02.129, 02.140, 
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02.144, 02.146, 02.147, 02.149, 02.150, 02.168, 02.191, 02.197, 02.206, 02.226, 02.230, 02.253, 
09.171, 09.614, 09.671 and 09.808]. For five of these substances [FL-no: 02.146, 02.147, 02.168, 
02.191 and 02.197] the stereoisomeric composition has not been specified sufficiently. For four of 
these five substances [FL-no: 02.147, 02.168, 02.191 and 02.197] the stereoisomeric composition of 
the mixture has not been specified. 
Twenty of the 32 candidate substances are classified into structural class I, 11 candidate substances are 
classified into stuctural class II and one is classified into structural class III according to the decision 
tree approach. 
Twenty-four out of the 32 candidate substances have been reported to occur in a wide range of food 
items.  
According to the default MSDI approach, 31 of the 32 flavouring substances in this group have intakes 
in Europe from 0.0012 to 27 microgram/capita/day, which are below the thresholds of concern for 
structural class I (1800 microgram/person/day), structural class II (540 microgram/person/day) and 
structural class III (90 microgram/person/day). The remaining substance, terpineol [FL-no: 02.230] 
belonging to structural class I, has an MSDI of 1200 microgram/capita/day, which is also below the 
threshold for this structural class. 
On the basis of the reported annual production volumes in Europe, the combined intakes of 17 
candidate substances belonging to class I and of 10 candidate substances belonging to class II would 
result in combined intakes of approximately 1200 and 3 microgram/capita/day, respectively. These 
values are lower than the thresholds of concern for structural class I and class II substances of 1800 
and 540 microgram/person/day, respectively. (The four substances for which additional data are 
requested are not included in the combined intake). The total combined intake of the candidate and 
supporting substances belonging to structural class I is approximately 24000 microgram/capita/day. 
This total combined intake exceeds the threshold for structural class I of 1800 micrograms/person/day. 
However, based on the available toxicological data and the anticipated efficient metabolism this 
combined intake is not considered to be of safety concern. The total combined intake of the candidate 
and supporting substances belonging to structural class II is approximately 6.5 microgram/capita/day, 
which is below the threshold of concern for structural class II (540 microgram/person/day). 
2-Methylpropan-2-ol [FL-no: 02.052] provided an equivocal evidence of genotoxicity in some in vitro 
assays, while it was clearly negative in vivo in cytogenetic tests conducted up to the maximum 
tolerated dose. The overall weight of the experimental evidence and the lack of structural alerts for 
genotoxicity for this substance and its metabolites do not raise concern for in vivo genotoxicity. For 
the other substances in this group the available data considered valid do not give rise to any safety 
concerns with respect to genotoxicity.  
Twenty-eight of the candidate substances are anticipated to be metabolised to innocuous products. For 
the remaining four candidate substances no metabolism data are available and therefore they cannot be 
predicted to be metabolised to innocuous products. No appropriate NOAEL was available for these 
four candidate substances [FL-no: 02.146, 02.185, 02.191 and 09.669] or for the supporting 
substances. Therefore, additional data are required for these four candidate substances.  
It is considered that, on the basis of the default MSDI approach, 28 of the 32 candidate substances 
[FL-no: 02.041, 02.052, 02.054, 02.120, 02.123, 02.129, 02.140, 02.144, 02.147, 02.149, 02.150, 
02.168, 02.171, 02.181, 02.184, 02.197, 02.203, 02.206, 02.219, 02.226, 02.230, 02.253, 09.171, 
09.356, 09.614, 09.617, 09.671 and 09.808] would not give rise to safety concerns at the estimated 
levels of intake arising from their use as flavouring substances. For the remaining four substances [FL-
no: 02.146, 02.185, 02.191 and 09.669], no appropriate NOAEL was available or for the supporting 
substances. Therefore, additional data are required for these four candidate substances.  
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The mTAMDI values for the 20 candidate substances from structural class I range from 3900 to 14000 
microgram/person/day. For 10 of the 11 candidate substances from structural class II, the mTAMDI 
values are 3900 microgram/person/day for each of nine candidate substances, and 1600 
microgram/person/day for one candidate substance. For one candidate substance [FL-no: 02.146] from 
structural class II no data on use and use levels are provided. For the one candidate substance from 
structural class III the mTAMDI is 5700 microgram/person/day. Accordingly, the estimated intakes 
for the 31 candidate substances for which use levels are provided are above the thresholds of concern 
for their structural classes. Therefore, for these 31 substances more reliable exposure data are required. 
On the basis of such additional data, these flavouring substances should be reconsidered along the 
steps of the Procedure. Following this Procedure additional toxicological data might become 
necessary.  
In order to determine whether the conclusion for the candidate substances can be applied to the 
materials of commerce, it is necessary to consider the available specifications. Adequate specifications 
including complete purity criteria and identity for the materials of commerce have been provided for 
all 32 candidate substances. However, information on the stereoisomeric composition has not been 
specified sufficiently for five substances [FL-no: 02.146, 02.147, 02.168, 02.191 and 02.197]. In 
addition, the composition of the mixture of [FL-no: 02.129] is missing and for [FL-no: 02.129 and 
02.146] are other information on specifications lacking. Thus, the final evaluation of the materials of 
commerce cannot be performed for six substances [FL-no: 02.129, 02.146, 02.147, 02.168, 02.191 and 
02.197], pending further information. 
In conclusion, for four flavouring substances [FL-no: 02.146, 02.185, 02.191 and 09.669] the Panel 
considered that additional data are needed. For six substances [FL-no: 02.129, 02.146, 02.147, 02.168, 
02.191 and 02.197] information on specifications/stereoisomerism/composition of mixture is missing. 
For 24 flavouring substances [FL-no: 02.041, 02.052, 02.054, 02.120, 02.123, 02.140, 02.144, 02.149, 
02.150, 02.171, 02.181, 02.184, 02.203, 02.206, 02.219, 02.226, 02.230, 02.253, 09.171, 09.356, 
09.614, 09.617, 09.671 and 09.808] evaluated using the Procedure the Panel considered that they 
would present no safety concern at their estimated levels of intake estimated on the basis of the MSDI 
approach.  
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TABLE 1: SPECIFICATION SUMMARY OF THE SUBSTANCES IN THE FLAVOURING GROUP EVALUATION 18, REVISION 2 
Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation18, Revision 2 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility in water 
1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
02.041 
 
2-Methylbutan-2-ol 
OH  
 
515 
75-85-4 
Liquid 
C5H12O 
88.15 
Slightly soluble 
1 ml in 1 ml 
102 
 
MS 
96 % 
1.402-1.408 
0.805-0.813 
 
 
02.052 
 
2-Methylpropan-2-ol OH
 
 
698 
75-65-0 
Liquid 
C4H10O 
74.12 
Slightly soluble 
1 ml in 1 ml 
82 
 
MS 
95 % 
1.384-1.390 
0.780-0.790 
 
 
02.054 
 
p-Menthane-1,8-diol 
OH
OH
 
 
701 
80-53-5 
Solid 
C10H20O2 
172.27 
Slightly soluble 
1 ml in 1 ml 
260 
116 
MS 
95 % 
n.a. 
n.a. 
 
 
02.120 
 
Cedrol 
OH
H
 
10190 
77-53-2 
Solid 
C15H26O 
222.37 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
286 
86 
MS 
95 % 
n.a. 
n.a. 
 
 
02.123 
 
2-Methylbut-3-en-2-ol 
OH  
 
11794 
115-18-4 
Liquid 
C5H10O 
86.13 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
97 
 
MS 
98 % 
1.413-1.419 
0.818-0.827 
 
 
02.129 
 
Bisabola-1,12-dien-8-ol    
OH
H
(l)-alpha-Bisabolol shown  
4666 
10178 
23089-26-1 
Liquid 
C15H26O 
222.37 
Insoluble 
Soluble 
 
 
MS 
>94 % 
1.493-1.499 
0.927-0.935 
BP 8). 
Register name to be changed 
to (l)-alpha-Bisabolol. 
Secondary components (no 
amount given):  
(d)-alpha-Bisabolol (CAS 
No. 23178-88-3),  
(l)-epi-alpha-Bisabolol 
(CAS No.78148-59-1), 
(d)-epi-alpha-Bisabolol 
(CAS No. 76738-75-5). 
02.140 
 
1,2-Dihydrolinalool OH
 
 
 
2270-57-7 
Liquid 
C10H20O 
156.27 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
90 (16 hPa) 
 
MS 
95 % 
1.452-1.458 
0.857-0.863 
 
Racemate. 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation18, Revision 2 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility in water 
1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
02.144 
 
2,6-Dimethyloct-7-en-2-ol OH
 
 
 
18479-58-8 
Liquid 
C10H20O 
156.27 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
86 (15 hPa) 
 
MS 
95 % 
1.434-1.440 
0.824-0.830 
 
Racemate. 
02.146 
 
3,7-Dimethylocta-1,5,7-trien-3-ol   
6) 
OH  
 
10202 
29957-43-5 
Liquid 
 
 
Insoluble 
 
 
 
MS 
 
1.489-1.495 
0.878-0.886 
AV 7), BP 8). 
CASrn in Register to be 
changed to 53834-70-1, 
which covers (E)-3,7-
Dimethylocta-1,5,7-trien-3-
ol. Register name to be 
changed to (E)-3,7-
Dimethylocta-1,5,7-trien-3-
ol.  
(R)- or (S)-enantiomer not 
specified by CASrn 53834-
70-1. 
02.147 
 
3,6-Dimethyloctan-3-ol    OH
 
 
 
151-19-9 
Liquid 
C10H22O 
158.28 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
195 
 
MS 
95 % 
1.434-1.440 
0.831-0.837 
 
Mixture of diastereo isomers 
(EFFA, 2010a). 
Stereoisomeric composition 
to be specified. 
02.149 
 
Elemol 
HO
 
10205 
639-99-6 
Solid 
C15H26O 
222.37 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
123 (5 hPa) 
50 
MS 
95 % 
n.a. 
n.a. 
 
Register name to be changed 
to (-)-alpha-elemol = 
(1R,3S,4S)-isomer.  
02.150 
 
Geranyl linalool 
OH
 
 
 
1113-21-9 
Solid 
C20H34O 
290.49 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
153 (5 hPa) 
51 
MS 
95 % 
1.484-1.490 
0.878-0.881 
 
Racemate of (6E,10E)-
isomer. Name to be changed 
accordingly. 
02.168 
 
Isophytol    
OH
 
 
10233 
505-32-8 
Liquid 
C20H40O 
296.54 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
138 (0.1 hPa) 
 
MS 
95 % 
1.457-1.462 
0.847-0.853 
 
Mixture of diastereo isomers 
(EFFA, 2010a). 
Stereoisomeric composition 
to be specified. 
02.171 
 
p-Menthan-8-ol 
OH
 
 
 
498-81-7 
Solid 
C10H20O 
156.27 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
208 
35 
MS 
95 % 
1.460-1.466 
0.909-0.915 
 
 
02.181 
 
2-Methylpentan-2-ol OH
 
 
10274 
590-36-3 
Liquid 
C6H14O 
102.18 
Slightly soluble 
1 ml in 1 ml 
122 
 
MS 
1.409-1.415 
0.823-0.829 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation18, Revision 2 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility in water 
1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
95 % 
02.184 
 
3-Methylpentan-3-ol OH
 
 
10277 
77-74-7 
Liquid 
C6H14O 
102.18 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
121 
 
MS 
95 % 
1.415-1.421 
0.824-0.830 
 
 
02.185 
 
Myrcenol 
OH
 
 
 
543-39-5 
Liquid 
C10H18O 
154.25 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
91 (13 hPa) 
 
MS 
95 % 
1.470-1.476 
0.873-0.879 
 
 
02.191 
 
Ocimenol    
OH
 
 
 
5986-38-9 
Liquid 
C10H18O 
154.25 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
94 (16 hPa) 
 
MS 
95 % 
1.480-1.486 
0.871-0.877 
 
Mixture of (E)- and (Z)-
isomers (EFFA, 2010a). 
Composition of 
stereoisomeric mixture to be 
specified. 
02.197 
 
1,2,3,4,4a,5,6,7-Octahydro-2,5,5-
trimethylnaphthalen-2-ol    
OH
 
 
10173 
41199-19-3 
Solid 
C13H22O 
194.32 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
82 (1 hPa) 
68 
MS 
95 % 
n.a. 
n.a. 
 
Mixture of diastereo isomers 
(EFFA, 2010a). 
Stereoisomeric composition 
to be specified. 
02.203 
 
2-Phenylpropan-2-ol 
OH
 
 
11704 
617-94-7 
Liquid 
C9H12O 
136.19 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
218 
 
MS 
95 % 
1.529-1.535 
0.971-0.977 
 
 
02.206 
 
Sclareol 
H
OH
OHS
S
R
R
R
 
10311 
515-03-7 
Solid 
C20H36O2 
308.5 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
182 (1.33 hPa) 
106 
MS 
98 % 
n.a. 
n.a. 
 
 
02.219 
 
2,6-Dimethyl-2-heptanol 
OH  
 
 
13254-34-7 
Liquid 
C9H20O 
144.26 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
171 
 
MS 
98 % 
1.421-1.427 
0.816-0.822 
 
 
02.226 
 
[S-(cis)]-3,7,11-Trimethyl-1,6,10-
dodecatrien-3-ol 
HO
 
 
67 
142-50-7 
Liquid 
C15H26O 
222.37 
Practically insoluble 
or insoluble 
Soluble 
291.92 
20.98 
MS 
95 % 
1.478-1.483 
0.870-0.876 
 
Register name to be changed 
to [S-(cis)]-3,7,11-
Trimethyl-1,6,10-
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation18, Revision 2 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility in water 
1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
dodecatrien-3-ol (Also 
called S-(Z)-(+)-nerolidol 
(EFFA, 2010a). 
02.230 
 
Terpineol 
OH
alfa-Terpineol shown  
 
 
8000-41-7 
Liquid 
C10H18O 
154.25 
Practically insoluble 
or insoluble 
Freely soluble 
210-24 to 235-6 
 
MS 
91-99 % 
1.480-1.488 
0.928-0.937 
 
The specification covers 
alpha-, beta-, gamma- and 
delta-terpineol. Composition 
of mixture:  
55-75 % alpha,  
16-23 % gamma,  
1-10 % cis-beta,  
1-13 % trans-beta,  
0-1 % delta (EFFA, 2007h).  
02.253 
1850 
2,4-Dimethyl-4-Nonanol OH
 
4407 
 
74356-31-3 
Liquid 
C11H24O 
172.31 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
212 
 
MS 
95 % 
1.434-1.440 
0.825-0.833 
 
Racemate (EFFA, 2010a). 
09.171 
 
Cedryl acetate 
O
H
O
 
527 
77-54-3 
Solid 
C17H28O2 
264.41 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
158 (10.7 hPa) 
156 
MS 
95 % 
n.a. 
n.a. 
 
 
09.356 
 
1,1-Dimethylethyl propionate 
O
O
 
 
 
20487-40-5 
Liquid 
C7H14O2 
130.19 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
118 
 
MS 
95 % 
1.390-1.396 
0.862-0.868 
 
 
09.614 
 
Linalyl valerate O
O
 
10738 
10471-96-2 
Liquid 
C15H26O2 
238.37 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
238 
 
MS 
95 % 
1.450-1.456 
0.897-0.903 
 
Racemate. 
09.617 
 
p-Menthan-8-yl acetate 
O
O
 
 
58985-18-5 
Liquid 
C12H22O2 
198.29 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
115 (13 hPa) 
 
MS 
95 % 
1.449-1.455 
0.930-0.940 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation18, Revision 2 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility in water 
1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
09.669 
 
Myrcenyl acetate 
O
O
 
10857 
1118-39-4 
Liquid 
C12H20O2 
196.29 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
112 (13 hPa) 
 
MS 
95 % 
1.456-1.462 
0.915-0.921 
 
 
09.671 
 
Nerolidyl acetate 
O
O
 
10862 
56001-43-5 
Liquid 
C17H28O2 
264.41 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
107 (0.4 hPa) 
 
MS 
95 % 
1.467-1.473 
0.901-0.907 
 
(3S,6Z)-isomer. Name to be 
changed accordingly. 
09.808 
 
Guaiyl acetate 
O
O
 
10659 
134-28-1 
Solid 
C17H28O2 
264.41 
Practically insoluble 
or insoluble 
1 ml in 1 ml 
269 
96 
MS 
95 % 
n.a. 
n.a. 
 
 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 %  ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
6) Stereoisomeric composition not specified. 
7) AV: Missing minimum assay value. 
8) BP: Missing boiling point. 
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TABLE 2A: SUMMARY OF SAFETY EVALUATION APPLYING THE PROCEDURE (BASED ON INTAKES CALCULATED BY THE MSDI APPROACH) 
Table 2a: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
02.054 
 
p-Menthane-1,8-diol 
OH
OH
 
11 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.120 
 
Cedrol 
OH
H
13 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.140 
 
1,2-Dihydrolinalool OH
 
0.044 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.144 
 
2,6-Dimethyloct-7-en-2-ol OH 0.0012 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.149 
 
Elemol 
HO
1.6 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.168 
 
Isophytol 
OH
0.037 
 
Class I 
A3: Intake below threshold 
4) 7)  
02.171 
 
p-Menthan-8-ol 
OH
 
0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
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Table 2a: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
02.206 
 
Sclareol 
H
OH
OHS
S
R
R
R
0.67 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.219 
 
2,6-Dimethyl-2-heptanol 
OH
0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.226 
 
[S-(cis)]-3,7,11-Trimethyl-
1,6,10-dodecatrien-3-ol 
HO 0.049 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.230 
 
Terpineol 
OH
alfa-Terpineol shown
1200 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.253 
1850 
2,4-Dimethyl-4-Nonanol OH 0.24 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.171 
 
Cedryl acetate 
O
H
O
0.99 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.614 
 
Linalyl valerate O
O
0.43 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.617 
 
p-Menthan-8-yl acetate 
O
O
0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
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Table 2a: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
09.671 
 
Nerolidyl acetate 
O
O
0.061 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.808 
 
Guaiyl acetate 
O
O
0.0012 
 
Class I 
A3: Intake below threshold 
4) 6)  
02.185 
 
Myrcenol 
OH
 
0.012 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
02.191 
 
Ocimenol 
OH
 
0.012 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
09.669 
 
Myrcenyl acetate 
O
O
8.6 
 
Class I 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data required   
02.041 
 
2-Methylbutan-2-ol 
OH  
2.7 
 
Class II 
A3: Intake below threshold 
4) 6)  
02.052 
 
2-Methylpropan-2-ol OH
 
0.012 
 
Class II 
A3: Intake below threshold 
4) 6)  
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Table 2a: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
02.123 
 
2-Methylbut-3-en-2-ol 
OH  
0.0012 
 
Class II 
A3: Intake below threshold 
4) 6)  
02.146 
 
3,7-Dimethylocta-1,5,7-trien-3-
ol 
OH
12 
 
Class II 
A3: Intake below threshold 
Additional data required    
02.147 
 
3,6-Dimethyloctan-3-ol OH 0.0012 
 
Class II 
A3: Intake below threshold 
4) 7)  
02.150 
 
Geranyl linalool 
OH
0.026 
 
Class II 
A3: Intake below threshold 
4) 6)  
02.181 
 
2-Methylpentan-2-ol OH 0.12 
 
Class II 
A3: Intake below threshold 
4) 6)  
02.184 
 
3-Methylpentan-3-ol OH 0.0012 
 
Class II 
A3: Intake below threshold 
4) 6)  
02.197 
 
1,2,3,4,4a,5,6,7-Octahydro-2,5,5-
trimethylnaphthalen-2-ol 
OH 0.026 
 
Class II 
A3: Intake below threshold 
4) 7)  
02.203 
 
2-Phenylpropan-2-ol 
OH
 
0.0012 
 
Class II 
A3: Intake below threshold 
4) 6)  
09.356 
 
1,1-Dimethylethyl propionate 
O
O 0.0012 
 
Class II 
A3: Intake below threshold 
4) 6)  
02.129 
 
Bisabola-1,12-dien-8-ol 
OH
H
(l)-alpha-Bisabolol shown
27 
 
Class III 
A3: Intake below threshold 
4) 7)  
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
6) No safety concern at estimated level of intake of the material of commerce meeting the specification of Table 1 (based on intake calculated by the MSDI approach). 
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7) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on stereoisomerism. 
8) No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
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TABLE 2B: EVALUATION STATUS OF HYDROLYSIS PRODUCTS OF CANDIDATE ESTERS  
Table 2b: Evaluation Status of Hydrolysis Products of Candidate Esters 
FL-no EU Register name 
JECFA no 
Structural formula SCF status 1) 
JECFA status 2) 
CoE status 3) 
EFSA status 
Structural class 4) 
Procedure path (JECFA) 5) 
Comments 
 Guaiol 
OH
Not evaluated as flavour  Not in EU-Register 
02.013 Linalool 
356 
HO
 
 
No safety concern a) 
Category A b) 
 
Class I 
B3: Intake below threshold, B4: Adequate 
NOAEL exists 
 
02.018 Nerolidol 
1646 
OH  
 
Category B b) 
 
Class I 
A3: Intake below threshold 
 
02.052 2-Methylpropan-2-ol 
 
OH
 
 
 
Category B b) 
FGE.18 
Class II 
A3: Intake below threshold 
FGE.18: Tentatively regarded as presenting 
no safety concern (based on intake 
calculated by the MSDI approach) pending 
further information on the purity of the 
material of commerce and/or information 
on stereoisomerism. 
02.120 Cedrol 
 
OH
H
 
 
 
FGE.18 
Class I 
A3: Intake below threshold 
 
02.171 p-Menthan-8-ol 
 
OH
 
 
 
 
FGE.18 
Class I 
A3: Intake below threshold 
FGE.18: No safety concern based on the 
intake calculation by the MSDI approach. 
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Table 2b: Evaluation Status of Hydrolysis Products of Candidate Esters 
FL-no EU Register name 
JECFA no 
Structural formula SCF status 1) 
JECFA status 2) 
CoE status 3) 
EFSA status 
Structural class 4) 
Procedure path (JECFA) 5) 
Comments 
02.185 Myrcenol 
 
OH
 
 
 
 
FGE.18 
Class I 
B3: Intake below threshold, B4: No 
adequate NOAEL 
FGE.18: Additional data requested. 
08.002 Acetic acid 
81 
O
OH  
Category 1 c) 
No safety concern d) 
Category A b) 
 
Class I 
A3: Intake above threshold, A4: 
Endogenous 
 
08.003 Propionic acid 
84 
OH
O  
Category 1 c) 
No safety concern d) 
Category A b) 
 
Class I 
A3: Intake above threshold, A4: 
Endogenous 
 
08.007 Valeric acid 
90 
OH
O
 
Category 1 c) 
No safety concern d) 
Category A b) 
 
Class I 
A3: Intake below threshold 
 
1) Category 1: Considered safe in use   Category 2: Temporarily considered safe in use   Category 3: Insufficient data to provide assurance of safety in use   Category 4): Not acceptable due to evidence of toxicity 
2) No safety concern at estimated levels of intake. 
3) Category A: Flavouring substance, which may be used in foodstuffs Category B: Flavouring substance which can be used provisionally in foodstuffs 
4) Threshold of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
5) Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot. 
a) (JECFA, 2000a). 
b) (CoE, 1992). 
c) (SCF, 1995). 
d) (JECFA, 1999b.) 
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TABLE 3: SUPPORTING SUBSTANCES SUMMARY 
Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
01.002 1-Isopropyl-4-methylbenzene 
 
2356 
620 
99-87-6 
1325 
JECFA specification (JECFA, 
2005b) 
926  
No safety concern a) 
Category B b) 
 
01.008 Myrcene 
 
2762 
2197 
123-35-3 
1327 
JECFA specification (JECFA, 
2005b) 
290  
No safety concern a) 
Category B b) 
EFSA conclusion: B4-
No, additional data 
required (EFSA, 2009j). 
02.013 Linalool HO
 
2635 
61 
78-70-6 
356 
JECFA specification (JECFA, 
1998b) 
2200  
No safety concern c) 
Category A b) 
GrADI: 0-0.5 (JECFA, 
1980a) 
02.014 alpha-Terpineol 
HO
 
3045 
62 
98-55-5 
366 
JECFA specification (JECFA, 
1998b) 
2600  
No safety concern c) 
Category A b) 
 
02.015 Menthol 
OH
 
63 
89-78-1 
427 
JECFA specification (JECFA, 
1998b) 
16000  
No safety concern c) 
Category A b) 
ADI: 0-4 (JECFA, 
2000a). 
02.028 3,7-Dimethyloctan-3-ol OH
 
3060 
77 
78-69-3 
357 
JECFA specification (JECFA, 
1998b) 
47  
No safety concern c) 
Category B b) 
 
02.072 4-Terpinenol 
HO
 
2248 
2229 
562-74-3 
439 
JECFA specification (JECFA, 
2000d) 
150  
No safety concern c) 
Category B b) 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
02.085 Sabinene hydrate OH
 
3239 
10309 
546-79-2 
441 
JECFA specification (JECFA, 
2000d) 
0.91  
No safety concern c) 
 
 
02.095 2-Ethylfenchol 
OH
3491 
10208 
18368-91-7 
440 
JECFA specification (JECFA, 
2001c) 
0.74  
No safety concern c) 
 
 
02.096 1-Terpinenol OH
 
3563 
10252 
586-82-3 
373 
JECFA specification (JECFA, 
2000d) 
35  
No safety concern c) 
 
 
02.097 beta-Terpineol OH
 
3564 
10254 
138-87-4 
374 
JECFA specification (JECFA, 
2001c) 
1.3  
No safety concern c) 
 
 
09.013 Linalyl acetate O
O
2636 
203 
115-95-7 
359 
JECFA specification (JECFA, 
1998b) 
1700  
No safety concern c) 
Category A b) 
GrADI: 0-0.5 (JECFA, 
1980a). 
09.050 Linalyl butyrate O
O
2639 
276 
78-36-4 
361 
JECFA specification (JECFA, 
1998b) 
8.4  
No safety concern c) 
Category A b) 
 
09.052 Terpinyl butyrate 
O
O
3049 
278 
2153-28-8 
370 
JECFA specification (JECFA, 
2001c) 
5.1  
No safety concern c) 
Category A b) 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
09.068 Linalyl hexanoate O
O
2643 
318 
7779-23-9 
364 
JECFA specification (JECFA, 
1998b) 
0.85  
No safety concern c) 
Category A b) 
 
09.080 Linalyl formate O
O
 
2642 
347 
115-99-1 
358 
JECFA specification (JECFA, 
2003b) 
6.9  
No safety concern c) 
Category A b) 
GrADI: 0-0.5 (JECFA, 
1980a). 
09.081 alpha-Terpinyl formate 
O O
3052 
348 
2153-26-6 
367 
JECFA specification (JECFA, 
2001c) 
0.12  
No safety concern c) 
Category A b) 
 
09.116 Linalyl octanoate O
O
2644 
397 
10024-64-3 
365 
JECFA specification (JECFA, 
2000d) 
0.12  
No safety concern c) 
Category B b) 
 
09.130 Linalyl propionate O
O
2645 
411 
144-39-8 
360 
JECFA specification (JECFA, 
2003b) 
13  
No safety concern c) 
Category A b) 
 
09.142 Terpinyl propionate 
O
O
3053 
423 
80-27-3 
369 
JECFA specification (JECFA, 
1998b) 
0.024  
No safety concern c) 
Category B b) 
 
09.293 1-Acetoxy-1-
acetylcyclohexane 
O
O
O 3701 
 
52789-73-8 
442 
JECFA specification (JECFA, 
2001c) 
ND  
Additional data required c) 
 
Additional data required 
(JECFA, 2000a). 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
09.423 Linalyl isobutyrate 
O
O
2640 
298 
78-35-3 
362 
JECFA specification (JECFA, 
1998b) 
30  
No safety concern c) 
Category A b) 
 
09.425 Terpinyl 2-methylpropionate 
O
O
3050 
300 
7774-65-4 
371 
JECFA specification (JECFA, 
2000d) 
0.61  
No safety concern c) 
Category B b) 
 
09.454 Linalyl isovalerate O
O
2646 
449 
1118-27-0 
363 
JECFA specification (JECFA, 
2000d) 
4.6  
No safety concern c) 
Category B b) 
 
09.461 Terpinyl isovalerate 
O
O
3054 
456 
1142-85-4 
372 
JECFA specification (JECFA, 
2001c) 
0.12  
No safety concern c) 
Category B b) 
 
09.830 Terpineol acetate 
O
O
3047 
205 
8007-35-0 
368 
JECFA specification (JECFA, 
1998b) 
220  
No safety concern c) 
 
 
1) EU MSDI: Amount added to food as flavouring substance in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Category 1: Considered safe in use, Category 2: Temporarily considered safe in use, Category 3: Insufficient data to provide assurance of safety in use, Category 4: Not acceptable due to evidence of toxicity. 
3) No safety concern at estimated levels of intake. 
4) Category A: Flavouring substance, which may be used in foodstuffs, Category B: Flavouring substance which can be used provisionally in foodstuffs. 
a) (JECFA, 2005c). 
b) (CoE, 1992). 
c) (JECFA, 2000a). 
ND)  No intake data reported. 
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ANNEX I: PROCEDURE FOR THE SAFETY EVALUATION 
The approach for a safety evaluation of chemically defined flavouring substances as referred to in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a), named the "Procedure", is shown in schematic 
form in Figure I.1. The Procedure is based on the Opinion of the Scientific Committee on Food expressed on 
2 December 1999 (SCF, 1999a), which is derived from the evaluation Procedure developed by the Joint 
FAO/WHO Expert Committee on Food Additives at its 44th, 46th and 49th meetings (JECFA, 1995; JECFA, 
1996a; JECFA, 1997a; JECFA, 1999b). 
The Procedure is a stepwise approach that integrates information on intake from current uses, structure-
activity relationships, metabolism and, when needed, toxicity. One of the key elements in the Procedure is 
the subdivision of flavourings into three structural classes (I, II, III) for which thresholds of concern (human 
exposure thresholds) have been specified. Exposures below these thresholds are not considered to present a 
safety concern. 
Class I contains flavourings that have simple chemical structures and efficient modes of metabolism, which 
would suggest a low order of oral toxicity. Class II contains flavourings that have structural features that are 
less innocuous, but are not suggestive of toxicity. Class III comprises flavourings that have structural 
features that permit no strong initial presumption of safety, or may even suggest significant toxicity (Cramer 
et al., 1978). The thresholds of concern for these structural classes of 1800, 540 or 90 microgram/person/day, 
respectively, are derived from a large database containing data on subchronic and chronic animal studies 
(JECFA, 1996a). 
In Step 1 of the Procedure, the flavourings are assigned to one of the structural classes. The further steps 
address the following questions: 
• can the flavourings be predicted to be metabolised to innocuous products8 (Step 2)?  
• do their exposures exceed the threshold of concern for the structural class (Step A3 and B3)? 
• are the flavourings or their metabolites endogenous9 (Step A4)?  
• does a NOAEL exist on the flavourings or on structurally related substances (Step A5 and B4)? 
In addition to the data provided for the flavouring substances to be evaluated (candidate substances), 
toxicological background information available for compounds structurally related to the candidate 
substances is considered (supporting substances), in order to assure that these data are consistent with the 
results obtained after application of the Procedure.  
The Procedure is not to be applied to flavourings with existing unresolved problems of toxicity. Therefore, 
the right is reserved to use alternative approaches if data on specific flavourings warranted such actions. 
 
                                                     
 
8 “Innocuous metabolic products”: Products that are known or readily predicted to be harmless to humans at the 
estimated intakes of the flavouring agent” (JECFA, 1997a). 
 
9 “Endogenous substances”: Intermediary metabolites normally present in human tissues and fluids, whether free or 
conjugated; hormones and other substances with biochemical or physiological regulatory functions are not included 
(JECFA, 1997a). 
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Decision tree structural class 
Can the substance be predicted to be metabolised to innocuous products?
Procedure for Safety Evaluation of Chemically Defined Flavouring Substances 
Do the conditions of use result in an intake greater than the 
threshold of concern for the structural class?
Do the conditions of use result in an intake greater than the  
threshold of concern for the structural class? 
Data must be available on the  
substance or closely related  
substances to perform a safety 
evaluation
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is  high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
  Substance would not be    
expected to be of safety concern
Is the substance or are its metabolites endogenous?
Additional data required 
Step 1. 
Step 2. 
Step A3. 
Step A4. 
Step A5. 
Step B3. 
Step B4.
 Yes No
 Yes 
 No 
No
No
Yes
No
Yes
Yes
Yes
 No
Figure I.1 Procedure for Safety Evaluation of Chemically Defined Flavouring Substances
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ANNEX II: USE LEVELS / MTAMDI 
II.1 Normal and Maximum Use Levels 
For each of the 18 Food categories (Table II.1.1) in which the candidate substances are used, Flavour 
Industry reports a “normal use level” and a “maximum use level” (EC, 2000a). According to the Industry the 
”normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th 
percentile of reported usages (EFFA, 2002i). The normal and maximum use levels in different food 
categories have been extrapolated from figures derived from 12 model flavouring substances (EFFA, 2004e). 
Table II.1.1 Food categories according to Commission Regulation (EC) No 1565/2000 (EC, 2000a) 
Food category Description 
01.0 Dairy products, excluding products of category 02.0 
02.0 Fats and oils, and fat emulsions (type water-in-oil) 
03.0 Edible ices, including sherbet and sorbet 
04.1 Processed fruit 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), and nuts & seeds 
05.0 Confectionery 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & legumes, excluding bakery 
07.0 Bakery wares 
08.0 Meat and meat products, including poultry and game 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  
10.0 Eggs and egg products 
11.0 Sweeteners, including honey 
12.0 Salts, spices, soups, sauces, salads, protein products, etc. 
13.0 Foodstuffs intended for particular nutritional uses 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts 
15.0 Ready-to-eat savouries 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be placed in categories 01.0 - 15.0 
 
The “normal and maximum use levels” are provided by Industry for 31 of the 32 candidate substances in the 
present flavouring group (EFFA, 2004a; EFFA, 2005e; EFFA, 2006k; EFFA, 2007a; EFFA, 2007h; Flavour 
Industry, 2009c) (Table II.1.2). 
Table II.1.2 Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.18, Revision 2 
(EFFA, 2004a; EFFA, 2005e; EFFA, 2006k; EFFA, 2007a; EFFA, 2007h; Flavour Industry, 2009c). 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
02.041 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.052 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.054 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.120 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.123 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.129 10 
50 
10 
50 
8 
50 
10 
30 
- 
- 
20 
100 
10 
30 
4 
20 
- 
- 
- 
- 
- 
- 
- 
- 
20 
100 
- 
- 
10 
30 
10 
30 
- 
- 
10 
500 
02.140 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.144 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.147 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
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Table II.1.2 Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.18, Revision 2 
(EFFA, 2004a; EFFA, 2005e; EFFA, 2006k; EFFA, 2007a; EFFA, 2007h; Flavour Industry, 2009c). 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
02.149 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.150 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.168 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.171 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.181 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.184 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.185 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.191 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.197 - 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
5 
25 
- 
- 
- 
- 
- 
- 
02.203 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.206 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.219 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.226 2 
8 
- 
- 
2 
80 
- 
- 
- 
- 
200 
500 
2 
7 
2 
6 
- 
- 
- 
- 
- 
- 
- 
- 
1 
5 
- 
- 
2 
5 
30 
100 
2 
10 
- 
- 
02.230 20 
150 
10 
50 
50 
300 
- 
- 
- 
- 
50 
300 
- 
- 
50 
300 
5 
10 
- 
- 
- 
- 
- 
- 
50 
300 
- 
- 
10 
300 
60 
300 
50 
300 
- 
- 
02.253 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
- 
- 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.171 7 
35 
5 
25 
10 
50 
7 
35 
7 
35 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
2 
09.356 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.614 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.617 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.669 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.671 7 
35 
5 
25 
- 
- 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
09.808 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
II.2 mTAMDI Calculations 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values is 
based on the approach used by SCF up to 1995 (SCF, 1995). The assumption is that a person may consume 
the amount of flavourable foods and beverages listed in Table II.2.1. These consumption estimates are then 
multiplied by the reported use levels in the different food categories and summed up.  
Table II.2.1 Estimated amount of flavourable foods, beverages, and exceptions assumed to be consumed per 
person per day (SCF, 1995) 
Class of product category Intake estimate (g/day) 
Beverages (non-alcoholic) 324.0 
Foods 133.4 
Exception a: Candy, confectionery 27.0 
Exception b: Condiments, seasonings 20.0 
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Table II.2.1 Estimated amount of flavourable foods, beverages, and exceptions assumed to be consumed per 
person per day (SCF, 1995) 
Class of product category Intake estimate (g/day) 
Exception c: Alcoholic beverages 20.0 
Exception d: Soups, savouries 20.0 
Exception e: Others, e.g. chewing gum e.g. 2.0 (chewing gum) 
 
The mTAMDI calculations are based on the normal use levels reported by Industry. The seven food 
categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food categories as outlined in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a) and reported by the Flavour Industry in the 
following way (See Table II.2.2): 
• Beverages (SCF, 1995) correspond to food category 14.1 (EC, 2000a) 
• Foods (SCF, 1995) correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13, and/or 16 
(EC, 2000a) 
• Exception a (SCF, 1995) corresponds to food category 5 and 11 (EC, 2000a) 
• Exception b (SCF, 1995) corresponds to food category 15 (EC, 2000a) 
• Exception c (SCF, 1995) corresponds to food category 14.2 (EC, 2000a) 
• Exception d (SCF, 1995) corresponds to food category 12 (EC, 2000a) 
• Exception e (SCF, 1995) corresponds to others, e.g. chewing gum. 
Table II.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 (EC, 
2000a) into the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
 Food categories according to Commission Regulation (EC) No1565/2000 Distribution of the seven SCF food categories 
Key Food category Food Beverages Exceptions 
01.0 Dairy products, excluding products of category 02.0 Food   
02.0 Fats and oils, and fat emulsions (type water-in-oil) Food   
03.0 Edible ices, including sherbet and sorbet Food   
04.1 Processed fruit Food   
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), 
and nuts & seeds 
Food   
05.0 Confectionery   Exception a 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & 
legumes, excluding bakery 
Food   
07.0 Bakery wares Food   
08.0 Meat and meat products, including poultry and game Food   
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  Food   
10.0 Eggs and egg products Food   
11.0 Sweeteners, including honey   Exception a 
12.0 Salts, spices, soups, sauces, salads, protein products, etc.    Exception d 
13.0 Foodstuffs intended for particular nutritional uses Food   
14.1 Non-alcoholic ("soft") beverages, excl. dairy products  Beverages  
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts   Exception c 
15.0 Ready-to-eat savouries   Exception b 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be 
placed in categories 01.0 - 15.0 
Food   
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The mTAMDI values (See Table II.2.3) are presented for the 31 flavouring substances in the present 
flavouring group, for which Industry has provided use and use levels (EFFA, 2004a; EFFA, 2005e; EFFA, 
2006k; EFFA, 2007a; EFFA, 2007h; Flavour Industry, 2009c). The mTAMDI values are only given for 
highest reported normal use levels (See Table II.2.3). 
TableII.2.3 Estimated intakes based on the mTAMDI approach 
FL-no EU Register name mTAMDI 
(μg/person/day) 
Structural class Threshold of concern 
(µg/person/day) 
02.054 p-Menthane-1,8-diol 3900 Class I 1800 
02.120 Cedrol 3900 Class I 1800 
02.140 1,2-Dihydrolinalool 3900 Class I 1800 
02.144 2,6-Dimethyloct-7-en-2-ol 3900 Class I 1800 
02.149 Elemol 3900 Class I 1800 
02.168 Isophytol 3900 Class I 1800 
02.171 p-Menthan-8-ol 3900 Class I 1800 
02.206 Sclareol 3900 Class I 1800 
02.219 2,6-Dimethyl-2-heptanol 3900 Class I 1800 
02.226 [S-(cis)]-3,7,11-Trimethyl-1,6,10-dodecatrien-3-ol 7000 Class I 1800 
02.230 Terpineol 14000 Class I 1800 
02.253 2,4-Dimethyl-4-Nonanol 3900 Class I 1800 
09.171 Cedryl acetate 3900 Class I 1800 
09.614 Linalyl valerate 3900 Class I 1800 
09.617 p-Menthan-8-yl acetate 3900 Class I 1800 
09.671 Nerolidyl acetate 3900 Class I 1800 
09.808 Guaiyl acetate 3900 Class I 1800 
02.185 Myrcenol 3900 Class I 1800 
02.191 Ocimenol 3900 Class I 1800 
09.669 Myrcenyl acetate 3900 Class I 1800 
02.041 2-Methylbutan-2-ol 3900 Class II 540 
02.052 2-Methylpropan-2-ol 3900 Class II 540 
02.123 2-Methylbut-3-en-2-ol 3900 Class II 540 
02.146 3,7-Dimethylocta-1,5,7-trien-3-ol  Class II 540 
02.147 3,6-Dimethyloctan-3-ol 3900 Class II 540 
02.150 Geranyl linalool 3900 Class II 540 
02.181 2-Methylpentan-2-ol 3900 Class II 540 
02.184 3-Methylpentan-3-ol 3900 Class II 540 
02.197 1,2,3,4,4a,5,6,7-Octahydro-2,5,5-trimethylnaphthalen-2-ol 1600 Class II 540 
02.203 2-Phenylpropan-2-ol 3900 Class II 540 
09.356 1,1-Dimethylethyl propionate 3900 Class II 540 
02.129 Bisabola-1,12-dien-8-ol 5700 Class III 90 
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ANNEX III: METABOLISM 
III.1. Introduction 
A consideration of the chemical structures of the candidate substances in this Flavouring Group Evaluation, 
their anticipated pathways of metabolism and the extent to which data on one substance may support the 
metabolism of another substance has indicated that it is appropriate to divide the candidate substances in this 
evaluation into eight subgroups of more closely related structures (See Table III.1.). 
Table III.1. Candidate Substances Divided into Subgroups of Related Chemical Structures 
Subgroup FL-no Candidate substance Chemical group 
1 
02.041 2-Methylbutan-2-ol 
Aliphatic saturated tertiary 
alcohols and one ester thereof 
02.052 2-Methylpropan-2-ol 
02.147 3,6-Dimethyloctan-3-ol 
02.181 2-Methylpentan-2-ol 
02.184 3-Methylpentan-3-ol 
02.219 2,6-Dimethyl-2-heptanol 
02.253 2,4-Dimethyl-4-nonanol 
09.356 1,1-Dimethylethyl propionate 
2 
02.123 2-Methylbut-3-en-2-ol 
Aliphatic unsaturated tertiary 
alcohols with isolated 
terminal double bonds and 
two esters thereof 
02.144 2,6-Dimethyloct-7-en-2-ol 
02.150 Geranyl linalool 
02.168 Isophytol 
02.226 [S-(cis)]-3,7,11-Trimethyl-1,6,10-dodecatrien-3-ol 
09.614 Linalyl valerate 
09.671 Nerolidyl acetate 
 02.146 3,7- Dimethylocta-1,5,7-trien-3-ol  
3 
02.185 Myrcenol Aliphatic unsaturated tertiary 
alcohols with conjugated 
terminal double bonds and 
one ester thereof 
02.191 Ocimenol 
09.669 Myrcenyl acetate 
4 02.140 1,2-Dihydrolinalool 
Aliphatic unsaturated tertiary 
alcohol (without terminal 
double bond) 
5 
02.054 p-Menthane-1,8-diol 
Monocyclic saturated and 
unsaturated tertiary alcohols 
and one ester thereof 
02.129 Bisabola-1,12-dien-8-ol 
02.171 p-Menthan-8-ol 
02.230 Terpineol 
09.617 p-Menthan-8-yl acetate 
6 
02.149 Elemol Monocyclic and bicyclic 
unsaturated tertiary alcohols 
with isolated terminal double 
bonds 
02.206 Sclareol 
7 
09.808 Guaiyl acetate 
Bi- and tricyclic tertiary 
alcohols and esters 
02.197 1,2,3,4,4a,5,6,7-Octahydro-2,5,5-trimethylnapthalen-2-ol 
02.120 Cedrol 
09.171 Cedryl acetate 
8 02.203 2-Phenylpropan-2-ol Tertiary alcohol with an aromatic substituent 
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III.2. Absorption, Distribution and Elimination 
Specific information on absorption, distribution and excretion is available for the candidate substances, 2-
methylpropan-2-ol (tertiary butanol) [FL-no: 02.052], elemol [FL-no: 02.149], sclareol [FL-no: 02.206] and 
terpineol [FL-no: 02.230].  
2-Methylpropan-2-ol [FL-no: 02.052] was administered by gastric intubation to female Wistar rats at a single 
dose of 1853 mg/kg bw and blood concentrations were monitored for 20 hours. 2-Methylpropan-2-ol was 
eliminated slowly from the blood of rats in this study, with concentrations in blood at 2, 5 and 20 hours 
measured as 13.2, 12.6 and 11.4 mM, respectively (Beaugé et al., 1981). The high bolus dose of 2-
methylpropan-2-ol may have exceeded the capacity of the metabolic pathways for detoxication and 
contributed to the relatively slow clearance time from the blood.  
The pharmacokinetic profile for 2-methylpropan-2-ol was characterised in male (four/dose) and female 
(three/dose) F-344 rats following intravenous administration of 37.5, 75, 150 and 300 mg 2-methylpropan-2-
ol/kg bw. Blood samples were collected in heparinised syringes at 5, 10, 20, 30, 40 and 60 min, and 4, 8, 12, 
16 and 24 hours from the cannula implanted in the right jugular vein of each animal. The data fit a two-
compartment model with the distribution half-life (T½ α) about 3 min and the elimination half-life (T½ β) 
about 3.8 hours in male and female rats for doses less than 300 mg/kg bw. Consistent with another study 
(Beaugé et al., 1981), the elimination of 2-methylpropan-2-ol appears to get saturated at higher doses, as 
evidenced by a disproportional increase in area under the concentration – time curve and decreased rate of 
clearance in this study. After administration of a 300 mg/kg bw dose of 2-methylpropan-2-ol, the means of 
T½ β were increased to 5.0 and 4.3 hours in male and female rats, respectively. The steady-state volume of 
distribution for 2-methylpropan-2-ol was approximately 4.5-fold greater than total body water, suggesting 
significant tissue distribution (Poet et al., 1997). 
Potential pharmacokinetic outcomes in mammalian plasma were analysed by intravenous administration of 
sclareol [FL-no: 02.206] at 100 mg/kg bw to two male Wistar rats. Plasma samples were collected at 5, 15, 
30, 60, 180, 360, 720 and 1440 min after administration, and sclareol concentrations were quantified by gas-
liquid chromatography using an internal standard. At 5 min post-injection, plasma levels of sclareol were 
84.9 μg/ml. The sclareol plasma concentration dropped to 42.9 μg/ml after 180 min, and was not detectable 
at 720 min. This study indicated a rapid biphasic disappearance of sclareol from plasma following 
intravenous treatment. The authors suggest that sclareol may be distributed in fatty tissue due to its high 
lipophilicity. Sclareol was administered to two male Wistar rats by intravenous administration at 100 mg/kg 
bw, and to male Wistar rats by oral gavage at 1 g/kg bw in 3:1 propylene glycol-ethanol. Urine and faecal 
samples were collected from all rats at periodic intervals over 144 or 72 hours, respectively. Bile samples 
were collected only from rats given intravenous injections at periodic intervals over 30 hours. No sclareol 
was detected in urine or urine treated with β-glucuronidase at any time. No sclareol was detected in faecal 
samples from intravenous treated rats, but 9 % of the initial sclareol dose was found in faecal samples from 
rats given oral administration. The bile samples from rats given intravenous administration showed very low 
levels (0.02 %) of sclareol over a 3 hours period. Very low levels (0.04 %) of oxidised metabolites were 
found in bile after 3 hours, including 3-alpha-hydroxysclareol (0.24 %), 3-betahydroxysclareol (0.075 %), 
18-hydroxysclareol (0.056 %), and 3-ketosclareol (0.03 %). Sclareol or its oxidised metabolites were not 
observed in bile samples collected at any other time during the 30 hours study. The authors hypothesized that 
the low sensitivity of the assay technique may have prevented detection of low levels of sclareol and its 
metabolites over the course of the experiment. While only a very small percentage of intravenously 
administered sclareol (<0.05 %) could be accounted for in these experiments, the authors suggested that 
other mammalian metabolites were formed that were not detected in the assays used (Kouzi et al., 1993). 
Incubation of sclareol with 37 different microorganisms found that sclareol is oxidised to more polar 
metabolites, including 3-ketosclareol, 2α-hydroxysclareol, 3β-hydroxysclareol, 18-hydroxysclareol, 2α,18-
dihydroxysclareol, and three glucoside conjugates (Kouzi et al., 1993). 
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Intravenous administration of sclareol to rats, however, found very low levels of the hydroxylated and 
glycosidic metabolites or the parent compound in the urine.  
A metabolism study on the structurally related elemol [FL-no: 02.149] indicates that substances of this type 
are absorbed from the gastrointestinal tract and mainly excreted in conjugation with glucuronic acid or 
sulphate, although one oxidised metabolite, hydroxyelemol, was also found in lower amounts. No oxidation 
of the isolated terminal double bond of elemol was found; accordingly, epoxidation of this candidate 
substance would not be anticipated.  
alpha-Terpineol, the major component of terpineol [FL-no: 02.230], undergoes allylic oxidation of the 
exocyclic methyl group, which can then be further oxidised to a carboxylic acid group (Madyastha & 
Srivatsan, 1988b). In a minor pathway, the doublebond of alpha-terpineol is epoxidized and then hydrolysed 
to yield the triol metabolite 1,2,8-trihydroxy-p-menthane, which also has been reported in humans following 
inadvertent oral ingestion of a pine oil disinfectant containing alpha-terpineol (Horning et al., 1976). It is 
expected that after single dose exposures, alpha terpineol would undergo metabolism via glucuronic acid 
conjugation and excretion in the urine (Chadha & Madyastha, 1984; Hill et al., 1975; Wright, 1945). 
(-)-Elemol (2 g) was orally given to rabbits (2-3 kg) and the urine was collected for the three following days 
(72 hours). In total 80 % of the administered dosage was recovered from the urine (Asakawa et al., 1986).  
In addition, there is information on absorption and excretion for the four supporting substances linalool, 
myrcene, menthol and 1-isopropyl-4-methylbenzene (synonym: p-cymene).  
[1,2-14C]-Linalool was orally administered to rats at a single dose of 500 mg/kg bw. The majority (55 %) of 
the radioactivity was excreted in the urine as the glucuronic acid conjugate, whereas 23 % was excreted as 
CO2 in expired air, and 15 % was excreted in the faeces within 72 hours of administration. Only 3 % of the 
radioactivity was detected in tissues after 72 hours, with 0.5 % in the liver, 0.6 % in the gut, 0.8 % in the skin 
and 1.2 % in the skeletal muscle (Parke et al., 1974a). 
When given to male Japanese White rabbits by gavage at a dose of 670 mg/kg bw per day for two days, 
approximately 25 % of the total administered amount (19 g to six rabbits) of myrcene could be recovered 
from the urine excreted over a period of three days following administration (Ishida et al., 1981).  
In humans 79 % of a 1000 mg oral dose (Quick, 1928b) or 78 % of a 10 to 20 mg oral dose (Atzl et al., 
1972) of menthol administered to volunteers was eliminated as the glucuronic acid conjugate. For eight days 
750 mg l-menthol was administered orally to two human volunteers followed by oral or intravenous 
administration of 200 mg [6-13C]-glucuronolactone or [6-13C]-sodium glucuronate. For two days after 
administration of the isotopic compound, menthyl glucuronide was excreted in an average daily yield 
ranging from approximately 27 % to 84 % of the l-menthol administered (Eisenberg et al., 1955). Four males 
were given an oral dose of 180 mg peppermint oil. Between 37 and 116 mg menthol glucuronide were 
excreted in the urine after 14 hours (Kaffenberger & Doyle, 1990).  
Non-cannulated and bile duct-cannulated male Fischer 344 rats were administered a single oral dose of 500 
mg [3-3H]-1-menthol/kg bw. Urine and faeces were collected over the next 24 and 48 hours from non-
cannulated rats. In the bile duct-cannulated rats, bile samples were collected at 2-hours intervals for the first 
6 hours and then from 6 to 24 hours. The 0-24 hours urine was collected in the same rats. In the bile duct-
cannulated rats, total recovery of the dose of the radiolabeled substance in the urine or bile was 74.2 % after 
24 hours. The amount of radioactivity found in the urine after 24 hours from the non-cannulated and the bile 
duct-cannulated rats differed from 19 to 7.3 %, but indicates that most of the compound is excreted in the 
bile during the first 24 hours (Yamaguchi et al., 1994).  
Of an oral dose of 100 mg/kg bw of p-cymene given to male Wistar rats or Dunkin Hartley guinea pigs, 80 
% or 71 %, respectively, was excreted in the urine within the following 48 hours in the form of extractable 
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metabolites. It was speculated that the rest of the dose was either excreted via the faeces or as unextractable 
metabolites in the urine (Walde et al., 1983). 
In conclusion, the candidate substance 2-methylpropan-2-ol is anticipated to be absorbed and to undergo 
rapid excretion when administered at lower doses. However, when administered at higher doses the 
metabolic capacity may be exceeded. The candidate substances elemol and sclareol are absorbed but excreted 
rather slowly. The candidate substance terpineol is anticipated to be absorbed and excreted. The supporting 
substances, menthol and p-cymene, are readily absorbed and excreted rapidly with approximately 70 % 
recovery within 24 hours and 70-80 % recovery within 48 h, respectively. Linalool is absorbed but rather 
slowly excreted. The slowest absorption and excretion was observed for myrcene where only 25 % of 
administered dose was recovered in urine after 72 h. 
III.3. Biotransformation 
III.1 Ester hydrolysis 
Aliphatic esters are hydrolysed to the component alcohols and carboxylic acid by carboxyl-esterases found in 
most tissues throughout the body, the most important of which are the beta-esterases (Heymann, 1980). In 
mammals these enzymes occur within the body in most tissues including the gut lumen and intestinal wall, 
but predominate in the hepatocytes (Heymann, 1980). The wide range of tissue distribution and the 
multiplicity of the esterases generally give rapid hydrolyse of esters in vivo. 
No hydrolysis studies on the candidate esters [FL-no: 09.171, 09.356, 09.614, 09.669, 09.671, 09.808 and 
09.617] are available. Two hydrolysis studies on a supporting substance, linalyl acetate [FL-no: 09.013], 
were found. In an in vitro hydrolysis study, linalyl acetate was easily hydrolysed in water and simulated 
gastric and pancreatic fluids. The mean half-lives for linalyl acetate hydrolysis were 5.5 and 52.5 min in 
gastric and pancreatic fluids, respectively (Hall, 1979). In neutral gastric juice, linalyl acetate is slowly (t½ = 
121 min) hydrolysed to a mixture of linalool and the ring-closed isomer alpha-terpineol. In acidic artificial 
gastric juice, linalyl acetate is rapidly hydrolysed (t½ < 5 min) to yield linalool (Buck & Renwick, 1998). 
Linalyl acetate was slowly hydrolysed (t½ = 153 – 198 min) in intestinal fluid with or without pancreatin. 
Linalyl acetate also hydrolyses in homogenates of rat intestinal mucosa, blood and liver, but at rates much 
slower than in acidic gastric juice (rate constant for hydrolysis, k = 0.01 to 0.0055 min-1 vs. > 5 min-1 in 
gastric juice). Based on these observations it can be concluded that linalyl acetate hydrolyses in gastric juice 
to yield linalool and acetic acid (Buck & Renwick, 1998). Further, it has been demonstrated that linalyl 
acetate can be hydrolysed to linalool in in vitro studies after incubation with rat caecal flora (Rahman, 
1974a). 
III.2 Subgroup 1 - Aliphatic saturated tertiary alcohols and ester 
For three of the eight candidate substances in this subgroup, 2-methylpropan-2-ol [FL-no: 02.052], 2-
methylbutan-2-ol [FL-no: 02.041] and 2-methylpentan-2-ol [FL-no: 02.181], there are one or more 
metabolism studies.  
2-Methylpropan-2-ol (tert-Butanol [FL-no: 02.052]) 
[2-13C]-2-Methylpropan-2-ol was orally administered in a gel capsule at a dose of 5 mg/kg bw to one human 
volunteer (44 year old, 80 kg male). Urine was collected in 12-hours intervals for 48 hours and analysed by 
13C-NMR. All of the urine samples of this human volunteer showed the presence of 2-methylpropan-2-ol, 2-
methylpropan-2-ol glucuronide, 2-hydroxyisobutyrate, and 2-methyl-1,2-propanediol. In contrast to the rat 
urine samples in which 2-methylpropan-2-ol sulphate was observed as a major metabolite, the sulphate was 
only present in trace amounts in the human volunteer urine samples. The low recovery of 2-methylpropan-2-
ol sulphate in the urine of the human volunteer is likely based on a low affinity of human sulphotransferase 
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for 2-methylpropan-2-ol as compared to rats. On the other hand, 2-hydroxyisobutyrate was the major 
metabolite excreted by the human volunteer. The likely pathway for the formation of the 2-
hydroxyisobutyrate and 2-methyl-1,2-propanediol metabolites involves methyl group oxidation of 2-
methylpropan-2-ol by CYP-450 to yield 2-methyl-1,2-propanediol. Further oxidation of 2-methyl-1,2-
propanediol results in the formation of 2-hydroxyisobutyrate, and acetone is likely formed by further 
oxidation of the intermediate diol and/or 2-hydroxyisobutyrate (Bernauer et al., 1998).  
Three male rats per experiment were administered a single 250 mg/kg bw dose of [12C]- or [13C]- 2-
methylpropan-2-ol dissolved in corn oil by oral gavage. All animals were maintained in individual 
metabolism cages for 72 hours, after which they were sacrificed by cervical dislocation. Urine was collected 
at 24 and 48 hours and analysed by 13C-NMR. In the 24-hours urine samples, it was determined that 2-
methylpropan-2-ol sulphate, 2-methyl-1,2-propanediol, and 2-hydroxyisobutanoate (i.e. alpha-
hydroxyisobutanoate) are the major metabolites of 2-methylpropan-2-ol in rats; minor metabolites were 
identified as free 2-methylpropan-2-ol, 2-methylpropan-2-ol glucuronide, and [13C]-acetone. Identical 
metabolites were present at lower concentrations in the urine collected between 24 and 48 hours after dosing. 
Extensive biotransformation of tert-butyl alcohol in rats by conjugation and oxidation was confirmed by the 
results of these experiments (Bernauer et al., 1998).  
2-Methylpropan-2-ol was administered by gastric intubation to chinchilla rabbits at a 297 mg/kg bw. 2-
Methylpropan-2-ol was conjugated to a large extent with glucuronic acid, and conjugates were readily 
isolated from urine. Of the administered dose, 24.4 % was excreted as glucuronic acid conjugate in the urine 
within 24 hours after administration. The investigators suggested that the volatile alcohol may also be 
eliminated to some extent via the lungs. No aldehydes or ketones were detected in the expired air of a rabbit 
administered 6 ml of 2-methylpropan-2-ol (Kamil et al., 1953a).  
2-Methylbutan-2-ol (tert-amyl-alcohol [FL-no: 02.041]) 
2-Methylbutan-2-ol was administered by gastric intubation to chinchilla rabbits at a single dose of 441 
mg/kg bw. 2-Methylbutan-2-ol was conjugated to a large extent with glucuronic acid and 58 % of the dose 
was excreted as such conjugates via the urine within 24 hours post dosing (Kamil et al., 1953a).  
Three male rats were administered a single 250 mg/kg bw dose of [2-13C]-2-methylbutan-2-ol dissolved in 
corn oil by oral gavage. All animals were maintained in individual metabolism cages for 48 hours. Urine was 
collected at 24 and 48 hours and analysed by 13C-NMR. In the 24-hour urine samples, it was determined that 
2-methylbutan-2-ol glucuronide, 2-methyl-2,3-butanediol and 2-methyl-2,3-butanediol glucuronide are the 
major metabolites of 2-methylbutan-2-ol; minor metabolites were identified as free 2-methylbutan-2-ol, 2-
hydroxy-2-methylbutanoic acid and 3-hydroxy-3-methylbutanoic acid. The low concentration of 2-
methylbutan-2-ol recovered in the urine suggests extensive metabolism of the alcohol. In the 48-hour urine 
samples, only 2-methyl-2,3-butanediol and 2-methyl-2,3-butanediol glucuronide were detected, suggesting 
the rapid excretion of 2-methylbutan-2-ol glucuronide following oral exposure. Glucuronidation appears to 
be the major pathway of metabolism, resulting in urinary excretion of the 2-methylbutan-2-ol glucuronide. In 
addition, it appears that 2-methylbutan-2-ol is oxidised to 2-methyl-2,3-butanediol, which is further 
conjugated to 2-methyl-2,3-butanediol glucuronide and excreted in the urine. A minor metabolic pathway 
seems to be oxidation of the carbon atom at the C4 position resulting in 2-methyl-2,4-butanediol as an 
intermediate, which is further oxidised to 3-hydroxy-3-methylbutanoic acid. Finally, oxidation of the methyl 
side chain is another minor transformation pathway that results in the formation of 2-methyl-1,2-butanediol 
as an intermediate, which is further oxidised to produce 2-hydroxy-2-methylbutanoic acid (Amberg et al., 
1999) (See Figure III.1.) 
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Figure III.1. Metabolism of 2-methybutan-2-ol (tert-amyl-alcohol) in rats (Amberg et al., 1999). Main metabolism 
products are in bold. 
 
2-Methylpentan-2-ol (tert-hexylalcohol [FL-no: 02.181]) 
2-Methylpentan-2-ol was administered by gastric intubation to chinchilla rabbits at a single dose of 851 
mg/kg bw. 2-Methylpentan-2-ol was conjugated to a large extent with glucuronic acid, and 57 % of the dose 
was excreted within 24 hours post dosing as such conjugates via the urine (Kamil et al., 1953a). 
III.3 Subgroup 2 - Aliphatic unsaturated tertiary alcohols and esters with isolated terminal double bonds 
There are no metabolism studies on the candidate substances 2-methylbut-3-en-2-ol, 2,6-dimethyloct-7-en-2-
ol, geranyl linalool, isophytol, [S-(cis)]-3,7,11-trimethyl-1,6,10-dodecatrien-3-ol, linalyl valerate and 
nerolidyl acetate, [FL-no: 02.123, 02.144, 02.150, 02.168, 02.226, 09.614 and 09.671]. However, there is a 
metabolism study for linalool, supporting substance to 2-methylbut-3-en-2-ol, geranyl linalool, isophytol, [S-
(cis)]-3,7,11-trimethyl-1,6,10-dodecatrien-3-ol, linalyl valerate and nerolidyl acetate [FL-no: 02.123, 02.150, 
02.168, 02.226, 09.614 and 09.671,], which have the isolated double bond in close proximity to the tertiary 
alcohol group. 
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Figure III.2 Metabolism of linalool (Chadha & Madyastha 1984). 
 
Seventy-two hours after intragastrical administration of 500 mg/kg bw 14C-labelled linalool/kg bw to 12-
weeks old rats 58-60 % of the dose was excreted in the urine, 12-15 % in the faeces and 25-27 % in the 
expired air. In tissues 3-4 % residual activity was found. Beyond unchanged linalool the main metabolites in 
urine and faeces were dihydrolinalool and tetra hydrolinalool, mainly conjugated with sulphate or glucuronic 
acid. The study also indicated that the reduction mainly took place in the gut (Rahman, 1974a). 
In another study, male rats were given a daily 800 mg/kg bw oral dose of linalool for 20 days. Urinary 
metabolites formed by CYP-450-mediated allylic oxidation of linalool included 8-hydroxylinalool and 8-
carboxylinalool (Chadha & Madyastha, 1984) (Figure III.2). No oxidation of the terminal double bond was 
observed, indicating no formation of epoxide intermediates.  
No metabolism studies on supporting substances to 2,6-dimethyloct-7-en-2-ol [FL-no: 02.144], which has 
the isolated double bond far from the tertiary alcohol group, are available. 
III.4 Subgroup 3: Aliphatic unsaturated tertiary alcohols and ester with conjugated terminal double bonds 
No metabolism studies are found for the candidate substances, 3,7-dimethylocta-1,5,7-trien-3-ol, myrcenol, 
ocimenol or myrcenyl acetate [FL-no: 02.146, 02.185, 02.191 and 09.669]. For the supporting substance, 
myrcene, two studies on metabolism are found. 
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Figure III.3 Metabolism of myrcene (Ishida et al., 1981 and Madyastha & Srivatsan 1987). Intermediate products are 
in brackets and main metabolism products are in bold. 
 
In the urine of rabbits orally administered myrcene (single dosage of 670 mg/kg bw) via gavage, more than 
80 % of the metabolites were neutral metabolites, the rest were acidic metabolites. The main metabolites 
identified in urine were myrcene-3,10-glycol, myrcene-1,2-glycol and uroterpenol (40.7, 20.8 and 11.8 %, 
respectively, of the neutral metabolites after 72 hours). Additionally, the glycols underwent further oxidation 
to yield 2-hydroxymyrcene-1-carboxylic acid and 3-hydroxymyrcene-10-carboxylic acid (no quantitative 
data were given for these acidic metabolites).  
The authors suggested that uroterpenol (or limonene-8,9-diol) may have been formed from limonene, which 
is derived from cyclization of myrcene in the acidic conditions of the rabbit stomach (Ishida et al., 1981). 
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When rats were administered 800 mg/kg bw myrcene per day via gavage for 20 days, the principal 
metabolites isolated from the urine were 10-hydroxylinalool (or myrcene-3,10-glycol) and, to a lesser extent, 
7-methyl-3-methylene-oct-6-ene-1,2-diol (or myrcene-1,2-glycol). Other minor metabolites included the 
hydroxy acids of both the 3,10- and 1,2-glycols (10-carboxylinalool (or 3-hydroxymyrcene-10-carboxylic 
acid) and 2-hydroxy-7-methyl-3-methylene-oct-6-enoic acid (or 2-hydroxymyrcene-1-carboxylic acid), 
respectively) and a cyclic diol, 1-hydroxymethyl-4-isopropenylcyclohexanol (or p-menth-8-ene-1,7-diol), 
formed by intramolecular cyclization of an open chain metabolite (Madyastha & Srivatsan, 1987).  
It was demonstrated that the biotransformation of myrcene was cytochrome P450 (CYP)-mediated and that it 
could be enhanced by pretreatment of animals with phenobarbital (Madyastha & Srivatsan, 1987). These 
studies indicate the oxidation of the terminal double bonds of myrcene via intermediate epoxidation of the 
1,2- and 3,10- double bonds (Figure III.3). 
III.5 Subgroup 4: Aliphatic unsaturated tertiary alcohols 
After incubation of linalool or linalyl acetate with gut microflora from rat, mice or sheep, dihydrolinalool 
and tetrahydrolinalool are formed as metabolites (Rahman, 1974a). In vivo metabolism studies in rats on 14C-
labelled linalool demonstrated that linalool can be metabolised to dihydrolinalool and further to 
tetrahydrolinalool in the gut and excreted in urine and faeces as sulphates and glucoronides (Rahman, 
1974a). 
III.6 Subgroup 5: Monocyclic saturated tertiary alcohols and esters 
There are no metabolism studies on the candidate alicyclic substances p-menthane-1,8-diol, bisabola-1,12-
dien-8-ol, p-menthan-8-ol, terpineol and p-menthan-8-yl acetate [FL-no: 02.054, 02.129, 02.171, 02.230 and 
09.617]. p-Menthan-8-yl acetate is anticipated to be hydrolysed to give p-menthan-8-ol. There are 
metabolism studies on two substances, alpha-terpinol and menthol, which are supporting substances to p-
menthane-1,8-diol, p-menthan-8-ol, and p-menthan-8-yl acetate (Figure III.4). 
In a repeated dose study, male albino rats were orally administered the alicyclic tertiary alcohol alpha-
terpineol at a daily dose of 600 mg/kg bw for 20 days. Oxidation of the allylic methyl group was observed to 
yield the corresponding carboxylic acid, which was hydrogenated, to a small extent, to yield the 
corresponding saturated carboxylic acid (Madyastha & Srivatsan, 1988b). 
In rats, the vast majority of orally administered menthol is eliminated in either the urine or faeces as the 
glucuronic acid or various oxidation products (Madyastha & Srivatsan, 1988b; Yamaguchi et al., 1994). 
Non-cannulated and bile duct-cannulated male Fischer 344 rats were given a single oral dose of 500 mg/kg 
bw [3-3H]-1-menthol. Urine and faeces were collected over the next 24 and 48 hours from non-cannulated 
rats. In the bile duct-cannulated rats, bile samples were collected at 2-hours intervals for the first 6 hours and 
then from 6 to 24 hours. The 0-24 hours urine was collected in the same rats (Yamaguchi et al., 1994). The 
major metabolites found were menthol glucuronide in the bile and a variety of oxidation products in the 
urine. Menthol glucuronide formed in the liver passes into the bile with subsequent elimination or entry into 
enterohepatic circulation. Oxidation products of menthol are primarily p-menthane-3,8-diol, 3,8-dihydroxy-
p-menthane-7-carboxcylic acid and 3-hydroxy-p-menthane-7-carboxylic acid (Figure III.4). Minor 
metabolites are p-menthane-3,7-diol, p-menthane-3,7,8-triol, p-menthane-3,9-diol and 3-hydroxy-p-
menthane-9-carboxylic acid. The monohydroxylated menthols are excreted in the urine in part as 
glucuronide (Yamaguchi et al., 1994). 
The study by Madyastha & Srivatsan (Madyastha & Srivatsan, 1988b) supports the finding of p-menthane-
3,8-diol and 3,8-dihydroxy-p-menthane-7-carboxcylic acid as the main metabolites of menthol in urine after 
giving rats an oral dosage of 800 mg/kg bw. They also found p-menthane-3,9-diol as a minor metabolite. 
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Figure III.4. Metabolism of menthol in rats (Yamaguchi et al., 1994). Main metabolism products are in bold. 
 
III.7 Subgroup 6: Monocyclic unsaturated tertiary alcohols with isolated terminal double bonds 
There is one metabolism study on one of the two candidate substances in this group, elemol [FL-no: 02.149]. 
(-)-15-Hydroxyelemol was the only metabolite (10 % of the natural metabolites) detected after 72 hours in 
the urine of rabbits (2-3 kg) given 2g (-)-elemol. Most of the (-)-elemol (70 %) was recovered as elemol 
conjugated with glucuronic acid or sulphate. No oxidation of the double bond of the vinyl group was 
observed, indicating that no epoxide intermediates was formed. 
III.8 Subgroup 7: Bi- and tricyclic tertiary alcohols and esters 
For the candidate substances guaiyl acetate [FL-no: 09.808], 1,2,3,4,4a,5,6,7-octahydro-2,5,5-
trimethylnaphtalen-2-ol [FL-no: 02.197] and cedryl acetate [FL-no: 09.171] there are no metabolism studies 
available. Two metabolism studies were found for the candidate substance cedrol [FL-no: 02.120]. In the 
study by Bang and Ourisson (1975) rabbits were given natural cedrol (1 g) suspended in a 1 % mathyl-
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cellulose mucilage (20 ml) administered by gavage followed by 25 ml water. The urine was collected at 24, 
48 and 96 hours after administration. The urine was acidified to pH 4.5 and hydrolysed at 37° C for 24 hours 
with 6 ml snail (D-glucuronide)-glucuronidase. Five percent of the dose was excreted as conjugation product 
of unchanged cedrol. Thirtyfive percent of the dose was recovered as a mixture of stereochemically different 
3-hydroxycedrol metabolites. Twelve percent of the dose was recovered as a C7-C8 dehydrated C3-
hydroxylation product of cedrol (both 3-R and 3-S) (Bang & Ourisson, 1975). 
Trifilieff et al. (1975) administered 2 grams of cedrol to a phenobarbital-pretreated fasted dog. The 
metabolites described below (see also Figure III.5) were found in the first 24 hours urine. Urine was acidified 
with hydrochloric acid and treated with glucuronidase-sulphatase to hydrolyse conjugates. Three metabolite 
fraction, isolated by chromatography on silica columns and acetylation, were obtained in the following 
amounts: 130 mg of diol (1), 100 mg of a mixed fraction of diols (2 plus 3), and 40 mg of an acid (4). Diol 
(1) was identified by spectral data and correlation with α-epi-isobiotol (= 3-hydroxycedrol) and the 
corresponding ketone. In contrast to the rabbit the dog produced only the 3S isomer. Diols (2 plus 3) were 
identified as 15-hydroxycedrol and 2-hydroxycedrol, respectively, by separation after dehydration and 
further derivation and identification of the reaction products by comparison of the spectral data with 
literature data. The acid (4) was identified as the C14 carboxylic acid derivation product of 2-hydroxycedrol. 
In total only 270 mg ( 13 % of the dose) was recovered, but elimination of cerdol (-conjugates) was not 
studied / reported (Trifilieff et al., 1975). For structures of cedrol and the four metabolites in the dog see 
scheme below (Figure III.5): 
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Figure III.5 Metabolism of cedrol in a dog treated with phenobarbital. The carboxylic acid is presumably formed from  
2-hydroxycedrol, but this was not further studied (after Trifilieff et al, 1975). 
III.9 Subgroup 8: A aromatic tertiary alcohols 
No metabolism studies were found for the candidate substance 2-phenylpropan-2-ol [FL-no: 02.203]. 
However, several metabolism studies were found for the supporting substance p-cymene. 
The main metabolites in the urine of rabbits given a single oral dose of 670 mg p-cymene /kg bw were p-
cymen-9-ol and p-cymen-8-ol (50 % and 28 %, respectively, of the neutral metabolites). Acidic metabolites 
identified were alpha-p-tolylpropionic acid, alpha-tolyl-alpha-hydroxylpropionic acid, p-isopropylbenzoic 
acid and p-1-hydroxyisopropylbenzoic acid. Ring hydroxylation did not occur (Ishida et al., 1981).  
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Following an oral dose of 100 mg/kg bw of p-cymene to male rats, the principal urinary metabolites were p-
isopropylbenzoic acid (19 % of the administered dose) and 2-p-carboxyphenylpropionic acid (16 %). Other 
less important urinary metabolites included 2-p-tolylpropan-1-ol (8 %), 2-p-tolylpropan-2-ol (9 %), 2-p-
carboxyphenylpropan-2-ol (9 %), 2-p-(hydroxymethyl)phenylpropionic acid (4 %), 2-p-
carboxyphenylpropan-1-ol (11 %), p-isopropylbenzoylglycine (2 %), p-isopropylbenzyl alcohol (1 %), and 
2-p-tolylpropionic acid (1 %) (Walde et al., 1983). When the same dose was given to male guinea pigs, 
similar urinary metabolites were identified, however in different quantities. The primary urinary metabolite 
in guinea pigs was p-isopropylbenzoylglycine (31 %), indicating that conjugation with glycine was more 
prevalent in guinea pigs than in rats. Another major metabolite in guinea pigs was 2-p-tolylpropan-2-ol (14 
%). In addition, whereas ring hydroxylation of p-cymene was not reported in rats (Bakke & Scheline, 1970; 
Walde et al., 1983) and rabbits (Ishida et al., 1981), trace amounts of the ring hydroxylation metabolites 
hydroxyl-p-cymene and hydroxycarvacrol (dehydroxyl-p-cymene) were detected in guinea pig urine. Ring 
hydroxylation in guinea pigs only occurred in ortho position to the methyl group (Walde et al., 1983). 
Boyle et al. (1999) studied the metabolite pattern of p-cymene in rats following oral doses equivalent to 50 
and 200 mg/kg bw. The major metabolites in 0-48 hours urine after administration of the 50 mg/kg bw dose 
were 2-p-tolypropan-2-ol (39 % of recovered dose) and 2-p-carboxphenylpropan-2-ol (19 %). The former 
metabolite is the product of allylic hydroxylation of the isopropyl substituent, while the latter metabolite is 
the product of allylic hydroxylation of both the isopropyl substituent and the methyl substituent. Minor 
metabolites in rat urine were 2-p-carboxyphenylpropan-1-ol (10 %), 2-p-carboxyphenylpropionic acid (14 
%), and p-isopropylbenzoic acid (17 %). A large percentage of the urinary metabolites at this dose was 
conjugated (66 % conjugated vs 34 % free) both to glucuronic acid and glycine. The same metabolites were 
observed after the high dose, but conjugation was considerably reduced (18 % conjugated vs 82 % free), 
suggesting saturation of the conjugation pathway (Boyle et al., 1999). 
III.10 Oxidation of terminal double bonds 
13 candidate substances [FL-no: 02.123, 02.168, 02.144, 02.146, 02.185, 02.191, 02.150, 02.206, 02.226, 
09.614, 09.669, 09.671 and 02.149] possess terminal double bonds. These double bonds may be oxidised to 
the corresponding epoxide. Epoxides are highly reactive molecules, due to the large strain associated with 
the three membered ring structures, and they react easily with nucleophilic sites of cellular macromolecules. 
For this reason, several aliphatic alkene-derived epoxides have been demonstrated to be carcinogenic 
(Melnick, 2002). 
Two of the main metabolites of one of the supporting substances, myrcene, were found to be produced 
through epoxidation of the double bonds followed by hydrolysis to diols by epoxide hydroxylase (see 
above). Theoretically these reactions may also occur in the candidate substances with conjugated terminal 
double bonds. However, linalool or elemol were not found to give oxidation of terminal double bounds, 
indicating that terminal double bonds as such will not give rise to intermediate epoxides. 
III.4. Summary and Conclusions 
Seven candidate flavouring substances in this group are esters [FL-no: 09.171, 09.356, 09.614, 09.669, 
09.671, 09.808 and 09.617]. Hydrolysis data are not available for any of these esters. However, for the 
supporting substance, linalyl acetate, in vitro hydrolysis data indicate that these esters may be hydrolysed, 
which would also be expected based on general knowledge about ester hydrolysis. The carboxcylic acids 
resulting from the hydrolysis of these six candidate flavouring substances are acetic acid, propanoic acid and 
valeric acid, which will be incorporated in normal physiological processes such as beta-oxidation and citric 
acid cycle. The alcohols resulting from the hydrolysis of these esters are tertiary alcohols as are all the 
remaining candidate substances in this flavouring group. The tertiary alcohols in this FGE are subdivided 
into eight subgroups according to their chemical structures. 
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Subgroup 1: Metabolism studies of the three candidate substances, 2-methylpropan-2-ol [FL-no: 02.052], 2-
methylbutan-2-ol [FL-no: 02.041] and 2-methylpentan-2-ol [FL-no: 02.181] show that these are conjugated 
with glucuronic acid before excretion in the urine. When rats were treated with 2-methylpropan-2-ol, acetone 
was excreted in small amounts, and when administered 2-methylbutan-2-ol, diols were excreted. This 
indicates that an additional metabolism pathway of the three candidate substances is oxidation of the methyl 
group. From these metabolism studies it is anticipated that the candidate substances 2-methylpropan-2-ol, 2-
methylbutan-2-ol, 3-methylpenta-3-ol, 2-methylpentan-2-ol, 2,6-dimethyl-2-heptanol, 2,4-dimethyl-4-
nonanol, 3,6-dimethyloctan-3-ol and 1,1-dimethylethyl propionate [FL-no: 02.052, 02.041, 02.184, 02.181, 
02.219, 02.253, 02.147 and 09.356] are conjugated with glucuronic acid and excreted in the urine, or that 
they can undergo oxidation to yield the corresponding diols. They are also expected to be excreted as their 
respective glucuronic acid conjugates. 
Subgroup 2: Linalool is a supporting substance to the candidate substances 2-methylbut-3-en-2-ol, geranyl 
linalool, isophytol, [S-(cis)]-3,7,11-trimethyl-1,6,10-dodecatrien-3-ol, linalyl valerate and nerolidyl acetate 
[FL-no: 02.123, 02.150, 02.168, 02.226, 09.614 and 09.671,], which have the isolated double bond in close 
proximity to the tertiary alcohol group. As these substances or their respective alcohol moieties have a free 
hydroxyl group, they may be directly conjugated. Seventy-two hours after intragastrical administration of 
500 mg/kg bw 14C-labelled linalool to 12-weeks old rats 58-60 % of the dose was excreted in the urine, 12-
15 % in the faeces and 25-27 % in the expired air. In tissues 3-4 % residual activity was found. Beyond 
unchanged linalool the main metabolites in urine and faeces were dihydrolinalool and tetra hydrolinalool, 
mainly conjugated with sulphate or glucuronic acid. The study also indicated that the reduction mainly took 
place in the gut. In addition, the metabolism of linalool indicates that these candidate substances may also be 
metabolised by omega-oxidation of methyl groups, excreted in the urine as such or in conjugation with 
glucuronic acid. No oxidation of the terminal double bond in linalool was observed, indicating no formation 
of epoxide intermediates. 
For 2,6-dimethyloct-7-en-2-ol [FL-no: 02.144] the structure differs from the supporting substance linalool 
and the other candidate substances in this group in that the isolated terminal double bond is located distant 
from the tertiary group. However, any risk from epoxide formation of this compound is considered to be low 
since the substance can be directly conjugated with glucuronic acid or the alcohol group can be expected to 
be readily attacked by oxidation processes, ultimately yielding the corresponding carboxylic acid. 
Biochemical attack of this carboxylic acid via beta-oxidation or conjugation with glucuronic acid is expected 
to be more efficient and rapid than microsomal oxidation. Any epoxides formed may be metabolised by 
conjugation with glutathione or by epoxide-hydrolase mediated hydrolysis. 
Subgroup 3: Myrcene is a supporting substance to the candidate substances 3,7-dimethylocta-1,5,7-trien-3-
ol, myrcenol, ocimenol and myrcenyl acetate [FL-no: 02.146, 02.185, 02.191 and 09.669]. These substances 
also have alcohol moieties that can be directly conjugated. In addition, further oxidation of methyl groups 
may occur. As shown for myrcene, oxidation of conjugated terminal double bonds in the candidate 
substances may occur, giving rise to epoxide intermediates. It should be noted that the available genotoxicity 
data for myrcene do not indicate a genotoxic potential for this substance even in the presence of metabolic 
activation. However, it cannot be anticipated that these candidate substances will be metabolised to 
innocuous products. 
Subgroup 4: 1,2-Dihydrolinalool [FL-no: 02.140] can be expected to be directly conjugated to glucuronic 
acid like the supporting substance linalool, and excreted. After incubation of linalool or linalyl acetate with 
gut microflora from rat, mice or sheep, dihydrolinalool and tetrahydrolinalool are formed as metabolites. In 
vivo metabolism studies in rats on 14C-labelled linalool demonstrated that linalool can be metabolised to 
dihydrolinalool and further to tetrahydrolinalool in the gut and excreted in urine and faeces as sulphates and 
glucoronides. Additionally, it might be oxidised at the methyl groups, introducing new hydroxyl groups that 
also can be conjugated and excreted. 
Subgroup 5: From the metabolism studies of alpha-terpineol and menthol it is anticipated that the candidate 
substances terpineol [FL-no: 02.230], p-menthane-1,8-diol [FL-no: 02.054], bisabola-1,12-dien-8-ol [FL-no: 
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02.129] and p-menthan-8-ol [FL-no: 02.171] (also an hydrolysis product of candidate substance [FL-no: 
09.617]) may undergo allylic oxidation of the exocyclic methyl group. This could be further oxidised to a 
carboxylic acid group. Alternative or subsequent metabolism may occur by conjugation to glucuronic acid, 
followed by excretion in the urine. 
Subgroup 6: A metabolism study on elemol indicate that the substance is absorbed from the gastrointestinal 
tract and mainly excreted in conjugation with glucuronic acid or sulphate, although one oxidised metabolite, 
hydroxyelemol, was also found in lower amounts. No oxidation of the isolated terminal double bond of 
elemol was found; accordingly, epoxidation of elemol [FL-no: 02.149] and sclareol [FL-no: 02.206], which 
have the same structural features as elemol, would not be anticipated. 
Subgroup 7: Two metabolism studies on cedrol [FL-no: 02.120] indicate that the candidate substances 
1,2,3,4,4a,5,6,7-octahydro-2,5,5-trimethylnaphthalen-2-ol [FL-no: 02.197], cedrol [FL-no: 02.120] and  
cedryl acetate [FL-no: 09.171] and guaiyl acetate [FL-no: 09.808] will be further hydroxylated and excreted 
in urine as such or as conjugates.  
Subgroup 8: In metabolism studies, the supporting substance 1-isopropyl-4-methylbenzene [FL-no: 01.002] 
(synonym: p-cymene) was oxidised at the isopropyl side chain yielding 2-(p-tolyl)-2-propanol, which is not 
further oxidised, but excreted unchanged or as a glucuronic acid conjugate. It is anticipated that the candidate 
substance 2-phenylpropan-2-ol [FL-no: 02.203] will follow the same pathway and be excreted unchanged or 
in conjugation with glucuronic acid. 
In summary, 28 of the candidate substances [FL-no: 02.041, 02.052, 02.054, 02.120, 02.123, 02.129, 02.140, 
02.144, 02.147, 02.149, 02.150, 02.168, 02.171, 02.181, 02.184, 02.197,  02.203, 02.206, 02.219, 02.226, 
02.230, 02.253, 09.808, 09.171, 09.356, 09.614, 09.617 and 09.671] are anticipated to be metabolised to 
innocuous products.  
Four of the candidate substances [FL-no: 02.146, 02.185, 02.191 and 09.669] (subgroup 3) contain 
conjugated terminal double bonds and data from a supporting substance indicate that these may be oxidised, 
giving rise to epoxide intermediates. Thus, it cannot be anticipated that these four substances will be 
metabolised to innocuous products. Despite evidence for the formation of epoxide intermediates, the 
supporting substance produced negative results in in vitro genotoxicity studies. 
 
 
Flavouring Group Evaluation 18, Revision 2
 
 
61 EFSA Journal 2011; 9(5):1847 
ANNEX IV: TOXICITY 
Oral acute toxicity data are available for 16 candidate substances of the present Flavouring Group Evaluation from chemical group 6 and 8, and for 19 
supporting substances evaluated by the JECFA at the 51st meeting (JECFA, 1999a). The supporting substances are listed in brackets. 
TABLE IV.1: ACUTE TOXICITY 
Chemical Name [FL-no] Species  Sex  Route  LD50 
(mg/kg bw)  
Reference  Comments 
2-Methylpropan-2-ol [02.052] Rat NR Oral 3500 (Schaffarzick & Brown, 1952)  
 Rat M, F Gavage 3046 (Johnson, 1981a)  
 Rat M, F Gavage 2733 (Johnson, 1981b)  
 Rat NR Oral > 3800 (Eastman Kodak Co., 1994c)  
 Rabbit M, F Gavage 3560 (Munch, 1972)  
2-Methylbutan-2-ol [02.041] Rat NR Oral 1000 (Schaffarzick & Brown, 1952)  
 Rat NR Oral 1000 – 2000 (Dow Chemical Company, 
1982b) 
 
 Rabbit M, F Gavage 2027 (Munch, 1972)  
3-Methylpentan-3-ol [02.184] Rat NR Oral 710 (Brown et al., 1955)  
2,6-Dimethyl-2-heptanol [02.219] Rat NR Oral 6800 (BASF, 1979b)  
 Rat NR Oral > 5000 (Moreno, 1976a)  
3,6-Dimethyloctan-3-ol [02.147] Rat NR Oral > 5000 (Moreno, 1973n)  
2-Methylbut-3-en-2-ol [02.123] Rat NR Oral 1800 (BASF, 1972)  
(Linalool [02.013]) Rat M, F Gavage 2790 (Jenner et al., 1964)  
 Mouse M, F Oral 2200 (Rhône-Poulenc, Inc., 1992a)  
 Mouse M, F Oral 3918 (Hoffman-LaRoche, Inc., 1967b)  
 Mouse M, F Oral 30001
17002 
(Rhône-Poulenc, Inc., 1992a)  
(3,7-Dimethyloctan-3-ol [02.028]) Rat NR Oral > 5000 (Moreno, 1976r)  
2,6-Dimethyloct-7-en-2-ol [02.144] Rat NR Oral 3600 (Moreno, 1973o)  
Myrcenol [02.185] Rat NR Oral 5300 (Moreno, 1972g)  
Ocimenol [02.191] Rat NR Oral 1700 (Wohl, 1974f)  
Geranyl linalool [02.150] Rat NR Oral > 5000 (Moreno, 1982i)  
 Mouse M, F Oral 14,632 (Hoffman-LaRoche, Inc., 1967a)  
(Linalyl formate [09.080]) Rat NR Oral > 5000 (Russell, 1973e)  
 Mouse M Oral 5389 (Hoffman-LaRoche, Inc., 1967b)  
(Linalyl acetate [09.013]) Rat M, F Gavage 14,550 (Jenner et al., 1964)  
 Rat NR Oral 10,000 (Zeller, 1969)  
 Mouse NR Gavage 13,360 (Jenner et al., 1964)  
 Mouse M Oral 13,539 (Hoffman-LaRoche, Inc., 1967b)  
(Linalyl propionate [09.130]) Rat NR Oral > 5000 (Moreno, 1973p)  
 Mouse M Oral 13,874 (Hoffman-LaRoche, Inc., 1967b)  
(Linalyl butyrate [09.050]) Rat NR Oral > 5000 (Levenstein, 1975i)  
 Mouse M Oral > 8907 (Hoffman-LaRoche, Inc., 1967b)  
(Linalyl isobutyrate [09.423]) Rat M, F Gavage > 36,300 (Jenner et al., 1964)  
 Mouse NR Gavage 15,100 (Jenner et al., 1964)  
 Mouse M Oral > 17,698 (Hoffman-LaRoche, Inc., 1967b)  
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TABLE IV.1: ACUTE TOXICITY 
Chemical Name [FL-no] Species  Sex  Route  LD50 
(mg/kg bw)  
Reference  Comments 
(Linalyl isovalerate [09.454]) Rat NR Oral > 5000 (Moreno, 1975l)  
 Mouse M, F Oral 25,165 (Hoffman-LaRoche, Inc., 1967b)  
(Linalyl hexanoate [09.068]) Mouse M, F Oral 37,869 (Hoffman-LaRoche, Inc., 1967a)  
Myrcenyl acetate [09.669] Rat NR Oral 6300 (Moreno, 1972h)  
(Linalyl octanoate [09.116]) Mouse M, F Oral 48,849 (Hoffman-LaRoche, Inc., 1967a)  
Nerolidyl acetate [09.671] Rat NR Oral > 5000 (Moreno, 1976s)  
(alpha-Terpineol [02.014]) Rat NR Oral 43003 (Moreno, 1971)  
 Mouse M Gavage 2830 (Yamahara et al., 1985)  
(alpha-Terpinyl formate [09.081]) Rat NR Oral > 5000 (Moreno, 1976t)  
(Terpinyl acetate [09.830]) Rat M, F Gavage 5075 (Jenner et al., 1964)  
(Terpinyl propionate [09.142]) Rat NR Oral > 5000 (Moreno, 1973q)  
(Terpinyl 2-methylpropionate [09.425]) Rat NR Oral > 5000 (Moreno, 1982j)  
(4-Terpinenol [02.072]) Rat NR Oral 1300 (Moreno, 1977v)  
Guaiyl acetate [09.808] Rat NR Oral > 5000 (Moreno, 1973r)  
2-Phenylpropan-2-ol [02.203] Rat NR Oral 10374 (Patty, 1982a)  
(beta-Terpineol) [02.097]) Rat NR Oral 43003 (Moreno, 1971)  
p-Menthan-8-ol [02.171]  Rat NR Oral > 5000 (Moreno, 1973s)  
(1-Acetoxy-1-acetylcyclohexane [09.293]) Rat M, F Gavage 2150 (Piccirillo & Hartman, 1980b)  
(Menthol [02.015]) Mouse  M  Gavage  2652  (Food and Drug Research 
Laboratories, Inc., 1975a) 
 
 Mouse  M  Gavage  4384  (Food and Drug Research 
Laboratories, Inc., 1975a) 
 
 Mouse  NR  Gavage  3100  (Wokes, 1932)  
 Rat  M, F  Gavage  3180  (Jenner et al., 1964)  
 Rat  M  Gavage  940  (Food and Drug Research 
Laboratories, Inc., 1975a) 
 
Bisabola-1,12-dien-8-ol [02.129] Rat NR Oral > 5000 (CIR, 1999)  
 Mice NR Oral 0.633  (CIR, 1999)  
 Rat M, F Oral M: 14,9 ml/kg bw 
F: 15.6 ml/kg bw 
(Habersang et al., 1979)  
 Mice M, D Oral 15.1 ml/kg bw (Habersang et al., 1979)  
1Value represents calculated LD50 when substance was administered in peanut oil.  
2Value represents calculated LD50 when substance was administered as an emulsion in an aqueous Arabic gum solution at 10 %.  
3Reported for a mixture of alpha- and beta-terpineol.  
4LD50 value reported as 1.07 ml; conversion based on a density of 0.97 g/ml. 
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Subacute / Subchronic / Chronic / Carcinogenic toxicity data are available for six candidate substances of the present Flavouring Group Evaluation from 
chemical group 6 and 8, and for eight supporting substances evaluated by the JECFA at the 51st meeting (JECFA, 1999a) or at the 63rd meeting (JECFA, 
2006a). The supporting substances are listed in brackets. 
TABLE IV.2: SUBACUTE / SUBCHRONIC / CHRONIC / CARCINOGENICITY STUDIES 
Chemical Name [FL-no] Species; Sex 
No./Group 
Route Dose levels Duration NOAEL 
(mg/kg bw/day) 
Reference Comments 
2-Methylpropan-2-ol [02.052] Rat; M 
5-6 
Drinking 
water 
0 or 0.5 %, equivalent 
to 0 or 500 mg/kg 
bw/day 
10 weeks  None (Acharya et al., 1997) Histological examination of liver and 
kidney only. 
 Rat; M, F 
20 
Drinking 
water 
0, 0.25, 0.5, 1, 2 or 4 %, 
equivalent to 0, 250, 
500, 1000, 2000 or 
4000 mg/kg bw/day 
90 days  None 
 
(Lindamood et al., 1992; 
NTP, 1995b) 
Fully described NTP study. No NOAEL for 
males or females.  
 Rat; M 
10 
Drinking 
water 
0, 0.25, 0.5, 1, 2 or 4 %, 
equivalent to 0, 250, 
500, 1000, 2000 or 
4000 mg/kg bw/day 
90 days  None (Takahashi et al., 1993) Good quality investigative study using extra 
renal samples from the above 90-day study; 
indicates nephropathy in male F344 rats is 
due to alpha-2 µ-globulin. No NOAELs. 
 Rat; M, F 
1204 
Drinking 
water 
Males: 0, 0.125, 0.25 or 
0.5 %, equivalent to 0, 
90, 200 or 420 mg/kg 
bw/day 
 
Females: 0, 0.25, 0.5 or 
1 %, equivalent to 0, 
180, 330 or 650 mg/kg 
bw/day 
2 years  None 
 
(Cirvello et al., 1995; NTP, 
1995b) 
Fully described NTP study. No NOAELs. 
NTP conclusions on carcinogenicity: some 
evidence of carcinogenic activity in males, 
no evidence of carcinogenicity in females. 
 Rat; M, F 
20 
Drinking water 0, 0.25, 0.5, 1, 2 or 4 %, 
equivalent to 0, 250, 
500, 1000, 2000 or 
4000 mg/kg bw/day 
90 days Male: 0.5 %, equivalent 
to 500 mg/kg bw/day 
Female: 1 %, equivalent 
to 1000 mg/kg bw/day 
(Brown & Wheeler, 1979) The report is incomplete as it is lacking 
tables. 
 Mouse; M, F 
20 
Drinking water 0, 0.25, 0.5, 1, 2 or 4 %, 
equivalent to 0, 625, 
1250, 2500, 5000 or 
10,000 mg/kg bw/day 
90 days  (Brown & Wheeler, 1979) The report is incomplete as it is lacking 
tables. 
 Mouse; M, F 
20 
Drinking 
water 
0, 0.25, 0.5, 1, 2 or 4 %, 
equivalent to 0, 625, 
1250, 2500, 5000 or 
10,000 mg/kg bw/day 
90 days Male: 1 %, equivalent to 
2500 mg/kg bw/day 
Female: 2 %, equivalent 
to 5000 mg/kg bw/day 
(Lindamood et al., 1992; 
NTP, 1995b) 
Fully described NTP study. 
 Mouse; M, F 
120 
Drinking 
water 
0, 0.5, 1 or 2 %, 
equivalent to 0, 540, 
1040 or 2070 mg/kg 
bw/day in males and 0, 
510, 1020 or 2100 
mg/kg bw/day in 
females 
2 years M: None 
F: 0.5 %, equivalent to 
510 mg/kg bw/day 
(Cirvello et al., 1995; NTP, 
1995b) 
Fully described NTP study. NTP 
conclusions on carcinogenicity: equivocal 
evidence of carcinogenic activity in males, 
some evidence of carcinogenic activity in 
females. 
2-Methylbut-3-en-2-ol [02.123] Rat; M, F 
10 
Gavage 0, 30, 150 or 750 mg/kg 
bw/day 5 days/week 
4 weeks 150 (BASF, 1994a) Full study details provided. Study 
considered valid. Dosing only 5 days/week 
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TABLE IV.2: SUBACUTE / SUBCHRONIC / CHRONIC / CARCINOGENICITY STUDIES 
Chemical Name [FL-no] Species; Sex 
No./Group 
Route Dose levels Duration NOAEL 
(mg/kg bw/day) 
Reference Comments 
but a clear NOAEL. 
(Linalool [02.013]) Rat; M, F 
NR 
Diet2 0 or 50 mg/kg bw/day1 84 days 501 (Oser, 1967) Unpublished report. Administered as 50 % 
mixture of linalool and citronellol. Slight 
retardation of growth in males at 50 mg/kg 
bw/day, not related to food intake. 
 Mouse; F 
30 
Gavage 0 or 365 mg/kg bw/day 5 days 3751, 3 (Gaworski et al., 1994) Immunotoxicity study only. 
 Rat; F 
100 
Gavage  21 days 500 (Lewis, 2006)  
(Linalyl acetate [09.013]) Rat; M, F 
NR 
Diet5 0 or 24 mg/kg bw/day1 84 days 241 (Oser, 1967) Unpublished report. Administered as 
mixture of linalyl acetate (24 mg/kg 
bw/day), linalyl isobutyrate (27 mg/kg 
bw/day) and geranyl acetate (48 mg/kg 
bw/day). Slight growth retardation of 
females. 
(Linalyl isobutyrate [09.423]) Rat; M, F 
NR 
Diet6 0 or 27 mg/kg bw/day1 84 days 271 (Oser, 1967)  
 Rat; NR 
20 
Diet 0, 1000, 2500 or 10,000 
ppm, equivalent to 0, 
50, 125 or 500 mg/kg 
bw/day 
18 weeks 500
(10,000 ppm) 
(Hagan et al., 1967) Very limited details provided. 
(Linalyl cinnamate [09.736]7) Rat; M, F 
10 
Diet 0, 1000, 2500 or 10,000 
ppm, equivalent to 0, 
50, 125 or 500 mg/kg 
bw/day 
17 weeks 5001
(10,000 ppm) 
(Hagan et al., 1967) Very limited details provided. 
(Geranyl acetate [09.011]
/Citronellyl acetate[09.012]8) 
Mouse; M, F 
50 
Gavage  103 weeks -9 (NTP, 1987a)  
 Rat; M, F 
50 
Gavage  103 weeks 1000 
(710; 290)8 
(NTP, 1987a)  
(Myrcene [01.008]) Rat; M, F 
10 
Gavage 0, 250, 500, 1000, 2000 
or 4000 mg/kg bw/day 
13 weeks None (NTP, 2004a) Draft results only available. Evaluated by 
the JECFA. No NOAEL as most sensitive 
adverse effect (nephropathy) present at 
lowest dose tested (JECFA, 2006a). 
 Mouse; M, F 
10 
Gavage 0, 250, 500, 1000, 2000 
or 4000 mg/kg bw/day, 
5 days/week 
13 weeks Male: None 
Female: 250 mg/kg 
bw/day 
(NTP, 2004a) Draft results only available. Evluated by the 
JECFA. Liver hypertrophy in males at all 
doses (JECFA, 2006a). 
(Menthol [02.015]) Mouse; M, F 
50 
Diet  0, 2000 or 4000 ppm, 
equivalent to 0, 300 or 
600 mg/kg bw/day 
103 weeks  6001  (National Cancer Institute, 
1979) 
Good quality. 
 Mouse; F  
30 
I.P. injection 0, 500 or 2000 mg/kg,  
3 times/week 
24 weeks  None (Stoner et al., 1973) Good quality. 
 Rat; M, F 
20 
Gavage  0, 200, 400 or 800 
mg/kg bw day 
28 days  None (Thorup et al., 1983a) Relative good quality. 
 Rat; M, F  
80 
Diet  0, 100 or 200 mg/kg bw 5.5 weeks  2001  (Herken, 1961) Limited information. 
 Rat; M, F 
50  
Diet  0, 3750 or 7500 ppm, 
equivalent to 0, 188 or 
103 weeks  3751  (National Cancer Institute, 
1979) 
Good quality. 
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TABLE IV.2: SUBACUTE / SUBCHRONIC / CHRONIC / CARCINOGENICITY STUDIES 
Chemical Name [FL-no] Species; Sex 
No./Group 
Route Dose levels Duration NOAEL 
(mg/kg bw/day) 
Reference Comments 
375 mg/kg bw/day  
(Terpinyl acetate [09.830]) Rat; M, F 
20 
Diet 0, 1000, 2500 or 10,000 
ppm, equivalent to 0, 
50, 125 or 500 mg/kg 
bw/day 
20 weeks 5001 (Hagan et al., 1967) Very limited details provided. 
Sclareol [02.206] Rat; M, F 
20 
Gavage 8.8 mg/kg bw/day 28  days 8.8  (IOFI, 2006a)  
Cedrol [02.120] Rat; M, F 
20 
Gavage 8.4 mg/kg bw/day 28 days 8.4  (IOFI, 2006a)  
2,6-Dimethyloct-7-en-2-ol [02.144] Rat; M, F 
40 
Gavage 10, 50, 500, 1000 
mg/kg bw/day 
90 days 50 (F) 
10 (M) 
(Dunster et al., 2007)  
Bisabola-1,12-dien-8-ol [02.129] Dog, NR 
20 
Gavage 1 ml/kg bw 14 days 850  (Habersang et al., 1979)  
 Rat, M,F 
20 
Gavage 2, 3 ml/kg bw 28 days 850 (Habersang et al., 1979)  
NR=Not Reported 
1The study was performed at a single dose level or multiple dose levels that produced no adverse effects. 
2Administered with citronellol as part of a 50/50 mixture.  
3Immunotoxicity study.  
4Three treatment groups per sex. Each dose group included 60 male and female animals. 
5Administered with linalyl isobutyrate and geranyl acetate as a part of a mixture.  
6Administered with linalyl acetate and geranyl acetate as a part of a mixture.  
7 Structurally related ester of linalool not evaluated as part of the supporting chemicals group.  
8 Structurally related terpenoid esters administered as a mixture: geranyl acetate, 71 %; citronellyl acetate, 29 %.  
9 A NOEL could not be established due to a high incidence of gavage errors and low survival associated with pneumonia.  
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Developmental and reproductive toxicity data are available for two candidate substances of the present Flavouring Group Evaluation from chemical group 6 
and 8, and for three of the supporting substances evaluated by the JECFA at the 51st meeting (JECFA, 1999a) or at the 63rd meeting (JECFA, 2006a). The 
supporting substances are listed in brackets. 
TABLE IV.3: DEVELOPMENTAL AND REPRODUCTIVE TOXICITY STUDIES 
Chemical Name [FL-no]  Study type 
Duration  
 
Species/Sex  
No/group 
Route  Dose  levels NOAEL (mg/kg/day) 
including information on 
possible maternal toxicity 
Reference  Comments 
2-Methylpropan-2-ol [02.052] Developmental Toxicity 
Gestation Days 6– 20 
Mouse; F 
15 
Liquid Diet 0, 0.5, 0.75 or 1 % (equivalent 
to approximately 0, 3400, 4900 
and 6400 mg/kg bw/day) 
Maternal: 0.5 % 
Foetal: None 
(Daniel & Evans, 
1982) 
Study considered valid. Dose related 
reduction of offspring performance in 
neurobehavioural tests (righting reflex, 
negative geotaxis, open file behaviour, 
cliff avoidance, roto-rod performance). 
 Developmental Toxicity: 
Gestation Days 6– 18 
Mouse; F 
9-12 
Gavage1 0 or 10.5 mmol/kg bw/day, 
equivalent to 1557 mg/kg 
bw/day 
Maternal: None 
Foetal: None 
(Faulkner et al., 
1989) 
Study considered valid. Increased foetal 
resorptions and decreased births per litter 
in treated group. 
(Linalool [02.013]) Reproductive & 
Developmental 
Toxicity: 33 – 39 days3 
Rat; F 
10 
Gavage 0, 250, 500 or 1000 mg/kg 
bw/day coriander oil, 
equivalent to 0, 182.3, 364.5 or 
729 mg/kg bw/day linalool 
Maternal: None 
Foetal: 364.5 
(Hoberman & 
Christian, 1989) 
Test substance was coriander oil. Linalool 
content 72.9 %. 
(Menthol [02.015]) Teratology 
Gestation days 6-15 
Mouse; F 
22 
Gavage  0, 1.85, 8.59, 39.9, 185 1852  (Food and Drug 
Research 
Laboratories, Inc., 
1973) 
 
 Teratology 
Gestation days 6-15 
Rat; F  
22-23 
Gavage  0, 2.18, 10.15, 47.05, 218 2182  (Food and Drug 
Research 
Laboratories, Inc., 
1973) 
 
 Teratology 
Gestation days 6-15 
Hamster; F 
20-22 
Gavage  0, 4.05, 21.15, 98.2, 405 4052  (Food and Drug 
Research 
Laboratories, Inc., 
1973) 
 
 Teratology 
Gestation days 6-18 
Rabbit; F 
9-11 
Gavage  0, 4.25, 19.75, 91.7, 425 4252 (Food and Drug 
Research 
Laboratories, Inc., 
1973) 
 
(Myrcene [01.008]) Teratology 
Gestation days 6-15 
Rat; F 
16-29 
Gavage 0, 250, 500, 1200 mg/kg 
bw/day 
Maternal: 500 mg/kg 
bw/day 
Foetal: 500 mg/kg bw/day 
(Delgado et al., 
1993a) 
Study considered valid. Evaluated by the 
JECFA. 
 Reproductive and 
developmental toxicity: 
Gestation day 15 to 
postanatal day 21 
Rat; F 
12-18 
Gavage 0, 250, 500, 1000, 1500 mg/kg 
bw/day 
Maternal: 500 mg/kg 
bw/day 
Foetal/neonatal: 250 mg/kg 
bw/day 
(Delgado et al., 
1993b) 
Study considered valid. Evaluated by the 
JECFA.  
  Reproductive and 
developmental toxicity: 
Prior to mating until 
postnatal day 214 
Rat; M, F 
60 
Gavage 0, 100, 300, 500 mg/kg bw/day Maternal/paternal: 500 
mg/kg bw/day 
Foetal: 300 mg/kg bw/day 
(Paumgartten et al., 
1998) 
Study considered valid. Evaluated by the 
JECFA. 
2,6-Dimethyloct-7-en-2-ol Developmental Toxicity: Rat, M, F Gavage 0, 250, 500, 1000 mg/kg Maternal: 500 mg/kg (Politano et al.,  
Flavouring Group Evaluation 18, Revision 2
 
 
67 EFSA Journal 2011; 9(5):1847 
TABLE IV.3: DEVELOPMENTAL AND REPRODUCTIVE TOXICITY STUDIES 
Chemical Name [FL-no]  Study type 
Duration  
 
Species/Sex  
No/group 
Route  Dose  levels NOAEL (mg/kg/day) 
including information on 
possible maternal toxicity 
Reference  Comments 
[02.144] Gestation Days 7– 17 25 bw/day bw/day 
Foetal: 500 mg/kg bw/day 
2008) 
1Test substance was administered to two strains of mice at a dose level of 778 mg/kg (10.5 mmoles/kg) twice daily.  
2The study was performed at a single dose level or multiple dose levels that produced no adverse effects.  
3Animals were dosed for seven days prior to mating, during mating (maximum of seven days), during gestation, delivery and four days post parturition.  
4Males were dosed for 91 days prior to mating and during mating; females were dosed from 21 days prior to mating to 21 days after birth.  
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In vitro mutagenicity/genotoxicity data are available for five candidate substances of the present Flavouring Group Evaluation from chemical group 6 and 8, 
and for eight supporting substances evaluated by the JECFA at the 51st meeting (JECFA, 1999a) or at the 63rd meeting (JECFA, 2006a). Supporting 
substances are listed in brackets. 
TABLE IV.4: GENOTOXICITY (IN VITRO) 
Chemical Name [FL-no] Test System Test Object Concentration 
 
Result Reference Comments 
2-Methylpropan-2-ol [02.052] Ames test S. typhimurium 
TA98; TA100; 
TA1535; TA1537; 
TA1538 
0.1, 0.5, 2.5, 5, 10 µl/plate 
(7800 µg/plate) 
Questionable1 (Haworth et al., 1981a) Unpublished GLP study. According to the conclusion of the report, 
the test substance “did cause a weak but significant increase in 
TA1535 revertants per plate in both the presence and absence of rat 
liver microsomes.” However, this result cannot be re-evaluated 
because the corresponding page with results on TA1535 in Table 
format is lacking. 
 Ames test S. typhimurium 
TA98; TA100; 
TA1535; TA1537; 
TA1538 
probably 1 to 10 µl/plate 
(7800 µg/plate) (corresponding 
pages of the report are lacking) 
Questionable1 (Haworth et al., 1981b) Unpublished GLP study. According to the conclusion of the report, 
the test substance (purity 99.9 %) “did not cause a significant 
increase in the number of revertants per plate in any of the tester 
strains with or without metabolic activation. It should be noted, 
however, that there was a slight increase in TA1535 revertants per 
plate observed in the presence and absence of rat liver 
microsomes.” However, this result cannot be re-evaluated because 
15 pages with all results in Table format are lacking. 
 Ames test S. typhimurium 
TA98; TA100; 
TA1535; TA1537 
10000 µg/plate Negative1 (Zeiger et al., 1987) Non-GLP study roughly in accordance with OECD guideline 471. 
There was a slight increase in TA1535 revertants per plate 
observed in the presence and absence of rat and hamster liver 
microsomes. This effect is dose-related only with hamster liver S9. 
Overall, the effects were less than twice compared to control. The 
study is considered valid. 
 Yeast mitochondrial 
mutation assay 
Several 
Saccharomyces 
strains 
4 % Positive (Jiménez et al., 1988) This non-GLP study was not in accordance with OECD guideline 
480 (1986), and the study protocol does not belong to standard 
protocols used in routine testing. However, the result is considered 
valid since main details of method and results are reported. 
Endpoint not relevant for genotoxicity. 
 Forward mutation 
assay 
Mouse lymphoma  
L5178Y TK +/- 
0, 1000, 2000, 3000, 4000, 5000 
µg/ml 
Negative1 (McGregor et al., 
1988b) 
Non-GLP study in accordance with OECD guideline 476 (1984). 
Study is considered valid. 
 
Forward mutation 
assay 
Mouse lymphoma  
L5178Y TK +/- 
1.3 to 100 µl/ml 
(78000 µg/ml) 
Negative (Kirby et al., 1981) Unpublished GLP study. According to the report’s summary, test 
substance of high (99.9 %) purity did not induce any detectable 
increases in the mutant frequencies in the presence and absence of 
S9-mix. When cultures were tested in the presence of S9-mix with 
less pure test substance none of the cultures exhibited increases in 
mutant frequency. Without S9-mix this test substance did appear to 
induce an increase in the mutant frequency of cultures treated with 
the higher doses, but a dose-related response was not evident. In 
addition, in only one of two experiments was a greater than two-
fold increase in mutant frequency observed. However, this result 
cannot be re-evaluated because 47 pages with all results in Table 
format are lacking in the report submitted. 
 
Chromosomal 
aberration 
Chinese hamster 
ovary cells 
160 to 5000 microgram/ml Negative (NTP, 1984e) Limited validity. This non-GLP study was in accordance with 
OECD guideline 473 (1983) except that only a single harvest time 
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was used, however, the study protocol does not fully meet the 
criteria of the revised guideline from 1997. According to the 
version from 1997, a single sampling time should be equivalent to 
about 1.5 normal cell cycle lengths, duplicate cultures should be 
used at each concentration and 200 metaphases should be scored 
per concentration. 
 
Sister chromatid 
exchange 
Chinese hamster 
ovary cells 
6 concentrations ranging from 
0.625 to 20 µl/ml 
(15600 µg/ml) 
Negative (Putman, 1985) Unpublished GLP study. According to the report’s summary, test 
substance of high (99.9 %) purity caused a significant increase in 
sister chromatid exchanges at the high dose only in the assay 
without S9 and at the two highest doses in the assay with S9, 
however, the test article did not meet the criteria for a positive 
response (at least two-fold increase or a significant positive dose 
response over at least three doses). However, this result cannot be 
re-evaluated because pages with all results in Table format are 
lacking in the report submitted. 
 
Sister chromatid 
exchange 
Chinese hamster 
ovary cells 
20 µl/ml 
(15600 µg/ml) 
Negative (Thilagar et al., 1981) Unpublished GLP study is considered valid. A marginal increase in 
SCE frequency was observed in the tests with and without S9, 
while only the highest concentration without S9 resulted in a 
significant increase. Thus, the test article did not meet the criteria 
for a positive response (at least two-fold increase or a significant 
positive dose response over at least three doses). (All relevant 
tables were submitted). 
2-Methylbutan-2-ol [02.041] Mutagenicity assays S. typhimurium 
TA1535; TA1537; 
TA1538; 
S. cerevisiae 
NR Negative (Dow Chemical 
Company, 1982b) 
Very short abstract only. 
 Sister chromatid 
exchange 
 
Chinese hamster 
ovary cells 
160, 500, 1600, 5000 µg/ml Positive3
Negative2 
(NTP, 1997c)  
 Sister chromatid 
exchange 
 
Chinese hamster 
ovary cells 
2000, 3000, 4000, 5000 µg/ml Negative1 (NTP, 1997c)  
2-Methylbut-3-en-2-ol [02.123] Ames test S. typhimurium 
TA98; TA100; 
TA1535; TA1537 
20 – 5000 µg/plate Negative1 (BASF, 1989d) Summary in IUCLID data set only. According to this summary, the 
assay was not in compliance with GLP but in accordance with 
OECD guideline 471. The unpublished study report is not available 
for re-evaluation. 
 Liquid suspension 
assay 
S. typhimurium  
TA98; TA100 
20 – 5000 µg/plate Negative1 (BASF, 1991a) Summary in IUCLID data set only. According to this summary, the 
assay was not in compliance with GLP but in accordance with 
OECD guideline 471. The unpublished study report is not available 
for re-evaluation. 
Isophytol [02.168] Ames test S. typhimurium 
TA97; TA98; 
TA100; TA1535 
 100, 333, 1000, 3333, 10000 
microgram/plate 
Equivocal1 (NTP, 1994b) This non-GLP study is considered valid. It is in accordance with 
OECD guideline 471 (1983). The study is published in the Web 
and the report contains sufficient details. 
 Ames test S. typhimurium 
TA97, TA98, 
TA100, and TA1535 
five doses from 100 to 10000 
microgram/plate 
Negative (NTP, 2000c) This non-GLP study is considered valid. It is in accordance with 
OECD guideline 471 (1983). The study is published in the Web 
and the report contains sufficient details. 
(Linalool [02.013]) Ames test (modified) S. typhimurium 3 µl/2 ml Negative1 (Eder et al., 1980)  
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TA100 (2610 µg/2ml) 
incubation volume 1 mg/plate 
 Ames test S. typhimurium 
TA92; TA94; TA98; 
TA100; TA1535; 
TA1537 
(1000 µg/plate) Negative1 (Ishidate et al., 1984)  
 Ames test S. typhimurium 
TA98; TA100 
100 µl 
(87000 µg) 
Negative1 (Rockwell & Raw, 
1979) 
 
 Ames test S. typhimurium 
TA98; TA100; 
TA1535; TA1537; 
TA1538 
10000 nl/plate 
(8700 µg/plate) 
Negative1 (Heck et al., 1989) Some important details of method and results are not reported. 
Thus, the validity of this study cannot be evaluated. 
 Chromosomal 
aberration assay 
Chinese hamster 
fibroblasts 
0.25 mg/ml 
(250 µg/ml) 
Negative1 (Ishidate et al., 1984)  
 Unscheduled DNA 
synthesis 
Rat hepatocytes 50 nl/ml 
(43.6 µg/ml) 
Negative (Heck et al., 1989) Some important details of method and results are not reported. 
Thus, the validity of this study cannot be evaluated. 
 Mutation assay E. coli  
WP2 uvrA 
1 mg/plate 
(1000 µg/plate) 
Negative (Yoo, 1986) In Japanese (only summary and tables in English). Thus, the 
validity cannot be evaluated. 
 Rec assay B. subtilis 
H17 (rec+); M45 
(rec-) 
17 µg Negative (Oda et al., 1979)  
 Rec assay B. subtilis 
H17 (rec+); M45 
(rec-) 
10 µl/disk 
(8700 µg/disk) 
Positive (Yoo, 1986) In Japanese (only summary and tables in English). Thus, the 
validity cannot be evaluated. 
 Mammalian cell 
mutation 
Mouse lymphoma  
L5178Y TK+/- 
3.9 to 300 nl/ml Negative2
Positive3 
(Heck et al., 1989) Some important details of method and results are not reported. 
Thus, the validity of this study cannot be evaluated. 
 Sister chromatid 
exchange 
Chinese hamster 
ovary cells 
1000 µM 
(154250 µg) 
Negative1, 4 (Sasaki et al., 1989)  
(Linalyl acetate [09.013]) Ames test S. typhimurium 
TA98; TA100; 
TA1535; TA1537; 
TA1538 
25000 nl/plate 
(22575µg/plate) 
Negative1 (Heck et al., 1989) Some important details of method and results are not reported. 
Thus, the validity of this study cannot be evaluated. 
 Unscheduled 
DNA synthesis 
Fischer or SD rat 
hepatocytes 
300 nl/ml 
(271 µg/ml) 
Negative (Heck et al., 1989) Some important details of method and results are not reported. 
Thus, the validity of this study cannot be evaluated. 
 Rec assay B. subtilis 
H17 (rec+); M45 
(rec-) 
18 µg Negative (Oda et al., 1979)  
 Chromosome 
aberration 
Peripheral human 
lymphocytes 
180 µg/ml Negative1 (Bertens & van de 
Waart, 2000) 
 
(alpha-Terpineol [02.014]) Ames test S. typhimurium 
TA98; TA100; 
TA1535; TA1537; 
TA1538 
10000 µg/plate Negative (Heck et al., 1989) Some important details of method and results are not reported. 
Thus, the validity of this study cannot be evaluated. 
 Ames test S. typhimurium 
TA97a; TA98; 
TA100;  
2500 µg/plate  
Negative 
 
(Gomes-Carneiro et al., 
1998) 
The study is concidered valid. A slight but dose-related response 
was noted with TA102 with and without the use of metabolic 
activation.  
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  TA102 2500 µg/plate Weakly 
positive5 
  
 Ames test S. typhimurium 
TA98; TA100; 
TA1535; TA1537; 
TA1538 
1000 µg/plate Negative1 (National Cancer 
Institute, 1983) 
 
 Ames test S. typhimurium 
TA98 ; TA100 ; 
TA1535 ; TA1537 ; 
TA1538 
10000 µg/plate Negative1 (Lorillard, 1983b)  
 Spot test S. typhimurium 
TA98; TA100; 
TA1535; TA1537 
3 µ mol/plate 
(463 µg/plate) 
Negative1 (Florin et al., 1980)  
 Mammalian cell 
mutation 
Mouse lymphoma  
L5178Y TK +/- 
0.5 µl/ml (467µg/ml)  
0.75µl/ml (700 µg/ml) 
Negative3
Negative2 
(Kirby et al., 1984)  
 Mammalian cell 
mutation 
Mouse lymphoma  
L5178Y TK +/- 
300 nl/ml (280 µg/ml)  
250 nl/ml (233 µg/ml) 
Negative1 (Heck et al., 1989) Some important details of method and results are not reported. 
Thus, the validity of this study cannot be evaluated. 
 Mammalian cell 
mutation 
Mouse lymphoma  
L5178Y TK +/- 
15.6 -250 nl/ml 
15.6 -300 nl/ml 
Negative2
Negative3 
(Lorillard, 1982)  
 Rec assay S. cerevisiae NR Negative (Oda et al., 1979)  
(Terpinyl acetate [09.830]) Rec assay B. subtilis  
H17; M45 
19 µg Negative (Oda et al., 1979)  
(beta-Terpineol) [02.097]) Ames S. typhimurium 
TA98; TA100 
0.05 µl  
(100 µl ) 
Negative1 (Rockwell & Raw, 
1979) 
 
 Rec assay S. cerevisiae NR Negative1 (Oda et al., 1979) Article does not specify alpha- or beta-terpineol.
(1-Isopropyl-4-methylbenzene 
[01.002]) 
In vivo/in vitro Ames 
test 
S. typhimurium 
TA98 and TA100 
0.5 ml (equivalent to 1,706 mg/kg 
bw) administered to Sprague-
Dawley rats, urine collected and 
tested in vitro 
Negative5 (Rockwell & Raw, 
1979) 
 
(Myrcene [01.008]) Ames test S. typhimurium 
TA100; TA1535; 
TA97; TA98 
0, 33, 100, 333, 1000, 3333 and 
10000 μg/plate 
Negative1 (NTP, 1999b)  
 Chromosome 
aberration 
Human lymphocytes 0, 100, 500 and 1000 μg/ml Negative1 (Kauderer et al., 1991)  
 Sister chromatid 
exchange 
Human lymphocytes 0, 100, 500 and 1000 μg/ml Negative1 (Kauderer et al., 1991)  
 HPRT assay V79 Chinese 
hamster cells 
0, 100, 500 and 1000 μg/ml Negative1 (Kauderer et al., 1991)  
 Sister chromatid 
exchange 
V79 Chinese 
hamster cells 
0, 100, 250 and 500 μg/ml Negative1 (Röscheisen et al., 
1991) 
 
 Sister chromatid 
exchange 
HTC cells 0, 100, 250 and 500 μg/ml Negative (Röscheisen et al., 
1991) 
 
(Menthol [02.015]) Ames test  S. typhimurium, 
TA92, TA100, 
TA94, TA98, 
0, and 6 concentrations up to 5000 
µg/plate  
Negative1  (Ishidate et al., 1984) d,l-Menthol was used. The study is considered valid.  
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TA1535, TA1537 
 Ames test 
(preincubation 
method) 
S. typhimurium, 
TA1535, TA97, 
TA100, TA98 
3 – 666 µg/plate  Negative1 (Zeiger et al., 1988) d,l-Menthol was used. The study is considered valid.  
 Ames test  S. typhimurium, 
TA2637, TA100, 
TA98 
0, 5 – 500 µg/plate  Negative1  (Nohmi et al., 1985) d,l-Menthol was tested. The highest concentrations were cytotoxic. 
The study is considered valid. 
 Ames test  S. typhimurium, 
TA2637, TA100, 
TA98 
0, 20 – 500 µg/plate  Negative1  (Nohmi et al., 1985) l-Menthol was tested. The highest concentrations were cytotoxic. 
The study is considered valid. 
 Ames test  S. typhimurium, 
TA1537, TA1535, 
TA100, TA98 
0, 6.4, 32, 160, and 800 µg/plate  Negative1  (Andersen & Jensen, 
1984b) 
No indication of which enantiomer was used. In the absence of 
metabolic activation, the highest concentration was cytotoxic. The 
study is considered valid. 
 Ames test  E. coli WP2 uvrA 
(Trp-) 
100 – 800 µg/plate  Negative  (Yoo, 1986) l-Menthol was used. The article is not in English. The validity of 
the study cannot be evaluated. It is unclear whether metabolic 
activation or a control group was used. 
 Ames test  S. typhimurium 
TA97A; TA98; 
TA100; TA102 
0, 5 – 800 µg/plate  Negative1  (Gomes-Carneiro et al., 
1998) 
(-)-Menthol was used. The range of concentrations tested varied 
between the different strains. Cytotoxicity was observed with the 
highest concentrations tested with TA97A and, in the presence of 
metabolic activation, the highest concentration tested with TA102. 
The study is considered valid. 
 Rec assay  B. subtilis H17, M45 Up to 10000 µg/disk  Positive (Yoo, 1986) l-Menthol was used. Inhibition zone for rec- and rec+ was 42 and 
23 mm, respectively. The article is not in English. It is not clear 
from the study whether metabolic activation, or a control group 
was used. The validity of this study cannot be assessed. The 
method (Rec-assay) has poor predictive value. 
 Rec assay  B. subtilis H17, M45 20 µg/disk  Negative (Oda et al., 1979) l-Menthol was used. The article is not in English. Only one 
concentration level is mentioned at a table. No data on metabolic 
activation or control group. The validity of this study cannot be 
evaluated. The method (Rec-assay) has poor predictive value. 
 Alkaline elution 
assay 
Rat hepatocytes  0, 0.1 – 1.3 mM (203.2 µg/ml4) Negative (Storer et al., 1996) The experiment employed d-Menthol. An increase in DNA breaks 
was only observed at concentrations associated with cytotoxicity. 
The authors concluded that this was a false-positive result. The 
study is considered valid.  
 Sister chromatid 
exchange 
Chinese hamster 
ovary cells 
5 – 50 amd 0, 2 – 25 µg/ml3
0, 16 – 167 µg/ml 2 
Negative1  (Ivett et al., 1989) d,l-Menthol was used. The compound was tested up to toxic or 
nearly toxic concentration levels. The study is considered valid. 
 Sister chromatid 
exchange 
Human lymphocytes 0, 0.1, 1, 10 mM (1563 µg/ml4) Negative1  (Murthy et al., 1991) The study is considered valid. 
 Cytogenetic assay Human embryonic 
lung cells 
0, 0.1, 1, 10 µg/ml  Negative  (Food and Drug 
Research Laboratories, 
Inc., 1975a) 
The report does not mention exogenous metabolic activation. The 
study is considered valid. 
 Chromosome 
aberration 
Chinese hamster 
fibroblasts 
0 and three concentrations up to 
200 µg/ml  
Negative3  (Ishidate et al., 1984) The maximum concentration (cytotoxic) was selected by a 
preliminary test. The study is considered valid. 
 Chromosome 
aberration 
Chinese hamster 
ovary cells 
0, 50 – 250 µg/ml  Negative1  (Ivett et al., 1989) d,l-Menthol was used. The compound was tested up to toxic or 
nearly toxic concentration levels. The study is considered valid. 
 Chromosome Human lymphocytes 0, 0.1, 1, 10 mM (1563 µg/ml4)  Negative1  (Murthy et al., 1991) The study is considered valid. 
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aberration 
 Gene mutation assay Mouse lymphoma 
L5178Y TK+/-cells 
0, 12.5 – 200 µg/ml  Negative1 (Myhr & Caspary, 
1991) 
d,l-Menthol was used. The maximum concentration was selected by 
a preliminary test The study is considered valid. 
Bisabola-1,12-dien-8-ol [02.129] Ames test S. typhimurium, 
TA98, TA100, 
TA102, TA1535, 
TA1537 
0, 0.5 – 1500 µg/plate Negative1 (King & Harnasch, 
2002b) 
 
 Ames test S. typhimurium, 
TA97a, TA98, 
TA100, TA1535 
0, 1-400 µg/plate in ethanol Negative1 (Gomes-Carneiro et al., 
2005b) 
Publication in peer-reviewed journal. No reference to OECD and 
GLP-guidelines being made, but study is of good quality and 
considered valid. 
 Ames test S. typhimurium, 
TA98, TA100, 
TA1535, TA1537 
0, 20-5000 µg/plate in DMSO Negative1 (CIR, 1999) Review. 
 Chromosome 
aberration 
Chinese hamster 
fibroblast cells V79 
0, 0.78-40 µg/ml in DMSO Negative1 (CIR, 1999) Review. 
Cedrol [02.120] Ames test S. typhimurium, 
TA97a, TA98, 
TA102, TA1535 
0 – 5000 µg/plate Negative1 (Scheerbaum, 2001) Research report according to OECD guideline 471 and GLP-
guidelines, the study is considered valid. 
1,2-Dihydrolinalool [02.140] Ames test S. typhimurium, 
TA97, TA98, 
TA100, TA102, 
TA1535 
0 – 1000 µg/plate Negative1 (Gocke, 1999a) Research report according to OECD and GLP-guidelines, the study 
is considered valid. 
2,6-Dimethyloct-7-en-2-ol 
[02.144] 
Ames test S. 
typhimurium,TA98, 
TA100, TA102, 
TA1535, TA1537 
0 – 5000 µg/plate Negative1 (King, 2000) Research report according to OECD guideline 471 and GLP-
guidelines, the study is considered valid. 
1,2,3,4,4a,5,6,7-Octahydro-
2,5,5-trimethylnaphthalen-2-ol 
[02.197] 
Ames test S. 
typhimurium,TA98, 
TA100, TA1535, 
TA1537 
E. coli WP2 uvrA 
0 – 250 µg/plate3 
0 – 500 µg/plate2 
Negative (Watanabe, 2002) Research report according to OECD guideline 471, the study is 
considered valid. 
NR = Not Reported. 
1With and without metabolic activation.  
2With metabolic activation.  
3 Without metabolic activation.  
4 With and without pre-treatment with mitomycin C at 0.15 microM for 21 hours.  
5With and without presence of beta-glucuronidase. 
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and 8, and for three supporting substances evaluated by the JECFA at the 51st meeting (JECFA, 1999a) or at the 63rd meeting (JECFA, 2006a). Supporting 
substances are listed in brackets. 
TABLE IV.5: GENOTOXICITY (IN VIVO) 
Chemical Name  Test System Test Object  Route Dose Result  Reference  Comments 
2-Methylpropan-2-ol [02.052] In vivo Chromosomal 
Aberration assay 
Male rats Once via 
gavage 
0.2xLD50 
 
Positive1 (Barilyak & Kozachuk, 
1988) 
Validity questionable. This study was not in compliance with GLP and not in 
accordance with OECD guideline No. 475 (1983). Some main details of method 
and results are not available. 
The authors report the results of tests on a series of monohydric alcohols (from 
C1 to C16, 18 compounds) in rat bone marrow cytogenetic tests. All compounds 
were claimed positive compared to the untreated control group, even though no 
statistics is shown. It is noted that a single control group, with 0.0 % of cells 
with aberrations was used throughout the study. Lacking historical control data, 
it is not possible to establish whether the alleged positive results were due to and 
uniformly positive response elicited by all chemicals, or rather by an incidental 
very low frequency of aberrations in the group of rats (8 animals) used as 
control. In this respect it is noted that the incidence of chromosomal aberrations 
observed with some “positive” compounds, including 2-methylpropan-2-ol 
(1.6+/-0.5 %), are close to background incidences commonly observed. Even the 
lack of a concurrent raise in gaps in treated animals casts doubts on an induced 
genotoxic effect. Moreover, the lack of a positive control group in the study is 
noted. For these reasons, the results of this study are considered inconclusive. 
 In vivo Micronucleus 
assay 
Mouse bone marrow 
erythrocytes 
I.P. x 3  
at 24 hours 
intervals (=72 
hours)  
312.5, 625, and 1250 
mg/kg bw 
Negative (NTP, 1996c) This study is considered valid. It was not in compliance with GLP but in 
accordance with OECD guideline No. 474 (1983/1997) except that only 5 male 
animals were tested. The study is published in the Web and the report contains 
sufficient details. Due to the lack of an effect on the PCE/NCE ratio it is unclear 
whether the test substance has reached the bone marrow. Relevance of the result 
is limited. 
 In vivo Micronucleus 
assay 
Rat bone marrow 
cells 
I.P. x 3  
at 24 hours 
intervals (=72 
h) 
0, 39 – 1250 mg/kg 
bw,  
Negative (NTP, 1997c)  
 In vivo Micronucleus 
assay 
Mouse peripheral 
blood cells 
Drinking water 3000 - 40000 Negative (NTP, 1995b)  
2-Methylbut-3-en-2-ol [02.123] In vivo Micronucleus 
assay 
Mouse bone marrow 
erythrocytes 
Once via 
gavage 
500, 1000, 1500 
mg/kg 
Negative (BASF, 1992b) Summary in IUCLID data set only. According to this summary, the assay was 
perfomed in compliance with GLP and in accordance with OECD guideline 474. 
One thousand PCEs were conted per animal. The unpublished study report is not 
available for re-evaluation. 
(Linalool [02.013]) In vivo Micronucleus 
assay 
Mouse bone marrow 
erythrocytes 
Once via 
gavage 
1500 mg/kg Negative (Meerts & van de 
Waart, 2001) 
This study is considered valid. It was in compliance with GLP and in accordance 
with OECD Guideline 474 (1997). However, due to the lack of an effect on the 
PCE/NCE ratio it is unclear whether the test substance reached the bone marrow. 
Thus, the relevance of the result is limited. 
(Myrcene [01.008]) In vivo Micronucleus 
assay 
Rat bone marrow 
cells 
Gavage 0, 100, 500 or 1000 
mg/kg bw 
Negative (Zamith et al., 1993)  
 In vivo Micronucleus 
assay 
Mouse peripheral 
blood cells 
Gavage Up to 2000 mg/kg 
bw/day for 13 weeks 
Negative (NTP, 2001b)  
(Menthol [02.015]) Host mediated S. typhimurium  Gavage  0, 1.45 - 5000 mg/kg Equivocal (Food and Drug Negative results, with exception of the combination S. typhimurium  
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mutation assay TA1530 and G46; S. 
cerevisiae D3 
inoculated in mice 
(7-9 animals/group) 
bw (single dose) 
0, 1150 mg/kg 
bw/day (repeated 
doses) 
Research Laboratories, 
Inc., 1975a) 
TA1530 – 5000 mg/kg bw and S. cerevisiae D3 – 1150 mg/kg bw/day. This 
study is considered valid, but the equivocalresult might have low relevance since 
the effect was only observed at very high (lethal) dose levels. 
 In vivo  
Cytogenetic assay 
Male rat bone 
marrow cells 
Gavage 0, 1.45 - 3000 mg/kg 
bw (single dose) 
0, 1150 mg/kg 
bw/day (repeated 
doses) 
Negative (Food and Drug 
Research Laboratories, 
Inc., 1975a) 
Oral DL50 was determined as 940 mg/kg bw. The study is considered valid but 
the negative result is of limited relevance, since no effect on mitotic index was 
observed. However, testing at higher dose levels may not have been possible, 
due to lethality. 
 In vivo Micronucleus 
assay 
B6C3F1 male mouse 
bone marrow cells 
I.P. 0, 250 - 1000 mg/kg 
bw/day, during 3 
days 
Negative (Shelby et al., 1993) d,l-Menthol was used. The study is considered valid, but the negative result is of 
limited relevance, since no toxicity to the bone marrow was observed. However, 
testing at higher dose levels was not possible, because the highest dose caused 
50 % lethality. 
 In vivo  
Dominant lethal assay 
Male rat fertility, 
spermatozoa 
Gavage 0, 1.45 - 3000 mg/kg 
bw (single dose) 
0, 1150 mg/kg 
bw/day (repeated 
doses) 
Negative (Food and Drug 
Research Laboratories, 
Inc., 1975a) 
This study is considered valid. 
1Cytogenetic analysis indicated the following results for controls and 2-methylpropan-2-ol, respectively: % polyploid cells, 0.5 ± 0.3 / 0.8 ± 0.4; % cells with gaps 0.3 ± 0.2 / 0.4 ± 0.2; % cells with aberrations, 0 / 1.6 ± 0.5. Statistical comparisons 
were not performed.  
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ABBREVIATIONS 
ADI  Acceptable Daily Intake 
BW  Body Weight 
CAS  Chemical Abstract Service 
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
Chemical Abstract Service 
CHO  Chinese hamster ovary (cells) 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
EC European Commission 
EFFA  European Flavour and Fragrance Association 
EFSA  The European Food Safety Authority 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
GLP  Good Laboratory Practice 
ID   Identity 
IOFI  International Organization of the Flavour Industry 
IP   Intraperitoneal 
IR   Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
LD50  Lethal Dose, 50%; Median lethal dose 
MS  Mass spectrometry 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
NAD  Nicotinamide Adenine Dinucleotide  
NADP  Nicotinamide Adenine Dinucleotide Phosphate 
NMR  Nuclear Magnetic Resonance 
No  Number 
NOAEL No Observed Adverse Effect Level 
NOEL  No Observed Effect Level 
NTP  National Toxicology Program 
OECD  Organisation for Economic Co-operation and Development 
SCE  Sister Chromatid Exchange 
SCF  Scientific Committee on Food 
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SMART  Somatic Mutation and Recombination Test  
TAMDI Theoretical Added Maximum Daily Intake 
UDS  Unscheduled DNA Synthesis  
WHO  World Health Organisation  
